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ABSTRACT 
 
 
The recent advance in high-throughput sequencing and genotyping protocols allows rapid 
investigation of Mendelian and complex diseases on a scale not previously been possible. In 
my thesis research I took advantage of these modern techniques to study retinitis pigmentosa 
(RP), a rare inherited disease characterized by progressive loss of photoreceptors and leading 
to blindness; and hypertension, a common condition affecting 30% of the adult population.  
Firstly, I compared the performance of different next generation sequencing (NGS) platforms 
in the sequencing of the RP-linked gene PRPF31. The gene contained a mutation in an 
intronic repetitive element, which presented difficulties for both classic sequencing methods 
and NGS. We showed that all NGS platforms are powerful tools to identify rare and common 
DNA variants, also in case of more complex sequences. Moreover, we evaluated the features 
of different NGS platforms that are important in re-sequencing projects. 
The main focus of my thesis was then to investigate the involvement of pre-mRNA splicing 
factors in autosomal dominant RP (adRP). I screened 5 candidate genes in a large cohort of 
patients by using long-range PCR as enrichment step, followed by NGS. We tested two 
different approaches: in one, all target PCRs from all patients were pooled and sequenced as a 
single DNA library; in the other, PCRs from each patient were separated within the pool by 
DNA barcodes. The first solution was more cost-effective, while the second one allowed 
obtaining faster and more accurate results, but overall they both proved to be effective 
strategies for gene screenings in many samples. We could in fact identify novel missense 
mutations in the SNRNP200 gene, encoding an essential RNA helicase for splicing catalysis. 
Interestingly, one of these mutations showed incomplete penetrance in one family with adRP. 
Thus, we started to study the possible molecular causes underlying phenotypic differences 
between asymptomatic and affected members of this family. 
For the study of hypertension, I joined a European consortium to perform genome-wide 
association studies (GWAS). Thanks to the use of very informative genotyping arrays and of 
phenotipically well-characterized cohorts, we could identify a novel susceptibility locus for 
hypertension in the promoter region of the endothelial nitric oxide synthase gene (NOS3). 
Moreover, we have proven the direct causality of the associated SNP using three different 
methods: 1) targeted resequencing, 2) luciferase assay, and 3) population study. 
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RESUME 
 
 
Le récent progrès dans le Séquençage à haut Débit et les protocoles de génotypage a permis 
une plus vaste et rapide étude des maladies mendéliennes et multifactorielles à une échelle 
encore jamais atteinte. Durant ma thèse de recherche, j’ai utilisé ces nouvelles techniques de 
séquençage afin d’étudier la rétinite pigmentaire (RP), une maladie héréditaire rare 
caractérisée par une perte progressive des photorécepteurs de l’œil qui entraine la cécité; et 
l’hypertension, une maladie commune touchant 30% de la population adulte. 
Tout d’abord, j’ai effectué une comparaison des performances de différentes plateformes de 
séquençage NGS (Next Generation Sequencing) lors du séquençage de PRPF31, un gène lié à 
RP. Ce gène contenait une mutation dans un élément répétable intronique, qui présentait des 
difficultés de séquençage avec la méthode classique et les NGS. Nous avons montré que les 
plateformes de NGS analysées sont des outils très puissants pour identifier des variations de 
l’ADN rares ou communes et aussi dans le cas de séquences complexes. De plus, nous avons 
exploré les caractéristiques des différentes plateformes NGS qui sont importantes dans les 
projets de re-séquençage. 
L’objectif principal de ma thèse a été ensuite d’examiner l’effet des facteurs d’épissage de 
pre-ARNm dans une forme autosomale dominante de RP (adRP). Un screening de 5 gènes 
candidats issus d’une large cohorte de patients a été effectué en utilisant la long-range PCR 
comme étape d’enrichissement, suivie par séquençage avec NGS. Nous avons testé deux 
approches différentes : dans la première, toutes les cibles PCRs de tous les patients ont été 
regroupées et séquencées comme une bibliothèque d’ADN unique; dans la seconde, les PCRs 
de chaque patient ont été séparées par code barres d’ADN. La première solution a été la plus 
économique, tandis que la seconde a permis d’obtenir des résultats plus rapides et précis. 
Dans l’ensemble, ces deux stratégies se sont démontrées efficaces pour le screening de gènes 
issus de divers échantillons. Nous avons pu identifier des nouvelles mutations faux-sens dans 
le gène SNRNP200, une hélicase ayant une fonction essentielle dans l’épissage.  Il est 
intéressant de noter qu’une des ces mutations montre une pénétrance incomplète dans une 
famille atteinte d’adRP. Ainsi, nous avons commencé une étude sur les causes moléculaires 
entrainant des différences phénotypiques entre membres affectés et asymptomatiques de cette 
famille. 
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Lors de l’étude de l’hypertension, j’ai rejoint un consortium européen pour réaliser une étude 
d’association Pangénomique ou genome-wide association study Grâce à l’utilisation de 
tableaux de génotypage très informatifs et de cohortes extrêmement bien caractérisées au 
niveau phénotypique, un nouveau locus lié à l’hypertension a été identifié dans la région 
promotrice du gène endothélial  nitric oxide sinthase  (NOS3). Par ailleurs, nous avons prouvé 
la cause directe du SNP associé au moyen de trois méthodes différentes: i) en reséquençant la 
cible avec NGS, ii) avec des essais à la luciférase et iii) une étude de population. 
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1. THE MOLECULAR BASIS OF RETINITIS PIGMENTOSA 
1.1 The Retina 
1.1.1 Structural proprieties 
The retina is a multi-layered sensory tissue that extends over a large portion of the posterior 
pole of the eye (Fig. 1A). Developing as an outpocketing from the neural tube, the retina is 
part of the central nervous system. It contains millions of photoreceptors that capture the rays 
of light and convert them into action potentials, which travel along the optic nerve to the 
visual centers of the brain where they are turned into images. Before the rays of light enter the 
photoreceptor layer, they must pass through layers of blood vessels, nerve fibers and four 
other types of neurons: bipolar cells, ganglion cells, horizontal cells, and amacrine cells (Fig. 
1B). The most direct path for transmitting visual information to the brain is through a chain 
composed of three neurons: a photoreceptor, a bipolar cell, and a ganglion cell. Horizontal 
cells and amacrine cells mediate lateral interactions, which modify the main signal.  
 
A    B 
Figure 1. Anatomy of the vertebrate eye and structure of the retina. A) Anatomy of the eye. Image from [1]. B) 
The five neuronal cell types of the retina. Photoreceptors (PR), horizontal cells (HC), bipolar cells (BC), 
amacrine cells (AC) retinal ganglion cells (RGC) and displaced amacrine cells (dAC). RPE ‐ retinal pigment 
epithelium, OLM ‐ outer limiting membrane, ONL ‐ outer nuclear layer, OPL ‐ outer plexiform layer, INL ‐ inner 
nuclear layer, IPL ‐ inner plexiform layer, GCL ‐ ganglion cell layer, ILM ‐ inner limiting membrane. Image 
taken from [2]. 
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The cell bodies and processes of these neurons are stacked into different, alternate layers, 
which are organized as follows, in the sense of the rays of light (Fig. 1B): 
• Inner limiting membrane (ILM): is the inner surface of the retina, at the boundary with the 
vitreous body of the eye. It is composed of the conical feet of Müller glial cells and 
astrocytes. 
• Ganglion cell layer (GCL): contains the nuclei of retinal ganglion cells, the axons of which 
form the optic nerve fibers, and some displaced amacrine cells. 
• Inner plexiform layer (IPL): contains the synapses between the bipolar cell (BC) axons and 
the dendrites of the ganglion and amacrine cells (AC). 
• Inner nuclear layer (INL): contains the cell bodies of the bipolar, amacrine, horizontal and  
Müller cells. 
• Outer plexiform layer (OPL): contains the synapses between photoreceptors axons and 
dendrites of horizontal and bipolar cells. 
• Outer nuclear layer (ONL): contains the nuclei of photoreceptors and their inner segments 
(IS), where metabolism, biosynthesis and endocytosis take place. 
• Photoreceptor layer: contains the outer segments, i.e. the apical extensions of 
photoreceptors, composed of membranous disks containing light-sensitive photopigments 
and other proteins involved in the light transduction process. The outer segment 
communicates with the cell body trough the connecting cilium, essential for protein 
transport and structural integrity (Fig. 2A).  
• Retinal pigment epithelium (RPE): a single layer of cells with tight junctions. They play an 
essential role in the turnover of the disks by phagocytosis and of the photopigment 
molecules after they have been exposed to light. Moreover the RPE contains melanin, 
which has a fundamental role in reducing light scattering in the back of the eye [3]. 
 
1.1.2 Functional aspects 
There are two types of photoreceptors in the vertebrate retina: rods and cones. The first ones 
are specialized for vision at low light levels and the second for high visual acuity and the 
perception of colors in daytime lighting conditions. Three different pigments that absorb light 
of different wavelengths (red, green and blue) are packed in the disks of different types of 
cones, while there is only one kind of rod photopigment, called rhodopsin.  
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A B 
Figure 2. Schematic representations of A) a rod photoreceptor structure [4] and B) the phototransduction cascade 
[5]. RPE=retinal pigmented epithelium; ROS = rod outer segment; RIS = rod inner segment; PDE = 
phosphodiesterase. 
 
Rods are the most abundant photoreceptors; in human retina there are approximately 120 
million rods versus 6 million cones. Rods are also the most studied cell type of the retina, 
where mechanisms of phototransduction, visual cycle and electrophysiology have been 
elucidated.  In primates, only the cones are densely packed in a region of the retina called 
fovea centralis (Fig. 1A), responsible for sharp central vision. There the cell bodies of the 
neurons are shifted to the side to reduce distortion of light paths, and each cone has a private 
line to the visual cortex. Visual acuity decreases toward the periphery of the retina where the 
cones become less dense and single bipolar-ganglion cell transmission lines serve many 
photoreceptors [3].  
The cascade of events that transform light into an electric signal is called phototransduction 
(Fig. 2B) and starts with the absorption of a single photon, which induces the chromphore 
retinal (or vitamin A) to undergo a conformational change from 11-cis-retinal to all-trans 
retinal. Rhodopsin, which is bound to retinal, activates a G-protein (transducin), which 
amplifies the signal to hundreds of other G-proteins, which stimulate the cGMP 
phosphodiesterase (PDE) to hydrolyze cGMP into GMP. The decrease in cGMP concentration 
results in the closure of cGMP-gated cation channels, which in dark conditions pump sodium 
and calcium inside the cell.  The hyperpolarization of the cells after a light stimulus causes a 
reduction in release of neurotransmitter glutamate at the synaptic terminal, and as a 
consequence of this, a signal is sent to the ganglion cells through bipolar cells [1]. 
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The unique structural and functional specialization of the retina, and in particular of the 
photoreceptors, renders this tissue exceptionally susceptible to dysfunctions [6]. This 
vulnerability is enhanced by the continuous exposure to photons and free radicals and by the 
high metabolic energy demand, needed to sustain the phototransduction process. It is 
therefore not surprising that dystrophies of retinal photoreceptors cause most of adult 
blindness conditions in industrialized countries, among which retinitis pigmentosa represents 
the most prevalent of monogenic inheritable forms. 
1.2 Retinitis Pigmentosa 
1.2.1 Prevalence and classification 
Retinitis pigmentosa (RP) is a heterogeneous group of hereditary conditions characterized by 
progressive retinal dystrophy with typically a major involvement of rod photoreceptors. It 
affects more than one million individuals worldwide, with a prevalence of one in 4000 [7]. It 
has typical Mendelian inheritance patterns: autosomal dominant (adRP, ~20% of cases), 
autosomal recessive (arRP, ~30%) or X-linked (~10%) [8]. The remaining fraction of RP 
patients are isolates cases, likely misrecognized recessive or de novo. Moreover, some cases of 
RP are due to digenic inheritance of mutations [9].  
RP is usually a disease restricted to the eye (defined as non-syndromic RP), although there are 
several cases in which it can be part of more complex syndromes - 30 in total - and associates 
with non-ocular phenotypes (syndromic RP). The most common syndromic form of RP, which 
affects about 15% of all RP cases, is Usher syndrome, characterized by RP and hearing 
impairment [10]. The degree of deafness is variable and defines three types of Usher 
syndromes: it can be severe and present at birth (type I), moderate/mild (type II) or it can 
appear after childhood and progressively worsen during later years (type III). The second most 
common syndrome associated with RP (5% of cases) is Bardet-Biedl syndrome. The 
phenotype variably associates RP with obesity, developmental delay, polydactyly, 
hypogenitalism and structural renal abnormalities leading to renal failure and often 
transplantation. 
1.2.2 Symptoms 
Despite the name, retinitis pigmentosa does not involve an inflammation of the retina, as it 
was originally believed, but it is a result of progressive degeneration of photoreceptors. 
Conversely, the pigmented deposits observed in the fundus (the interior surface of the 
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posterior pole of the eye) are a hallmark for RP diagnosis. These pigmented granules, called 
bone-spicule deposits, are released by the RPE and accumulate in the neural retina, starting 
from the mid periphery. At later stages, the deposits are present all over the retina and the 
fundus appears depigmented (Fig. 3). Other characteristic consequences of retinal atrophy in 
RP are the attenuation of retinal vessels and cataracts. The visual symptoms of a typical RP 
patient reflect the primary degeneration of rods followed by degeneration of cones (often 
referred to as a rod-cone dystrophy). The first manifestation of RP is therefore nigh blindness 
in adolescence as consequence of early involvement of rods. This is followed by loss of 
peripheral visual field in young adulthood, the progressive constriction of the visual field 
leading to tunnel vision and the final loss of central vision by age of about 60, due to 
secondary, progressive degeneration of cones. 
These clinical manifestations can be highly variable within patients, even belonging to the 
same family. The main features that distinguish the different types of RP are the age of onset, 
the rate of progression and the degree of rod or cone contribution to the disease. For example 
some patients experience visual loss in childhood while other have the first symptoms at mid 
adulthood. Some forms of RP are more similar to cone-rod dystrophies, because the cones 
degenerate simultaneously with the rods and this leads to a greater and earlier impairment of 
central vision. 
 
 
Figure 3. Fundus of patient with retinitis pigmentosa from left to right: at early stage (similar to a normal 
fundus), mid stage (retinal atrophy and bone spicule pigmented deposits at the periphery) and end stage (the 
whole retina is depigmented and deposits are present all over). From [10]. 
 
An objective tool to provide a reliable diagnosis of RP and to monitor the progression of the 
disease is the electroretinogram (ERG), which measures the electric response of the retina 
after stimulation with a short flash of light. The stimuli are applied after dark adaptation and 
consist of a flash of dim blue light to measure the function of the rods, a brighter white light 
(0.5 Hz), which stimulate both cones and rods, and flickering white flashes (30 Hz) to 
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stimulate cones only (Fig. 4). With the single white light stimuli, in patients with retinitis 
pigmentosa the amplitude of the hyperpolarizarion of the photoreceptors (a wave) and of the 
depolarizarion of the bipolar cells (b wave) is reduced; with flickering white flashes, the 
response is reduced and delayed (Fig. 4) [11]. 
Genetics plays an important role in the determination of different types of RP even though a 
correlation between a specific mutation and a phenotype is not always possible. In general, 
autosomal dominant forms are milder and appear at older ages, while autosomal recessive and 
X-linked forms are more severe and have early onsets [7, 10]. In dominant patients, the 
amplitude of the a and b waves is usually moderately reduced while in recessive and X-linked 
patients is severely reduced or undetectable (Fig. 4).  
 
 
Figure 4. ERG responses from a normal subject and three patients with retinitis pigmentosa of autosomal 
dominant, recessive or X-linked inheritance. a=a wave, b=b wave. Arrows indicate the time from the stimuli 
(vertical bar) to the response. From [7]. 
 
 
1.2.3 Genetics 
One of the most distinctive elements of RP is its genetic heterogeneity. Non-syndromic RP 
alone is caused by 56 different known genes, among which 23 genes cause adRP, 36 cause 
arRP and 3 cause X-linked RP. For many of these genes, several mutations have been 
reported, and their sum reaches the value of ~3,000 (Table 1) [12].  
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Table 1. List of genes linked to retinitis pigmentosa, as reported in the Retnet database (sph.uth.edu/retnet). 
Modified from [12] with classification modified from [6]. 
 
 
 
Function Retina specificity Symbol Location Protein
Type of retinitis 
pigmentosa
Reported 
pathogenic 
changes
Cell-cell interaction - SEMA4A 1q22 Semaphorin 4A Autosomal dominant 3
Intermediary Metabolism - CA4 17q23.2 Carbonic anhydrase IV Autosomal dominant 6
Intermediary Metabolism - IMPDH1 7q32.1 Inosine monophosphate dehydrogenase 1 Autosomal dominant 14
Phototransduction + GUCA1B 6p21.1 Guanylate cyclase activating protein 1B Autosomal dominant 3
Pre-mRNA splicing - PRPF3 1q21.2 Human homolog of yeast pre-mRNA 
splicing factor 3
Autosomal dominant 3
Pre-mRNA splicing - PRPF6 20q13.33 Human homolog of yeast pre-mRNA 
splicing factor 6
Autosomal dominant 2
Pre-mRNA splicing - PRPF8 17p13.3 Human homolog of yeast pre-mRNA 
splicing factor C8
Autosomal dominant 21
Pre-mRNA splicing - PRPF31 19q13.42 Human homolog of yeast pre-mRNA 
splicing factor 31
Autosomal dominant 65
Pre-mRNA splicing - RP9 7p14.3 RP9 protein or PIM1-kinase associated 
protein 1
Autosomal dominant 2
Pre-mRNA splicing - SNRNP200 2q11.2 Small nuclear ribonucleoprotein 200!kDa 
(U5)
Autosomal dominant 7
Protein chaperones and 
degradation
- KLHL7 7p15.3 Kelch-like 7 protein (Drosophila) Autosomal dominant 3
Protein chaperones and 
degradation
- TOPORS 9p21.1 Topoisomerase I binding arginine/serine 
rich protein
Autosomal dominant 8
Retinal Development + CRX 19q13.32 Cone-rod otx-like photoreceptor homeobox 
transcription factor
Autosomal dominant 51
Outer segment structure + PRPH2/RDS 6p21.1 Peripherin 2 Autosomal dominant; 
digenic with ROM1
123
Outer segment structure + ROM1 11q12.3 Retinal outer segment membrane protein 1 Autosomal dominant; 
digenic w/ PRPH2
11
Ciliary trafficking and structure + RP1 8q12.1 RP1 protein Autosomal dominant; 
autosomal recessive
67
Ion channels + BEST1 11q12.3 Bestrophin 1 Autosomal dominant; 
autosomal recessive
232
Phototransduction + RHO 3q22.1 Rhodopsin Autosomal dominant; 
autosomal recessive
161
Retinal Development + NR2E3 15q23 Nuclear receptor subfamily 2 group E3 Autosomal dominant; 
autosomal recessive
45
Retinal Development + NRL 14q11.2 Neural retina lucine zipper Autosomal dominant; 
autosomal recessive
14
Visual cycle + RDH12 14q24.1 Retinol dehydrogenase 12 Autosomal dominant; 
autosomal recessive
66
Visual cycle + RPE65 1p31.2 Retinal pigment epithelium-specific 65!kDa 
protein
Autosomal dominant; 
autosomal recessive
134
Cell-cell interaction + CRB1 1q31.3 Crumbs homolog 1 Autosomal recessive 183
Ciliary trafficking and structure + CLRN1 3q25.1 Clarin-1 Autosomal recessive 23
Ciliary trafficking and structure + FAM161A 2p15 Family with sequence similarity 161 
member A
Autosomal recessive 6
Ciliary trafficking and structure + MAK 6p24.2 Male germ-cell associated kinase Autosomal recessive 9
Ciliary trafficking and structure +/- TTC8 14q32.11 Tetratricopeptide repeat domain 8 Autosomal recessive 14
Ciliary trafficking and structure + TULP1 6p21.31 Tubby-like protein 1 Autosomal recessive 31
Ciliary trafficking and structure + USH2A 1q41 Usherin Autosomal recessive 392
Ciliary trafficking and structure + C2ORF71 2p23.2 Chromosome 2 open reading frame 71 Autosomal recessive 13
Ciliary trafficking and structure - C8ORF37 8q22.1 Chromosome 8 open reading frame 37 Autosomal recessive 4
Extracellular matrix + EYS 6q12 Eyes shut/spacemaker (Drosophila) 
homolog
Autosomal recessive 118
Extracellular matrix + IMPG2 3q12.3 Interphotoreceptor matrix proteoglycan 2 Autosomal recessive 10
Intermediary Metabolism - IDH3B 20p13 NAD(+)-specific isocitrate dehydrogenase 
3 beta
Autosomal recessive 2
Ion channels + CNGA1 4p12 Rod cGMP-gated channel alpha subunit Autosomal recessive 8
Ion channels + CNGB1 16q13 Rod cGMP-gated channel beta subunit Autosomal recessive 6
Lipid metabolism - CERKL 2q31.3 Ceramide kinase-like protein Autosomal recessive 8
Outer segment structure + PROM1 4p15.32 Prominin 1 Autosomal recessive 9
Phagocytosis - MERTK 2q13 c-mer protooncogene receptor tyrosine 
kinase
Autosomal recessive 27
Phototransduction + PDE6A 5q33.1 cGMP phosphodiesterase alpha subunit Autosomal recessive 16
Phototransduction + PDE6B 4p16.3 Rod cGMP phosphodiesterase beta 
subunit
Autosomal recessive 39
Phototransduction + PDE6G 17q25.3 Phosphodiesterase 6G cGMP-specific rod 
gamma
Autosomal recessive 1
Phototransduction + SAG 2q37.1 Arrestin (s-antigen) Autosomal recessive 11
Protein glycosylation - DHDDS 1p36.11 Dehydrodolichyl diphosphate synthetase Autosomal recessive 1
Retinal Development - ZNF513 2p23.3 Zinc finger protein 513 Autosomal recessive 1
unknown + PRCD 17q25.1 Progressive rod-cone degeneration protein Autosomal recessive 2
unknown - SPATA7 14q31.3 Spermatogenesis associated protein 7 Autosomal recessive 15
Visual cycle + ABCA4 1p22.1 ATP-binding cassette transporter—retinal Autosomal recessive 680
Visual cycle + LRAT 4q32.1 Lecithin retinol acyltransferase Autosomal recessive 10
Visual cycle + RBP3 10q11.22 Retinol binding protein 3, interstitial Autosomal recessive 2
Visual cycle + RGR 10q23.1 RPE-retinal G protein-coupled receptor Autosomal recessive 7
Visual cycle + RLBP1 15q26.1 Retinaldehyde-binding protein 1 Autosomal recessive 20
Ciliary trafficking and structure - OFD1 Xp22.2 Oral-facial-digital syndrome 1 protein X-linked 127
Ciliary trafficking and structure - RP2 Xp11.23 Retinitis pigmentosa 2 (X-linked) X-linked 76
Ciliary trafficking and structure - RPGR Xp11.4 Retinitis pigmentosa GTPase regulator X-linked 151
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Some of these genes, such as NRL, RP1 and RHO can cause both adRP and arRP, depending 
on the specific mutation involved. Mutations in the rhodopsin gene for example, although they 
cause the majority of adRP cases (Fig. 5A), can also account for a small percentage of arRP 
cases. Genes involved in RP are in some cases causing also syndromic forms of RP or other 
retinal degeneration. As an example, recessive mutations of the usherin gene USH2A can 
cause Usher syndrome but also underlie a large fraction of non-syndromic arRP cases.  
Taken individually, the mutations in RP genes are very rare in the general population (minor 
allele frequency < 0.01) and they are usually highly penetrant, consistently with a mendelian 
monogenic disease [6]. However, low penetrance mutations and modifiers genes have been 
reported to play a role in RP and may even contribute to a large fraction of unresolved cases 
[13, 14]. The remarkable genetic and allelic variability of RP implies that each gene, with the 
exception of the most frequently mutated ones (RPGR, RHO and USH2A), contributes only to 
a small percentage of cases, and each allele - or particular mutation - even less. This has 
important consequences in the identifications of causal genes for diagnostics and also for the 
discovery of novel disease genes, which are predicted to underlie most of RP cases that still 
lack a molecular diagnosis.  
The high number of recessive alleles, each one contributing to a small fraction of RP cases, 
implies also a high number of carriers in the healthy population. If we consider the totality of 
recessive RP mutations in all known genes, it results that at least one unaffected individual out 
of five carries a null RP mutation in heterozygous state. Nevertheless, RP is still a rare disease 
because the chance of having two mutations in the same RP gene is very low, and digenic 
inheritance is a rather infrequent mechanism [9, 15]. 
From the functional point of view, the classes of gene products implicated in of RP are also 
very heterogeneous. Many disease genes encode for proteins important for the specific 
functions and structures of rods photoreceptors, or can be also present in cones and RPE. 
These include proteins of the phototransduction cascade and signaling (RHO, PDE, GUCA1B, 
CNGA1, CNGB1, SAG), cytoskeleton proteins of the outer segment (RDS, ROM1), proteins of 
the connecting cilium (C2orf71, C8orf37, CLRN1, FAM161A, MAK, OFD1, RP1, RP2, RPGR, 
TTC8, TULP1, USH2A) and retina specific transcription factors (NRL, NR2E3, CRX) (Table 
1). RP causing genes that are expressed in the RPE are involved in retinol metabolism and 
phagocytosis of the discs of the outer segment. Other RP genes do not localize specifically to 
the photoreceptors, but participate in more ubiquitous processes of all eukaryotic cells such as 
intermediate metabolism and pre-mRNA splicing. However, these processes are particularly 
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relevant for photoreceptors, which need intense activity of mRNA and protein synthesis for a 
massive production of proteins (rhodopsin, among all), therefore requiring high energy 
production and high rate and high fidelity of transcript processing. 
Mutations in splicing factor genes have particular relevance in dominant RP, as they represent 
a large fraction of cases, second only to mutations in the rhodopsin gene (Fig. 5A). Moreover, 
among the functional categories of RP genes (as defined in Table 1), this is the largest one 
(Fig. 5B). It is therefore very likely that mutations in other genes belonging to this family 
may provoke RP. This is the assumption that drove the candidate gene screenings described in 
this research thesis.   
 
 
A B  
Figure 5. Genes causing autosomal dominant RP. A) Contribution of each gene to adRP cases [7]. B) Functional 
classification of genes causing adRP, according to [6]. 
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2.  SPLICING DEFECTS IN DOMINANT RETINITS PIGMENTOSA 
2.1 The splicing machinery 
2.1.1 Splicing catalysis 
In the vast majority of eukaryotic genes, the protein-coding sequences, located in exons, are 
interrupted by non-coding regions, the introns, which are removed from the primary transcript 
(pre-mRNA) by the process of RNA splicing. On average, mammalian genes have 7-8 exons, 
of relatively short length (10-400 bp) and intervening introns that can be several kilobases 
long. The evolutionary meaning of such architecture can be linked to the role of exons in the 
creation of new genes by their duplication and diversification, each one representing a 
functional block [16]. In higher eukaryotes this allows obtaining different protein products 
staring from the same transcript, according to specific conditions or tissues. This process is 
called alternative splicing and concerns 90% of human intron-containing transcripts [17]. 
Splicing occurs in the nucleus, together with other modifications of the pre-mRNA: the 
capping at the 5’ end and the polyadenylation at the 3’ end. After this, the mature RNA is 
transported to the cytoplasm where can be translated. The specific removal of introns is 
ensured by cis-acting elements, i.e. consensus sequences and recognition sites, and trans-
acting elements, i.e. the proteins composing the splicing machinery.  
The consensus sequences necessary for intron removal are very short and conserved. They are 
located in the immediate surrounding of exon-inton boundaries and they define the splice sites 
(ss). The consensus sequence of the 5’ ss, or donor site, is agGURAGU (exonic nucleotides 
are in lower case), while the 3’ ss, or acceptor site is defined by the sequence YAG. The GU 
and AG nucleotides are the most conserved elements among all introns. In metazoans, the 
other important recognition sequences in the introns are the stretch of pyrymidines that 
precedes the 3’ ss and the so-called branch site (consensus YNCURAC), 18-40 nucleotides 
upstream the 3’ ss. In yeast, these consensus sequences are less degenerated and more 
conserved (Fig. 6B) [18]. 
The excision of the introns and joining of contiguous exons are achieved by two 
transesterification reactions (Fig. 6A). In the first step, a cut at the 5’ ss separates the left exon 
from the right intron-exon molecule, whose new 5’ end binds to the 2’ –OH of the adenylated 
residue of the branch-site. Such structure is called lariat, because of its shape, and is formed 
by the nucleophilic attack of the 2-OH to the 5’ss, resulting in the atypical phosphodiesterase 
bond 5’-2’ inside the intron. In the second step, the cleavage at the 3’ss releases the intron in 
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its lariat form and at the same time the two exons are joined together. This occurs through 
another nucleophilic attack by the 3’-OH of the 5’ exon to the 3’ss.  
RNA alone can catalyze the chemical reactions of splicing, since the transestereification 
reactions disrupt and create the same number of bounds with no energy consumption. This is 
well demonstrated by the existence of self-splicing RNAs [19]. However, the process needs to 
be fueled and coordinated by trans-acting elements, which are organized in a dynamic 
machinery [20]. They help cis-elements to come in close proximity for the reactions to take 
place and have a fundamental role in insuring accuracy, speed and regulation of intron 
removals. Trans-acting elements are both proteins and small RNA molecules, which form an 
elaborate network of dynamic interactions within a complex known as spliceosome. 
 
Figure 6. Pre-mRNA splicing of U2-type introns. A) Scheme of the two transesterification reactions necessary 
for intron removal. E= exon, A=branch point, p=phosphate groups of the splice sites (SS). B) Consensus 
sequences at the splice sites and branch site in metazoans and S. cerevisiae. Y=pyrimidine, R=purine. C) Steps of 
spliceosome assembly and disassembly during splicing. It is indicated when the DExH/D-box RNA 
ATPases/helicases are required for conformational rearrangements. Taken from [23].  
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2.1.2 Spliceosome assembly 
The splice sites and branch sites sequences are recognized by the components of the 
spliceosome, which assembles on the pre-mRNA in an ordered and stepwise manner, before 
the two splicing reactions occur. The core components of the spliceosome are five uridine-rich 
small nuclear ribonucleoproteins (snRNPs) – U1, U2, U4, U5, and U6. Each one of these 
particles is composed of one small nuclear RNA (snRNA) molecule, and eight associated 
proteins (Sm proteins) that are common to all five snRNPs. A small fraction of introns found 
in vertebrates and invertebrates (only 800 in humans [21]) have different cis elements that 
need another type of machinery for their removal. This is the so-called minor spliceosome (or 
U12 dependent spliceosome), to differentiate it from the major spliceosome (or U2-dependent 
spliceosome), and contains different homologous snRNPs: U11, U12, U4atac, U6atac [22]). 
Additionally, each snRNP has a set of exclusively associated proteins, which are 70 in total, 
plus another 30 proteins that join at different stages. Once assembled, the spliceosome is a 
massive (12 MDa) complex, which resembles the ribosome for size and composition.  
The first step of spliceosome assembly (Fig. 6C) is the recognition of the 5’ss by the U1 
snRNP via the base paring of the consensus sequence within the splice site and the 5’ hanging 
end of the U1 snRNA (complex E, for early pre-splicing). In the second stage, complex A is 
formed when U2 snRNP binds to the branch site, also by sequence complementarity between 
the two RNA elements. From this step on, the pre-mRNA is committed to splicing and the 
different rearrangements require ATP hydrolysis. Binding of the pre-assembled U4/U6.U5 
(so-called tri-snRNP) complex converts complex A to complex B, which is activated (Bact) 
after conformational rearrangements that lead to the release of U1 and U4 from the complex. 
This event is due to the active disruption of the extensive base pairing engaged within the 
snRNAs of U4 and U6, allowing this latter to bind to the U2 snRNA instead, and bringing the 
two splice sites in juxtaposition. The catalytic active site is now created and transesterification 
reactions can occur (complex C). The spliced mRNA is released at first and after the 
disassembly of the U2/U6 and U5 complex, also the lariat is released, linearized and degraded.  
In addition to the snRNPs, many proteins are involved in splicing processes: some of them 
have a direct role in splicing catalysis, but the majority of them is important for the 
conformational changes within snRNPs and regulation of spliceosome assembly. Some well-
characterized proteins belong for example to the SR family, an important group of Arg-Ser 
rich splicing factors and regulators, important for the recognition of the splice site and 
formation of the early spliceosome complex [18].  
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Another class of proteins is composed of DExH/D-box RNA ATPases/helicases (in yeast: 
Prp5, Sub2/UAP56, Prp28, Brr2, Prp2, Prp16, Prp22 and Prp43), essential for timing and 
fidelity of the splicing process. They unwind short RNA helices in ATP-dependent manner 
and promote structural rearrangements of RNA and RNA-protein substrates [24]. 
Mutational and biochemical studies performed in the S. cerevisiae have identified and 
elucidated the function of the fundamental proteins for the correct functioning and dynamics 
of the splicing machinery, which are largely conserved in metazoans. Some of the genes 
encoding for these proteins have been found to be mutated in humans and to give rise to 
diseases. 
2.1.2 Splicing and human diseases 
According to the Human Genome Mutation Database (HGMD), 15% of reported mutations 
are predicted, and in some instances confirmed, to interfere with splicing of the affected 
transcript since they disrupt or create splicing consensus sequences [25]. In most cases cis-
acting splicing mutations reduce or disrupt 5’ or 3’ ss strength and determine exon skipping or, 
less frequently, intron retention. Other mutations can activate cryptic splice sites that normally 
are not used. The final effect is often the disruption of the frame of the translation and the 
creation of a premature termination codon [21].  
Conversely, trans-acting mutations affecting proteins that are part of the splicing machinery 
are much less frequent, probably because they undergo selection due to early lethality 
phenotype. Alterations of expression of several splicing factors have been frequently found in 
cancer, and recurrent somatic mutations affecting spliceosome components have been found in 
different kinds of leukemia [26]. Splicing factor mutations have been reported for a number of 
inheritable neurodegenerative diseases such as spinal muscular athophy (SMA), myotonic 
dystrophy (DM) and retinitis pigmentosa. In SMA, motoneurons are specifically affected due 
to mutations or deletions of the SMN1 gene, important for the assembly of snRNPs [27]. In 
DM, microsatellite expansions in untranslated regions of DMPK and ZNF9 genes determine 
toxic gain of function of the mRNAs, which sequesters the MBNL splicing regulator, leading 
to splicing defects [28]. Finally, an emerging group of Mendelian pathologies caused by 
splicing factors is composed of craniofacial syndromic malformations like Nager syndrome 
[29], mandibulofacial dysostosis (MD) [30] and oesophageal atresia (OA) [31].  
However, the most studied splicing factor-linked disease is autosomal dominant RP, for which 
mutations in genes of the U4/U6.U5 tri-snRNP complex account for 11% of all cases. 
 26 
2.2 Pre-mRNA splicing factors and autosomal dominant retinitis 
pigmentosa (adRP) 
 
2.2.1 AdRP-linked tri-snRNP components and mutations 
 
Figure 7. Scheme of protein-protein interactions within the human tri-snRNP. The dots indicate demonstrated 
interactions between proteins. Modified from [32].  
 
So far, six splicing factors have been found mutated in adRP patients: PRPF31 (RP11) [33], 
PRPF8 (RP13) [34], PRPF3 (RP18) [35], PAP-1 (RP9) [36], SNRNP200 (RP33) [37, 38] and 
PRPF6 [39]. They are all components of the U4/U6.U5 tri-snRNP complex (Fig. 7), which is 
assembled before its recruitment on the complex A. 
PRPF31 is the most frequently mutated RP gene among the splicing factor category, the 
second most common of all dominant cases [7, 40]. It was discovered by screening families 
with adRP linked to the RP11 locus on chromosome 19 [13, 33]. More than 60 mutations in 
several exons, including missense, frameshift, deletion, nonsense and splice site changes have 
been identified, but a recurrent mechanism of haploinsufficiency seems to be the main way of 
action of PRPF31 mutations [41]. This is related to another particular feature of PRPF31-
linked RP, which is the correlation of the phenotype with the expression level of the wild type 
protein [42] [43]. Within a same family, carriers of PRPF31 mutations can either be 
asymptomatic lifelong or be severely affected at young age, because of a mechanism of 
incomplete penetrance [13]. PRPF31 encodes a 61-kDa protein homologous to yeast Prp31p, a 
stable component of the U4/U6 di-snRNP. In yeast, it plays a key role in the recruitment of the 
PAP-1 
 27 
tri-snRNP on the pre-spliceosome [44] and in humans is required for the tri-snRNP assembly 
and spliceosome activity [45]. Silencing of PRPF31 in HeLa cells was shown to inhibit tri-
snRNP assembly, which accumulates in Cajal bodies and block pre-mRNA splicing, 
eventually leading to cell death [46]. The complete depletion of Prp31p in yeast [44], mouse 
[47] and zebrafish [48] is lethal. 
The PRPF8 gene was identified as causative for adRP after the discovery of the RP13 locus by 
linkage mapping [34, 49]. Mutations of the PRPF8 gene determine a severe phenotype with 
early onset of night blindness and considerable reduction of the visual field. Although the 
phenotype is relatively uniform, it was lately reported that two families with adRP linked to 
two different PRPF8 mutations showed variability in RP phenotype and incomplete 
penetrance, respectively [50]. The human PRPF8 protein, similarly to the yeast ortologous 
Prpf8p, is the core of the U5 snRNP: it interacts with all main pre-RNA splicing signals (5’ 
and 3’ ss as well as the branch site) and mediates interactions among the spliceosomal 
components, coordinating the rearrangements necessary for the formation of the catalytic 
centre. Moreover, it is required for the formation of the U4/U6.U5 tri-snRNP [51]. PRPF8 
residues affected by RP mutations cluster in exon 42, encoding for the C terminal of the 
protein [52, 53]. This region was demonstrated to interact with an ATP-dependent helicase, 
Brr2p in yeast [54], hBrr2 in humans [55]. This 200-kDa enzyme is composed of two tandem 
helicase domains and is essential for the unwinding of the U4/U6 RNA duplex, which is the 
key step for the formation of the catalytic complex. Crystal structure of a hBrr2 fragment in 
complex with PRPF8 C-terminal domain demonstrated that PRPF8 extreme tail inserts into 
hBrr2’s RNA-binding pocket, serving as an intermittent repressor of its ATPase activity and 
probably preventing premature unwinding of U4/U6 [56]. In the same study the authors also 
correlate the position of PRPF8 point mutations with molecular mechanisms involved in 
splicing impairment. Mutations located in the proximal part of the C- terminal domain were 
shown to inhibit U4/U6-U5 tri-snRNP formation, because of a reduced solubility or reduced 
affinity for Brr2 [54, 57]. Conversely, mutations located in the most extreme terminal do not 
interfere with U4/U6-U5 tri-snRNP formation but disrupt PRPF8 repression on hBrr2. 
Very interestingly, hBrr2 has been recently implicated in retinitis pigmentosa. The 
SNRNP200 locus, encoding for hBrr2, was discovered in a Chinese family, after linkage 
analysis pointing to the RP-33 locus on chromosome 2 [37, 38, 58]. RP33-linked family 
presented with variable RP phenotypes with relatively late onset of night blindness (16-18 
years), and a full penetrant, autosomal dominant inheritance. The first two mutations found in 
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two Chinese families (S1087L and R1090L) locate to the ratchet helix of the first helicase 
domain and were shown to impair Brr2 mediated U4/U6 unwinding [38]. Other mutated 
residues are located in different regions of the first helicase domain [59] and may be 
important for the stabilization of domains folding [60].  
PRPF3 mutations were identified in adRP families with linkage to the RP18 locus [35]. 
PRPF3 protein is specifically associated with the U4/U6 snRNP and interacts with another 
splicing factor, PRPF4. It is required for the assembly and activation of the spliceosome, 
although its specific role is not yet clear [61]. Overexpressed PRPF3 proteins carrying the 
hotspot mutation T494M in photoreceptor cells form large aggregates inside the nucleus that 
lead to apoptosis of photoreceptor cells, but not of epithelial or fibroblast cells [62]. The three 
missense mutations identified so far cluster to a conserved C-terminal domain, next to binding 
sites for other splicing factors. PAP-1 is one of these interactors, but its precise function is 
currently not known [63]. This gene was found to be involved in adRP as well, mapping to 
the RP9 locus [36, 64] and two mutations were found. Also in the case of RP9 mutations, 
variability in phenotype expressivity and incomplete penetrance were observed [65]. 
PRPF6 is the latest tri-snRNP associated gene found to be causative for adRP [39]. The 
protein is thought to have a role in protein scaffolding between the U5 snRNP and the U4/U5 
di snRNP [66]. The mutation was identified by a candidate gene screening study on a cohort 
of American adRP patients and it was shown to cause accumulation of the mutated proteins 
within the Cajal bodies in the nucleus of patients’ lymphoblasts and HeLa cells transfected 
with the mutated construct. A possible impairment in the tri-snRNP assembly or recycling 
was suggested [39].  
Independently from the way of action of each mutation, the final effect of tri-snRNP 
associated mutations is the specific degeneration of rod photoreceptors. 
 
2.2.3 Why the retina?  
Considerable effort has been put in the elucidation of the mechanisms that would link 
mutations in the essential and ubiquitously expressed protein of the tri-snRNP complex to 
retina-specific phenotypes. Two main hypotheses have been addressed: one implies that RP 
mutations would affect splicing in the retina by disruption of specific protein-protein 
interaction or by affecting retina specific transcripts. A second one sees RP as a disease 
triggered by the lower threshold of tolerance for splicing defects in photoreceptor cells 
compared to other tissues. 
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Experimental approaches aimed at studying the effects of these mutations include the use of 
biochemistry techniques, in vitro assays for splicing efficiency assessment and animal 
models. Two knock-in mice for PRPF3 and PRPF8 missense mutations and a heterozygous 
knockout mouse mimicking haploinsufficient PRPF31 mutations were generated, but did not 
provide conclusive mechanistic answer. Mice showed a certain degree of retinal degeneration, 
primarily affecting the RPE with a late onest, especially for PRPF31 mouse model [47, 67]. 
Analysis of the eyes of a zebrafish model of PRPF31 knockdown showed defects in 
photoreceptors morphology and visual processing, and a down-regulation of retina-specific 
mRNAs, supporting the hypothesis that reduced levels of tri-snRNP proteins could 
specifically affect the splicing of genes important for retinal functions [48]. However, a 
control transcriptomic analysis from a non-retina tissue was not provided. In other studies, 
which used as disease model lymphoblastoid cell lines from human patients with mutations in 
PRPF3, 31, and 8, aberrant splice products were detected in transcripts that do not relate with 
functions in the retina [68]. Also, in the same non-retina model, they observed impairments in 
spliceosome kinetics of assembly, protein and snRNPs composition, and in alternative 
splicing. These evidences suggest that general splicing defects are likely present in all tissues, 
but have deleterious effects only in the retina, as a consequence of its higher requirement for 
splicing with respect to the other tissues. This is supported by the fact that retina is the tissue 
in which a highest number of spliced genes is maximally expressed [68] including the PRPF 
genes themselves [69].   
In agreement with this ‘threshold’ model, most of PRPF mutations seem to be hypomorphic, 
having as consequence a reduction in the quantity or in the activity of the proteins, rather than 
acting through dominant negative mechanisms. This is also supported by the many cases of 
incomplete penetrance - mainly associated to PRPF31 - in which compensatory mechanisms 
for the function impairments have been observed [42].  
Other non-verified hypotheses invoke unknown retina-specific functions or interactions of 
RP-linked splicing factors. 
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3. NEXT GENERATION SEQUENCING AS A NEW TOOL FOR GENE 
DISCOVERY IN RP  
3.1 Next generation sequencing methods  
3.1.1 Novelty and applications 
The recent breakthrough in genetics since 2005 [70] has been the radical change of DNA 
sequencing methods. Next generation sequencing (NGS), ultra high throughput sequencing 
(UHTS) and massive parallel sequencing (MPS) are the terms designating such technologies. 
As their names suggest, the major novelty with respect to the Sanger sequencing - or dideoxy 
- method [71], which dominated the field since the 70s, is their extraordinary sequencing 
capacity and speed, currently associated with a 10,000 times lower per base cost [72]. As 
most paradigmatic example, the human genome can be sequenced now in about a few weeks 
of work, starting from a few micrograms DNA and a single sequencer machine, for less than 
10 thousand dollars. Only 10 years ago, the sequencing of the human genome with traditional 
methods was achieved by a joint effort lasted 10 years and costed about 300 million dollars 
[73] [74] [75]. The possibilities offered by the huge throughput and low price of NGS are not 
limited to assemble genomes or to answer to “static” genetic questions, but inspired also a 
wide range of more “dynamic” applications, aimed at a better understanding of certain 
biological processes at the cell level. These latter applications include RNA-seq (sequencing 
of trasnscriptomes), ChIP-seq (sequencing of DNA fragment interacting with proteins), 
TRAP (purification of polysomal mRNA), Ribo-Seq (sequencing of ribosome-protected 
mRNA fragments), and many others [76]. 
Focusing back on human genetics questions, NGS transformed the approaches to comprehend 
the genetic basis of monogenic and complex diseases or cancer, with increasing 
implementation also in clinical diagnosis and in development of targeted therapies in the near 
future [77, 78]. NGS-based gene hunting has been particularly successful in identification of 
new genes associated to rare disorders and is predicted to solve most of Mendelian disorders 
in the next decade [79, 80]. Due to constant drop in costs, the sequencing of whole genomes 
(WGS) or whole known exonic sequences (WES) of an individual will probably replace all 
targeted approaches for gene identification (NGS based or not), such as sequencing of genes 
in large cohorts of patients or sequencing a linkage interval [81]. However, important ethical 
and practical issues still encourage many scientists to opt for targeted sequencing strategies. 
Among the practical issues, the bioinformatic analysis costs and knowledge represent one of 
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the main obstacles for whole-genome/exome approaches to become routine tools in research 
or diagnostic laboratories. Moreover, the analysis of a very restricted portion of the genome 
has the advantage to be more accurate, because each targeted region would be covered by a 
higher number of sequences than a whole exome or genome (the concept of coverage will be 
elucidated in the following section). Therefore, a series of DNA enrichment tools have been 
developed and commercialized to adapt the sequencing of small genomic portions to the 
incredible capacity of NGS instruments [82]. A review of these methods and examples of 
targeted approaches that I used in my study can be found in the publication section.  
 
3.1.2 Chemistry 
The “magic” of NGS relies on workflows leading to the sequencing of many templates in 
parallel. This is obtained through strategies based on cyclic-array sequencing, which is the 
sequencing of a dense array of DNA molecules by means of repetitive enzymatic reactions, 
and collection of data in the form of images [83]. First, DNA is randomly sheared into 
fragments of few hundred nucleotides, then fragments are ligated to universal adapters where 
primers for subsequent PCR amplification will anchor. The clonal amplification of these 
fragments is obtained using different approaches: emulsion PCR (used for instance by the 454-
Roche and the SOLiD-Life Technologies systems) or bridge PCR (used by the Solexa-
Illumina system). The first method is based on the amplification of single templates attached 
to beads in a water-in oil mixture, which are then distributed on a microarray of picoliters 
wells (Fig. 8A). The second method relies on PCR reactions occurring on a glass slide where 
primers are attached, generating clusters containing about 1000 copies of the same DNA 
fragment (Fig. 8B) [84]. 
 
Figure 8. Schematic explanation of library amplification by the method of A) emulsion PCR and B) bridge PCR. 
From [84] 
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The cyclic reactions used for sequencing of such clusters of DNA clones employ different 
enzymatic processes. The 454-Roche instruments use pyrosequencing reactions, in which at 
each cycle, a single nucleotide species is added together with the substrate for the production 
of light when pyrophosphate is released, at wells where the incorporation of the base occurred 
(Fig. 9A) [70]. With the Solexa-Illumina instruments, a modified version of the Sanger 
method, using reversible-terminator, fluorescence-labeled dNTPs is implemented on a array 
setting (Fig. 9B) [85, 86]. As a last example, the SOLiD-Life technologies platforms employ 
yet another method, based on the ligation of fluorescently labeled octamers which anneal to 
the template with the 2 central bases, in multiple cycles of ligation and cleavage (Fig. 9C) 
[87].  
 
 
Figure 9 Examples of three different methods used in high throughput sequencing platforms: A) pyrosequencing, 
B) reversible terminators sequencing by synthesis, C) two-base encoding ligation method. From [84] 
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3.2 Definitions and interpretation of results 
The analysis and interpretation of the data generated by NGS platforms require a certain 
familiarity with bioniformatic methods. This knowledge is rapidly diffusing also in 
laboratories and centers that are not specialized in computational biology, due to the 
progressive accessibility of NGS and to the development of bioniformatic pipelines with a 
graphic interface. The workflow for analysis of sequencing data generally follows the steps of 
alignment of the sequences and identification of differences between the sample and the 
reference, which in the context of medical genetics is important in order to identify 
pathogenic mutations. A summary of the terminology and the methods used in a NGS typical 
workflow for variation detection is listed below. 
Reads. A list of sequence reads (or just reads) is the usable output of NGS sequencers, 
computed after the conversion of images into nucleotides. NGS reads are shorter than Sanger 
reads, since their length ranges between 50 and 400 nucleotides, depending on the platform 
used. The ambiguity that can derive from assembly of shorter reads is one of the weakest 
points of NGS with respect to Sanger sequencing. An improvement in the mapping of short 
reads is obtained with paired end reads, which, in contrast to single end reads, derive from 
both ends of a library of DNA fragments. The length of such fragment is known (generally 
300-500 nucleotides) and helps to locate the paired sequences with respect to each other, as 
well as to detect insertion or deletions.  
Accuracy. Each base listed in the output file - usually in a FASTQ format - is provided in 
association with a quality value, calculated upon parameters relevant to a particular 
sequencing chemistry. The accuracy of a base call is expressed with a Phred score, which 
indicates the probability that a base call is incorrect, with a logarithmic relation. For example 
a Phred of 30, which is the benchmark for quality in NGS, indicates a 1 in 1000 probability of 
incorrect base call, or, a 99.9% accuracy [88, 89]. 
Mapping. Alignment or mapping of the reads onto a genomic reference sequence is the first 
step in re-sequencing analyses. In absence of a reference genome for a given organism or 
gene, a de novo assembly of reads into a contig (i.e. a consensus DNA sequence) can be 
performed, but this is obviously more challenging than mapping each read to a known 
reference. Alignment algorithms can be generally classified as global or local. In the first case 
an optimal alignment between the reference and the full length of the read is searched, 
whereas in the second case highly similar sequences within a read are aligned to the reference 
even if some parts of it do not align. This is very useful for NGS in which base quality drops 
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at the ending of a read, and it is possible to automatically remove the non-matching errors at 
the end of the reads. Algorithms can be further categorized in gapped or un-gapped by 
whether they allow gaps in the sequences or not. Some commonly used open source programs 
for short reads alignments are: BWA, Bowtie, SOAP and MAQ. Others, commercially 
available, are Novoalign and CLC Genomics. 
Coverage. A single read is not sufficient to determine accurately the sequence of the DNA of 
interest: it will contain an error at every given base (1000 if we consider a good Phred of 30, 
as mentioned before). To insure a reliable contig, and to allow confident identification of 
DNA variants, the target DNA must be sequenced at a higher depth or coverage, a safe 
threshold being at least 40 reads on average [90]. Different instruments have different 
throughputs, which adapt to a variety of applications requiring more or less coverage, 
depending on the size of the target DNA or on the number of samples to be sequenced. If 
more coverage is needed, multiple sequencing runs can be performed, if the target DNA is 
small, multiple samples can be sequenced in a same run. 
Variant calling. After the alignment step, the sample DNA can be compared to the reference 
genome and differences can be identified. A major challenge is to distinguish between true 
variations and sequencing or mapping errors, which can be rather common especially in 
difficult sequence contexts like GC-rich or repetitive regions. An increase of coverage is 
usually sufficient to determine most of single nucleotide substitutions with high confidence, 
while it is not easy to correctly identify insertions and deletions (indels), especially if they are 
longer than a few nucleotides. Structural variants - including indels, copy number variations, 
inversions and translocations - present some difficulties for mapping algorithms, which must 
be able to integrate the presence of a big difference and still align it to the reference. Other 
parameters are taken into account for the identification of larger rearrangements and include 
significant alterations in the coverage or in the insert size in case of paired-end reads.  
Filtering and annotation. Finally, the search of pathogenic variants is based on quality and 
functional criteria. Variants can be annotated with a number of elements such as predicted 
consequences at the protein level, presence in public polymorphism databases and position 
within the transcript. Annotation and filtering can be manual in case of short DNA sequences, 
but requires automatic procedures for analysis of large DNA sequences like exomes or 
genomes.  
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3.3 Implementation of NGS technology in RP genetic research and 
diagnostic  
About half of cases diagnosed with RP have unsolved molecular diagnosis, since their 
screening for known RP genes has resulted negative [7]. It is likely that a large part of this 
estimate is composed by novel mutations in known genes. In fact, Sanger sequencing-based 
screenings of known genes is often restricted to the coding sequence or even only to 
mutational hotspots. Intronic mutations are therefore likely to be missed, although it has been 
shown that they can play a role in the pathogenesis of RP ([91, 92]. Mutation microarrays 
(arrayed primer extension or APEX- technologies) are useful to pre-screen patients for known 
mutations, but again novel base changes cannot be excluded [93]. Due to the lower costs and 
shorter time associated with NGS strategies, it is now possible to create sequencing panels of 
genes known to cause RP or other retinal degenerations. This is very useful in a clinical 
setting where many samples need to be processed in a short time and more importantly it can 
help to distinguish between different retinal degeneration types, whose phenotype is often 
overlapping [94-97].  
The detection of novel disease genes is hampered by the genetic hetherogeneity of RP. 
Mutations in novel genes are in fact predicted to be very rare, although their number is hard to 
estimate [12]. A successful method that has led to the discovery of novel RP genes also in 
recent years has been linkage analysis or homozygosity mapping, very powerful in case of 
families with consanguinity history or originating from an isolated geographical region. 
However, the majority of RP cases are sporadic, therefore not suitable for linkage analysis. 
Genome-wide approaches like whole exome sequencing have already proven to be very 
effective methods to discover novel RP genes, also in absence of a linkage interval to guide 
the analysis [98]. On the other hand, whole genome sequencing is useful to detect changes 
lying outside commonly analyzed regions like intronic changes or structural variations. Such 
powerful methods, combined with novel approaches for analysis - for example by considering 
also non-monogenic or non-Mendelian mode of inheritance - will likely help to uncover the 
“missing heritability” of RP. 
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Project 1: Comparison of NGS platforms in the detection of human DNA 
variants 
 
One of the first questions that we wanted to address about the use of NGS technologies was to 
determine which platform is the most suitable for analyzing human genes and variations. We 
specifically aimed at testing the three main platforms described in the introduction in a 
routine workflow of gene and variations analysis, by means of a user-friendly bioinformatic 
tool. The input for the project was given by the discovery of an RP dominant mutation with 
reduced penetrance, found within an intronic repetitive region of the PRPF31 gene. This 
mutation was in fact missed by a first NGS experiment in our laboratory, because short reads 
could not uniquely align to repetitive sequences. Given this challenging peculiarity we 
considered it as a good benchmark for a comparative analysis. Furthermore, it gives an 
example of a mutation located in those non-coding regions that are normally excluded by the 
classical exon-PCR Sanger sequencing, but which should become more accessible thanks to 
NGS.  
As template for sequencing, we used a pool of 4 long-range PCR products encompassing the 
entire gene and its vicinities, which represents the simplest and most unbiased strategy to 
target a limited region of the genome for NGS. The sequences obtained from the three 
different platforms were analyzed by a commercial software, which did not require specific 
competence in programming and allowed to treat the different outputs in a uniform way. For 
comparison purposes, we evaluated several technical aspects of the different platforms 
including the number of sequences produced, average coverage obtained, read accuracy, 
mapping accuracy, variant detection efficiency (SNPs, indels, mutation), and alignment to the 
repetitive element. We concluded that, at least for the specific region analyzed, all sequencing 
methods performed very well and that they could all be safely and efficiently used as a tool 
for the detection of targeted human DNA variations. 
This study was published as “Ultra high throughput sequencing in human DNA variation 
detection: a comparative study on the NDUFA3-PRPF31 region”, in PLoSONE journal on 
September 29, 2010. 
 
Candidate’s roles: 
• Design and execution of the bioinformatic analyses. 
• Writing of the manuscript. 
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resequencing projects.
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Introduction
The recent commercialization of ultra high throughput
sequencing (UHTS) technologies, initially applied to the de novo
characterization of small genomes, is rapidly challenging the
classical methods of human genetic research as well. The
possibility of obtaining nucleotide sequences in the range of
hundreds of millions base pairs from various types of DNA
templates allows for example to extend mutational screenings to
very large portions of the genome, an experimental strategy that
would be too expensive and time consuming to perform with
methods based on the Sanger procedure [1]. Thanks to UHTS,
intronic and non-coding regions as well can theoretically be
included in routine resequencing processes (i.e. the analysis of a
DNA region for which a reference sequence is already known) of a
particular candidate gene or linkage interval, with minimal
additional costs and by a more complete approach with respect
to classical exon-PCR and sequencing.
However, these ‘‘next-generation’’ technologies still have some
limitations that must be taken into account. A well-recognized
problem associated with the mapping of UHTS sequences is
represented by the presence of repetitive elements or low-
complexity stretches to which short UHTS reads cannot uniquely
align [2,3]. To simplify assembly procedures of short sequencing
reads, these DNA segments are therefore generally excluded, with
the consequence of missing important disease-associated variants
present in intronic or extra-genic areas.
Recently, we discovered a mutation (c.1347+654C.G) in one
of these particular regions of the human genome associated with
dominant retinitis pigmentosa, an hereditary blinding disease [4].
This single-base substitution is comprised in a repetitive element
(variable number of tandem repeats, or VNTR) located within an
intron of the PRPF31 gene. As a proof of concept for UHTS to be
used in routine human genetic screenings, we sequenced 31 kb of
the human chromosome 19 encompassing the PRPF31 region in a
patient with this rare mutation as well as several common SNPs.
For comparative purposes, we used the three currently most
widespread UHTS platforms: Roche/454 GS FLX Titanium
(Roche 454), Illumina/Solexa Genome Analyzer II (Illumina GA)
and Applied Biosystems/SOLiD 3 (ABI SOLiD) instruments.
The Roche 454 technology is based on the clonal amplification
of DNA fragments attached on individual beads in an emulsified
PCR reaction. The beads are distributed on a 1.6 million wells
substrate (PicoTiterPlateTM) where pyrosequencing reactions
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e13071
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occur [5]. The most noticeable advantage of the Roche 454
platform is the large size of the reads produced (up to 500 nt),
while Illumina GA and ABI SOLiD produce shorter reads (34 and
50 nt, at the time this research was performed). In the Illumina
GA system the amplification step is achieved on the glass surface
that covers the flow cell (bridge amplification) and the sequencing
reactions are performed by using the ‘‘reversible terminator’’
chemistry [6]. ABI SOLiD is similar to Roche 454 in the
amplification step (emulsified beads) but is unique for its ligase-
dependent sequencing chemistry, based on multiple cycles of
hybridization and ligation. The main advantage of ABI SOLiD is
constituted by the possibility of reading each base twice by
independent events, which provides internal error correction and
enables higher accuracy, especially in SNP calling [7].
Materials and Methods
Ethics statement
This study was carried out in accordance with the tenets of the
Declaration of Helsinki and was approved by the Institutional
Review Boards of our University and of Harvard Medical School,
where the blood was collected and the cell line derived. Written
informed consent was obtained from the patient who participated
in this study and donated her blood for research.
Sample preparation
We extracted DNA from a lymphoblastoid cell line derived
from an affected individual carrying the PRPF31 c.1347+654C.G
mutation (cell line #13189) and amplified the 31-kb NDUFA3-
PRPF31 genomic region by 4 individually-amplified long-range
PCR, designed as previously described [4] (Fig. 1). We specifically
selected this region to have a well characterized reference
sequence to compare our experimental results to. The following
minor modifications were introduced to the original amplification
protocol. Each PCR was performed in a final reaction volume of
10 ml, containing 1X GC Buffer I (TaKaRa, Otsu, Shiga, Japan),
0.4 mM dNTPs, 0.2 mM primers (each), 0.5 U of TaKaRa LA
Taq (TaKaRa) and 100 ng of DNA. Such an amount of genomic
template DNA allows virtually eliminating the possibility that
errors introduced by the Taq polymerase are detected in
subsequent sequencing procedures. Reactions were incubated at
94uC for 1 min, followed by 35 cycles of 98uC for 5 sec and 68uC
for 17 min, and a final elongation step of 72uC for 10 min. After
agarose gel analysis and quantification, the four PCR fragments
were pooled together and processed for downstream applications.
Library preparation and sequencing
Preparation of DNA libraries was performed following the
guidelines provided by the manufacturers of each platform and
sequenced by using: 1/8 of a plate for the Roche 454 Genome
Sequencer FLX, Titanium series, 1 lane of an Illumina Genome
Analyzer version II, and 1 ‘‘quad’’ of an ABI SOLiD 3 instrument.
The exclusion of reads with very low quality was performed
automatically by the Roche 454 and Illumina GA sequencing
instruments, while for ABI SOLiD this had to be carried out a
posteriori with the ABI’s csfasta_quality_filter.pl application,
available from the SOLiD Software Development Community.
Alignment and analysis of reads
All analyses and statistics on quality-filtered reads were
performed using the relevant tools of the software package CLC
Genomics Workbench, version 3.7 (CLC bio, Denmark) as
described below.
Trimming. In this process the parts of the reads with low
quality scores were trimmed. The algorithm calculated base error
probabilities based on their quality values, normalized to a PHRED
scale. We set a cutoff value of 0.01, calculated as described in the
software package manual, and discarded trimmed reads below
20 nt of length, independently from their residual score.
Assembly. The original reads as well as the trimmed sets
were aligned to 31 kb of the corresponding reference sequence
(NC_000019.8: 59,297,572-59,328,826). To ensure uniformity, we
applied comparable settings to all platforms, considering the
different read length of each platform, inclusive of the color-space
option for the ABI SOLiD platform. Specifically, we used the local
gapped alignment algorithm for all alignments, keeping the default
parameters for mismatch and deletion costs. Reads that aligned to
more than one position of the reference sequence were discarded.
For the intronic repetitive DNA fragment we also re-assembled
the reads by using a de novo assembly procedure. The original reads
were first aligned onto the Sanger-obtained sequence of the region
by using the same parameters described above and by allowing
random matches of reads with multiple mapping positions.
Subsequently, we extracted the sequences that aligned to the
region and used them for de novo assembly with the same
parameters used for the reference assembly (no random matches).
Detection of variants. Variant detection was performed with
the SNP and INDEL detection tools. The settings for calling a
variant were described previously by Harismendy et al. [8]: if
heterozygous, 20%–80% of the reads covering a particular
nucleotide had to contain the alternative base with respect to the
reference sequence; if homozygous, more than 80% of the reads had
to contain the alternative allele. To test the limits of SNP detection,
discovery by setting a minimum variant threshold of 10% was also
performed. The minimum coverage allowed to call a SNP was of 15
reads for a given base. We applied the default restrictions on SNP
calling: the average quality of the central base was set to 20 (PHRED
score, corresponding to a base accuracy of 99%), the average quality
Figure 1. Schematic representation of the 31-kb genomic interval analyzed, containing the genes NDUFA3, TFTP, and PRPF31. Double-
headed arrows indicate the position of the 4 amplicons used as template for UHTS.
doi:10.1371/journal.pone.0013071.g001
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of the surrounding 10 bases was 20, and the maximum number of
mismatches or indels accepted within an 11-nt window was 3. Low
quality reads were removed from the calculation of SNP frequency
and coverage and the un-aligned parts of a read counted as
mismatches. We considered a variant as real if it was validated by
Sanger or, in absence of Sanger validation, if it was found in at least
one platform and previously annotated, or independently present in
at least 2 platforms and not annotated. For the detection of indels we
used the same criteria as for SNP detection.
Coverage simulation
We simulated different coverage depths by randomly sampling a
subset of the reads from the *.fastq files exported after the
trimming process. Each subset was sampled 3 times. Alignments to
the reference sequence were performed as described above for the
non-simulated sets of data. In order to have a balanced
representation of the 4 amplicons, we calculated the average
coverage at the level of the amplicons (and not of the entire region)
and joined the amplicons with the same average coverage,
considering them as a single (artificial) sampling event. For SNP
detection we maintained the same parameters as for the full
dataset, but with a minimum coverage of 5 and at least 2 reads
carrying the variant allele, to compensate for the reduced coverage
introduced by the simulations.
Sanger sequencing
Data from the Sanger sequencing of the PRPF31 gene were
available from previous analyses [4]. Additional SNPs located
outside of the PRPF31 gene were sequenced starting from the long-
range PCRs used as UHTS templates or from short-range PCRs
obtained using standard HotStartTaq DNA polymerase (Qiagen,
Venlo, The Netherlands) protocols. PCR products were enzimati-
cally purified using 1 ml ExoSAP-IT (USB, Cleveland, Ohio USA)
for 10-ml reactions, according to the manufacturer’s instructions.
Sequencing reactions were performed by mixing 5 ml of purified
PCR product, 0.75 mM of 20mer primers and 1 ul of BigDye
Terminator v1.1 cycle sequencing kit (Applied Biosystems, Foster
City, CA), and run on a ABI-3130XLS (Applied Biosystems).
Results
General considerations on the processing and analysis of
the reads
All computer-based analyses were performed with a commer-
cial, user-friendly software. This choice was taken in order to be as
close as possible to the setup of the average laboratory performing
routine genetic testing without the specific support of computer
analysts. The use of a simple pipeline, compatible with outputs
generated by different sequencing platforms, also allowed treating
the data in a uniform manner, thus eliminating possible biases
deriving from machine-specific software or algorithms.
Sequencing and trimming of the reads
For our analyses we used 1/8 of the total sequencing capabilities
of each machine. The Roche 454 platform (1 sector of the 8-sector
gasket) generated ,100,000 quality-passed reads with an average
length of 318 nt, Illumina GA (1 lane) ,4.6 million reads of 34 nt,
and ABI SOLiD (1 ‘‘quad’’) ,17,3 million reads of 50 nt,
corresponding to a throughput of ,32 Mb, ,157 Mb and
,862 Mb, respectively (Table 1). We did not consider the option
of using paired reads, since this technique would not provide any
justified benefits to the analyses made on our standard resequen-
cing project, given the absence of major genomic rearrangement
or the necessity of creating a de novo assembly.
All raw sequences underwent quality filtering procedures
consisting in the trimming of low quality nucleotides from the
reads. After this procedure, 27.2% of the bases from the original
throughput were discarded from the Roche 454 dataset, 12.4%
from the Illumina GA dataset, and 38.0% from the ABI SOLiD
dataset. However, despite the variable number of nucleotides that
were rejected, for all platforms the large majority of the reads
(.99.8%) were not eliminated, but simply shortened (Table 1, Fig.
S1). This outcome changed when, during the trimming procedure,
not only the quality of the reads, but also its length was considered.
By imposing a minimal size of 20 nt, following the rationale that
high-score reads of a few nucleotides are useless for practical
resequencing applications, Roche 454 was left with .99.6%,
Illumina GA with the 92.1%, and ABI SOLiD with the 78.7% of
the original number of reads, corresponding to a loss of 27.2%,
15.8%, and 43.5%, respectively, in terms of nucleotides.
Alignment to the targeted interval
Trimmed sequences, as well as un-trimmed ones, were mapped
to the reference sequence (ref_seq). Since the number and the
length of trimmed reads was lower with respect to raw reads, the
total amount of bases from trimmed sequences mapping to the
ref_seq was also lower. However, trimmed reads mapped to the
ref_seq in higher percents, as a consequence of their increased
content in high-quality bases, with the effect of producing in
principle more accurate consensus sequences (Table 2). These
Table 1. Sequence throughput obtained with the three UHTS platforms analyzed.
Sequencing
technology Reads Count Discarded reads
Average length
of a read (nt) Bases Trimmed bases
Roche 454 (1/8) Total (raw) 99,317 318 31,615,489
After trimming 99,317 0.00% 232 23,010,105 27.2%
After trimming (.20 nt) 98,975 0.34% 232 23,005,448 27.2%
Illumina GA (1 lane) Total (raw) 4,611,113 34 156,777,842
After trimming 4,610,388 0.02% 30 137,405,021 12.4%
After trimming (.20 nt) 4,245,639 7.9% 31 132,052,133 15.8%
ABI SOLiD (1 quad) Total (raw) 17,287,756 50 862,377,074
After trimming 17,287,610 0.00% 31 534,615,489 38.0%
After trimming (.201 nt) 13,597,456 21.3% 36 487,053,627 43.5%
doi:10.1371/journal.pone.0013071.t001
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observations were particularly relevant for Roche 454 and ABI
SOLiD alignments, rather than Illumina GA, since the latter was
less affected by the trimming process.
The selected interval was entirely covered using the three
datasets, with the exception of 2 very small gaps originating from
non-overlapping PCRs (Figs. 1 and 2), a 8-nucleotide gap (position
18,837-44 of the ref_seq) present in the assembled sequence from
Illumina GA reads, and 3 small gaps in long homopolymeric
stretches in the assembly of Roche 454’s trimmed reads (positions
9135-40, 9313-17, 10723-36). The VNTR present in intron 13 of
the PRPF31 gene also presented platform-specific gaps, as detailed
below.
Coverage varied depending on the specific LR-PCR product
analyzed, because of uneven loading of the individual PCR
products (Fig. 2). Similar to the effect of naturally-occurring copy
number variants (CNVs) or large-scale deletions, coverage across
the analyzed region displayed sudden changes, highlighting at the
same time the boundaries between different LR-PCR products.
Coverage also varied widely across platforms (Table S1), as a
direct effect of the different throughput of the 3 sequencers. High
coverage variation also occurred within the same PCR (coefficient
of variation for local alignments of untrimmed reads: 0.46 Roche
454, 0.41 Illumina GA, 0.56 ABI SOLiD, Table S1), with a strong
bias for the amplicons ends (Fig. 2), a well-known artifact of UHTS
[9]. As expected, the average coverage for each amplicon
decreased when trimmed sets were used, although it was still
much higher than the one required for confident ascertainment of
heterozygous genetic variations, estimated by others to be
approximately in the range of 10- to 40-fold [6,7,10,11]. In
downstream analyses, we kept saturating coverage values to ensure
a reliable comparison across platforms and to avoid differences
due to stochastic variations of single base coverage.
Read Accuracy
To evaluate the accuracy of a base call in each platform after
the alignment procedure, we used the ‘‘conservation’’ score,
generally used in relationship to alignments of sequences
originating from different species. In a resequencing context and
as defined by the software package used, this value indicates the
percent of the most represented base across the reads covering the
same nucleotide in a sequence. An alignment at a given position
would have a conservation score of 100% if all the reads carry the
same base. For sake of simplicity, to compare the three alignments
we selected only one PCR fragment (amplicon #3, ,8 kb),
brought to a simulated average coverage of ,250x by using
sampled trimmed reads. This procedure also allowed evaluating
reads that were already filtered by quality scores. The average
conservation values were similar across the three platforms
(99.38% for Roche 454, 99.56% for Illumina GA, and 99.72%
for ABI SOLiD,). However, important differences appeared when
values at each position were individually ascertained. In short-read
assemblies almost all nucleotides had perfect conservation, with
some outliers corresponding to heterozygous SNPs (around 50%).
In the long-read assembly the number of outliers was higher,
especially within the 80–100% range (Fig. 3). In this latter case, the
less conserved positions of the manually-inspected bases were
associated with homopolymers stretches and corresponded to
either an incorrectly called base or, more frequently, to a gap.
SNP detection
For comparative analysis of SNP detection performances we
considered neither the intronic VNTR containing the PRPF31
pathogenic mutation, nor another VNTR in the TFTP gene, also
present in this region.
The number of SNPs identified by setting an allelic threshold of
20% was very similar across all platforms (Table 3). Decreasing the
detection threshold to 10% allowed identifying a few more real
variants (confirmed by Sanger sequencing), but also 11 more false
positives in the Roche 454 and 1 in the Illumina GA datasets, all in
correspondence of homopolymeric traits (Table S2). No false
positives were detected in ABI SOLiD sequences, even when the
threshold was lowered to 10%. Performance in SNP detection was
not significantly affected by the use of trimmed vs. raw reads,
except for Roche 454 alignments, where the trimming process
decreased the number of false positives. This was probably due to
the reduction of the coverage below the minimal threshold needed
to call a SNP, operated by the trimming procedure itself.
For some heterozygous SNPs, mostly located within the 2nd
long range PCR fragment, the number of reads relative to one
allele was substantially higher with respect to reads belonging to
the other one. This effect was particularly visible for the short-read
platforms, to a point that the experimental results did not allow a
clear detection of the variant, or a clear ascertainment between
homozygous and heterozygous SNPs (Table S3). Electrophero-
grams from Sanger sequencing of the same PCR products used as
sequencing template for UHTS revealed the same allelic
imbalance for some of these SNPs (at positions 7661, 8337,
8564, 9081 of the ref_seq, Table S3). However, when using PCR
products obtained by short-range PCR amplification as Sanger
sequencing template, electropherograms showed clearly heterozy-
gous peaks for these same SNPs. Taken together, these results may
represent the effects of imbalanced amplification of the two alleles
prior to sequencing [12], rather then a UHTS-specific or mapping
effect.
In all three platforms, the algorithm interpreted the duplication
of a CAAG next to an A stretch (dbSNP:5828571) as 2 SNP.
Table 2. Features of reads mapping to the 31-kb reference sequence.
Sequencing
technology
Count of
Mapped Reads
Mapped
reads
Average length of
a mapped read (nt)
Total mapped
bases
Mapped
bases
Roche 454 Full length reads (99,3 K) 62,830 63% 372.85 23,426,369 74%
Trimmed reads (98,9 K) 78,766 80% 263.45 20,751,152 90%
Illumina GA Full length reads (4,6 M) 437,1967 95% 34.00 148,646,878 95%
Trimmed reads (4,2 M) 418,3505 99% 31.14 130,291,345 99%
ABI SOLiD Full length reads (17,3 M) 14,842,743 86% 49.92 740,988,589 86%
Trimmed reads (13,6 M) 12,790,106 94% 36.00 460,470,548 95%
doi:10.1371/journal.pone.0013071.t002
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SNP detection at simulated coverage depths
Coverage simulations were performed to ascertain the presence
of features emerging from non-saturating conditions and to
determine the minimum coverage required by each platform to
detect the correct number of SNPs. We randomly sampled reads
after the filtering and trimming procedure to obtain seven average
depths (350, 250, 100, 50, 20, 15, and 10x). The average coverage
of each fragment was proportional to the number of reads of a
given length used in the assembly (data not shown), so that it was
possible to calculate the number of reads to sample from each
dataset in order to obtain the desired coverage depth.
For each simulated sequencing experiment, we counted the
number of SNPs identified. We eliminated all variants detected
having less than 5x coverage, allowing at least 2 high-quality reads
carrying the variant, since these parameters were already
ascertained to produce reliable calls [6]. We chose as ‘‘reference
set’’ of detectable SNPs the list of variants reported in Table S3,
with the exception of the two entries corresponding to the CAAG
duplication (52 SNPs in total). SNP detection following mapping at
simulated coverage depths showed some platform-specific differ-
ences in the number of variants detected as function of the average
number of reads per base (Fig. 4). However, these differences
quickly disappeared as soon as the threshold coverage value
corresponding to ,50x was reached. After this limit there was
little or no increase in the SNP discovery rate and the different
samplings show nearly-similar results. Specifically, at 50x we
detected 88% SNPs with Roche 454, and 95% SNPs with Illumina
GA and ABI SOLiD, but at higher coverage all platforms reached
a plateau score of ,95%.
False positive appeared in all three platforms. Regardless of the
simulated average coverage, they were the outcome of random
errors in sequencing that could not be corrected by additional
reads covering the same position. At lower depths, this limitation
was the obvious effect a reduced number of available reads. At
higher depths, false positives invariantly showed to have local
coverage that was at least 10 times lower than the average
(simulated) one, likely because of mapping difficulties, and thus
easily recognizable as false calls.
Insertions and deletions detection
The automated identification of small insertions and deletions
(indels) is a difficult issue both for Sanger sequencing and UHTS
technologies. One heterozygous cytosine deletion (dbSNP:
34064860) downstream of the PRPF31 gene was found in
alignments for the three platforms. For Illumina GA and ABI
SOLiD this was the only indel detected, while for the Roche 454 we
could identify 88 (Table S4) and 124 (not shown) additional
deletions spanning one to four bp when trimmed and untrimmed
Figure 3. Read accuracy evaluation, on the 3rd long-range PCR fragment (,8 kb). Values on the Y axis (conservation) indicate the fraction
of the most prevalent base at a given position, as detected from the reads covering that position. Conservation scores below 0.5 represent gaps of
the assembly with respect to the reference sequence. In the Roche 454 assembly this occurs when the majority of the reads have an indel with
respect to the ref_seq, while in the Illumina GA alignment the point at 0% conservation corresponds to a region with no coverage (position: 18,837-
44).
doi:10.1371/journal.pone.0013071.g003
Figure 2. Coverage per bp of the analyzed region, by the assembly of untrimmed reads. Solid arrowheads indicate the boundaries of each
long-range PCR amplicon, while open arrowheads show the position of the VNTR in intron 13 of PRPF31.
doi:10.1371/journal.pone.0013071.g002
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reads, respectively, were used. All of them were found in
correspondence of homopolymers stretches and were considered
as false positives. Moreover, Sanger sequencing of the PRPF1 gene
did not reveal any of the deletions detected by Roche 454 in that
interval.
No insertion was automatically found in any of the sequences
generated by the three platforms, including the CAAG duplica-
tion, ascertained with Sanger sequencing and by manually
checking the UHTS alignments (dbSNP:5828571).
Alignment to the repetitive region of PRPF31 containing
the c.1347+654C.G mutation
Repetitive regions represent more than 50% of the human
genome [13]. These elements are generally masked in large-scale
assembly processes to avoid non-specific alignment of the reads. To
overcome this problem, which could have influenced the assessment
of variant detection, reads that had multiple matches on the ref_seq
were discarded from the analyses. This resulted in lowering the local
coverage of low-complexity regions but did not create noise in
variant detection. With respect to the VNTR, coverage patterns
were not uniform and were platform-specific (Fig. 5A). Unlike reads
from Illumina GA and ABI SOLiD, sequences generated by Roche
454 could cover the whole VNTR. Thanks to their longer range,
they aligned to the non-repetitive (anchoring) flanking sequences
and therefore represented the best option for sequencing this
repetitive element. However, the reads deriving from the core
repeats had multiple matches and were eliminated, thus resulting in
the coverage dip in the corresponding region.
Figure 4. SNP discovery rate at simulated coverage depths. We tested seven average coverage depths, with three random samples for each
point. SNPs and false positive hits are indicated by filled and open symbols, respectively. Squares, Roche 454; circles, Illumina GA; triangles, ABI SOLiD.
doi:10.1371/journal.pone.0013071.g004
Table 3. Number of SNPs and false positive variants detected, after alignments of untrimmed reads.
Sequencing
technology Alignments True variants .20% False positives.20% True variants .10%* False positives.10%*
Roche 454 Full length reads 48 4 49 15
Trimmed reads 46 1 47 6
Illumina GA Full length reads 49 0 52 1
Trimmed reads 49 0 52 1
ABI SOLiD Full length reads 48 0 51 0
Trimmed reads 50 0 51 0
*Values inclusive of the elements detected with a .20% threshold.
doi:10.1371/journal.pone.0013071.t003
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An additional element of complexity typical of repetitive
elements such as VNTRs is that they are polymorphic. The
individual analyzed here was homozygous for 6 VNTR repeats,
while the ref_seq reported a VNTR carrying 7 elements. None of
the three platforms analyzed could resolve the correct structure,
which was disclosed only by Sanger sequencing. When UHTS
reads were aligned onto the correct sequence, short reads
assemblies still could not match to the central portion, although
the sizes of the gaps were reduced and more sequence could be
covered, as consequence of the increased number of uniquely-
placed reads. On the contrary, long reads could precisely map the
entire region (Fig. 5B). The same occurred also for another VNTR
located in the TFTP gene: none of the three alignments could
clearly detect two repeats present in the patient with respect to the
four repeats reported in the ref_seq.
To bypass the limitation arising from forcing an alignment to a
reference sequence, we tried also de novo assembly of the subset of
reads matching the PRPF31 VNTR (544 Roche 454’s reads,
173,824 Illumina GA’s reads, 773,064 ABI SOLiD’s reads). A
contig could be obtained only with Roche 454 reads but, as before,
the number of the repeats did not correspond to the ones of the
patient (one of them was missing).
The mutation associated with adRP in the patient was clearly
detected by all three techniques with a frequency very close to
50% and a coverage similar to the rest of the fragment and
regardless of the ref_seq used, likely thanks to its proximity with
the 59 anchoring non-repetitive region.
Discussion
To provide a proof of concept for routine genomic DNA
resequencing by UHTS, specifically focused on the detection of
disease-causing variants, we processed a 31-kb human genomic
region with three next-generation sequencing platforms and
analyzed the results with a commercial, user friendly software.
In addition to several common SNPs and other typical variants of
the human genome, this interval contained a rare mutation
located in a particularly challenging region, thus representing an
interesting benchmark for a comparative analysis.
The raw sequence throughputs obtained were consistent with
the ones expected for the portion of the sequencing area used for
each instrument, as specified by each manufacturer. For all
platforms, the reads were minimally affected by the filtering
(trimming) procedure, as only 0.2% or less of them were discarded.
However, this result cannot be taken as a practical qualitative
parameter, since reads of excellent quality but of very short length
are basically useless in resequencing procedures. When a minimal
length of 20 nt was included as a parameter in the filtering process,
the three platforms began to reveal some differences. Roche 454
conserved basically all of the original reads, in virtue of its
chemistry producing sequences much longer than 20 nt, while the
other sequencers retained only 80–90% of them. It has to be
noted, however, that this trimming procedure was heavily
dependent on the strategies used by the single platforms to
eliminate low quality and polyclonal sequences from the raw
output and has only a relative value in terms of comparison across
the different UHTS systems. For example, ABI SOLiD’s low
quality reads were not discarded a priori by the machine since this
platform relies more on quality control steps (color space) during
the mapping procedure than during the pre-filtering process.
Following mapping procedures, different platforms produced
different coverage depths per base. This was simply the result of
the initial different sequencing throughput typical of each
platform, and not an issue related to the quality of the sequences
or to the mapping procedure. Considering, however, that the same
relative sequencing surface was used for all the machines (1/8 of
the total sequencing area), mapping of Roche 454 raw reads
produced an average coverage of ,770x/base, of Illumina GA
reads ,4,000x/base, and of ABI SOLiD reads ,26,000x/base.
The throughput of each machine is constantly increasing,
following the technical development of the respective chemistries,
making it difficult to provide updated comparisons relying on real
data analyses. For example, the new released models from
Illumina (HiSeq 2000) and ABI SOLiD (version 4) can reach a
throughput of 100 Gb per run or more.
Mapping accuracy appeared to correlate with the quality of the
individual reads, rather than with parameters related to the
mapping procedure itself. Specifically, short-read platforms
produced assemblies having higher accuracy than Roche 454,
simply because this latter platform is prone to introduce errors
(especially indels) when stretches of homopolymeric bases are
present [10,14].
Once the contigs were obtained, we focused on the detection of
the human variants contained in the targeted region (SNPs, small
insertions and deletions, other polymorphisms), the principal aim
being the simulated discovery of pathogenic mutations. SNP
detection was overall comparable across the three platforms;
however, some differences could be detected. In Roche 454’s long-
read alignments, false positives and negatives (undetected SNPs)
could be again connected to the typical errors of the 454
technology, related to homopolymer effects. We observed that the
use of quality-trimmed reads could reduce these false positive calls,
but it also reduced the number of true variants automatically
Figure 5. Coverage of the PRPF31 intronic VNTR. Values shown are relative to the mapping of the original ref_seq entry containing 7 repeats (A)
or of the experimentally-determined sequence containing 6 repeats (B). Untrimmed reads are represented here because they produced the best
alignment to this repetitive element. Vertical lines show the boundaries of the VNTR.
doi:10.1371/journal.pone.0013071.g005
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detected. Nevertheless, when manually inspected, these variants
could safely be identified. Similarly, in alignments from short-read
platforms false negatives (one of which was in common between
Illumina GA and ABI SOLiD) were due to the low frequency
displayed by the ‘‘non ref_seq’’ allele, and they become detectable
when the discovery threshold was lowered. In some particular
instances, especially for Illumina GA data, the under-detection or
the incorrect calling of SNPs as homozygous or heterozygous
variants were not a consequence of UHTS errors, but could be
explained by allelic unbalanced amplification. This phenomenon
occurs when one of the two alleles is enriched during the PCR
amplification of the template DNA, or perhaps during the
amplification of the libraries, and results in a problem that is
relevant also when high coverage depths are used [8]. Notably, in
Roche 454 this unbalance was present but less pronounced,
indicating probably an inferior sensitivity to this phenomenon.
Another interesting observation is that some of the SNPs with low-
limit frequency in short-read alignments were located in regions
that presented similarities with other segments of the analyzed
interval (Fig. S2). One hypothesis could be that some of the reads
sequenced from a particular SNP were mistakenly aligned to other
similar sequences and vice-versa, lowering the frequency of
detection at the real position. Yet, in other regions of similarities
SNPs were correctly identified, leading to the notion that errors in
allelic calling due to sequence repeats may not represent an
absolute rule, especially if the noise is reduced by eliminating reads
displaying multiple matches. Taken together, these results indicate
that, despite the fact that UHTS machines produce quantitative
results, other causes may influence the detection of heterozygous
variants when standard parameters are chosen in automated
detection. However, in practical terms this issue should not
represent a major concern, as the number of SNPs that were prone
to this miscalling represented in our test only a small fraction of the
total number of heterozygous SNPs.
Sensitivity in SNP detection with respect to the coverage
increased from Roche 454 to ABI SOLiD and finally to Illumina
GA. Since the differences detected were not too pronounced and
SNP detection was heavily dependent on the regional sequence
context, we can safely conclude that all platforms analyzed can be
considered as having similar performances with respect to
sensitivity at the same average coverage. Indeed, it is very hard
to extrapolate the results from their specific sequence or random
coverage contexts, as the mapping procedure (and the corre-
sponding local coverage of a given SNP) was influenced by the
complexity of the DNA to be sequenced and the number of reads
available. At lower average coverage depths, the rate of discovery
decreased sensitively and different random samplings gave
different results because the number of poorly-covered regions
was higher. As mentioned, in correspondence of false positive calls
local coverage was low even when the average coverage depth was
high, indicating a direct influence of the mapping procedure on
automated identification of variants.
With respect to detection of small insertions and deletions, the
most relevant observation relates to the identification of a large
number of false positive deletions in homopolymers stretches
obtained with Roche 454 alignments, as also noted by others in
analyses of longer genomic intervals [8]. Considering the
importance of indels in human hereditary diseases, our experi-
ments indicate that Roche 454 sequences would require the use of
specific downstream algorithms, able to systematically detect the
presence of sequence-dependent false positives.
The c.1347+654C.G mutation in the 56-bp intronic VNTR of
PRPF31 was taken as a benchmark to assess whether ‘‘difficult’’
DNA variants could be detected by UHTS. Large-scale sequencing
projects almost invariantly clash with the problem of mapping and
carefully analyzing repetitive DNA elements [2,3]. Roche 454’s long
sequences (and presumably any newer UHTS chemistry or
technology producing extended reads) represent without doubts
the best tool for covering repetitive regions, at least for elements that
do not exceed in size the average length of ,1.5 to 2 reads. Our
results support this assumption, since the Roche 454 reads provided
the most complete coverage of both the PRPF31 and TFPT VNTRs
analyzed. Nevertheless, it was not possible to precisely resolve the
number of repeats composing these elements, neither by aligning
them to a reference sequence, nor by de novo assembly.
Conversely, despite the presence of repeats, all three platforms
tested could successfully detect the mutation associated with the
disease in the patient’s genome. This favorable outcome is
probably due to the presence of the pathogenic variant within
the first of the 6 elements composing the VNTR, thus allowing the
‘‘anchoring’’ of some reads to the non-repetitive DNA region in 59
of this repeat. Although previous attempts to identify this mutation
with an earlier version of the Illumina GA (the ‘‘GA I’’ platform)
failed in such a task [4], this can be explained by the algorithms
used for aligning Illumina reads, rather than by the improvements
made by the Solexa technology. Specifically, all software used
previously allowed random alignment of reads having multiple
matches, thus creating noise in the detection of the variant in
nearly-identical repeats.
Other rearrangements of the human genome characterized by a
variable number of large and unique DNA copies (CNVs, large
duplication and deletions, genetic amplification in cancer, etc.) are
in general easily detected by UHTS. Because of the quantitative
nature of the sequencing results, such rearrangements produce
very noticeable variations of coverage when aligned to a ref_seq.
For example, CNVs, sparse and non-repetitive elements spanning
kilobases to megabases of DNA [15], are simply detected as
sudden variations of the coverage by all UHTS platforms analyzed
here [7,11,16,17].
The increase of read length in UHTS platforms, an issue on
which manufacturers are putting constant efforts, will probably
help reducing some of the current weaknesses of this technology
and accelerate the transition from Sanger sequencing to UHTS.
Illumina, for example, has increased the length of the reads from
35 nt to 100 nt in less than a year; ABI SOLiD, from 50 to 75 nt.
However, if we exclude repeats-related concerns, our data seem to
indicate that this ever changing dimension in UHTS systems
should not have a major impact on DNA variants detection in
resequencing efforts (since the reference sequence is known
already), whereas the quality of the reads produced should.
Hence, the data produced here can very likely be extrapolated to
future longer reads from the same platforms, provided that the
sequencing chemistry and procedures remain the same.
In our analysis we did not consider the costs of sequencing as a
comparative parameter, although it obviously represents an
important factor to be taken into account while designing a
sequencing project. From our results, no striking qualitative
difference appeared across the three platforms, when appropriate
conditions in terms of reads and coverage depths were fulfilled. As
a general rule then, the less expensive platform producing the
needed amount of sequences for a given project would probably
also be the most suitable one, unless platform-specific character-
istics (e.g. long reads, usable throughput, etc.) are critical for the
tests to be carried out or other endeavors with respect to genomic
DNA resequencing (e.g. transcriptome sequencing) are performed.
In conclusion, in our work we show that identification of DNA
variants in complex DNA sequences such as the human genome can
be achieved by highly-parallel techniques, with investments in terms
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of cost and time that represent a fraction of what is usually spent for
conventional sequencing. Furthermore, our successful adoption of a
user-friendly software and a straightforward analytical pipeline
demonstrates that a strong bioinformatic background is not a
compulsory requirement for investigators dealing with UHTS
technology. In our example, we performed the analysis of a large
genomic region from a single individual amplified by LR-PCR.
However, the power of UHTS can be applied to sequence shorter
DNA regions obtained by sequence capture or conventional PCR in
multiple patients, i.e. to a procedure that is more similar to current
routine setups in medical genetic laboratories. Although some
limitations to this latter UHTS application still exist, the use of
sample pooling [18,19] and individual DNA barcoding
[20,21,22,23] is now facilitating the adoption of highly-parallel
sequencers by conventional genetic labs. Taken together, our data
indicate that the so-called ‘‘next-generation’’ sequencing, regardless
of the platform used, can be efficiently and safely used by the current
generation of human geneticists as well.
Supporting Information
Figure S1 Distributions of read lengths from the three platforms
tested. The output generated from short-read platforms consists in
reads having the same length: Illumina GA generated only reads of
34 nt and ABI SOLiD generated mostly reads of 50 nt, with only
a small fraction of them (0.4%) having shorter lengths.
Found at: doi:10.1371/journal.pone.0013071.s001 (0.61 MB TIF)
Figure S2 Similarity plot of the region analyzed. The VNTRs
within the TPFT and PRPF31 sequences are indicated by arrows.
Vertical lines (corresponding horizontal lines are omitted) indicate
the position of SNPs rs35705606 and rs2668836 at coordinates
13,761 and 14,098, respectively, that were under-detected by short
read platforms.
Found at: doi:10.1371/journal.pone.0013071.s002 (7.67 MB TIF)
Table S1 Coverage of individual amplicons.
Found at: doi:10.1371/journal.pone.0013071.s003 (0.05 MB
DOC)
Table S2 Details on false positive results detected, after assembly
of untrimmed reads.
Found at: doi:10.1371/journal.pone.0013071.s004 (0.06 MB
DOC)
Table S3 SNPs detected after mapping of UHTS untrimmed
reads. Black: SNPs detected by using the default threshold for
heterozygozity (20%). Red: SNPs detected with a threshold
between 10% and 20%. Blue: SNPs with a borderline limit
definition of homo-heterozygosity. Green: variants corresponding
to the CAAG insertion. Grey shadow: SNPs located in the 2nd
long range PCR fragment, showing allelic imbalance. SNPs
identified in the tandem repeats are not reported.
Found at: doi:10.1371/journal.pone.0013071.s005 (0.22 MB
DOC)
Table S4 Deletions detected with Roche 454 (false positives),
using trimmed reads. The deletion at position 30,672 was also
found using the other 2 platforms, likely being the only real small
deletion.
Found at: doi:10.1371/journal.pone.0013071.s006 (0.16 MB
DOC)
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Assembly of raw reads 
 
Assembly of trimmed reads 
 
 
Sequencing 
technology 
 
 
Amplicon Median 
coverage 
 
Mean 
coverage 
 
Coefficient 
of variation* 
 
Median 
coverage 
 
Mean 
coverage 
 
Coefficient of 
variation* 
 
 
 
   
 
Mean 
     
Mean 
 
1 821 916 0.56 727 786 0.56 
2 464 438 0.48 420 408 0.51 
3 1172 1188 0.31 1039 1050 0.34 
Roche 454 (1/8)  
4 583 541 0.49 
0.46 
  
497 479 0.50 
0.48 
  
1 2391 2560 0.36 2082 2250 0.37 
2 9174 9823 0.46 7888 8635 0.48 
3 1777 1894 0.38 1539 1663 0.40 
Illumina GA (1 lane) 
4 2043 1955 0.44 
0.41 
  
1794 1776 0.37 
0.40 
  
1 32332 33266 0.61 19672 21074 0.69 
2 13569 13846 0.52 8202 8861 0.65 
3 17368 18998 0.58 10614 11912 0.62 
ABI SOLiD (1 quad) 
4 37036 37580 0.53 
0.56 
  
21700 22971 0.59 
0.64 
  
 
*The coefficient of variation for each amplicon is calculated as the ratio of the standard deviation to the mean. 
 
 
 
Table S2. 
 
 
 
 
 
Ref_seq 
pos. 
Alleles Frequencies Coverage 
Count 
of 2
nd
 
allele 
Gene 
 
      
17133 C/T 61.5/38.5 78 30 PRPF31 
23116 A/C 67.9/28.6 28 8 PRPF31 
29924 T/C 66.7/33.3 15 5  
Roche 454 
at 20% 
threshold 
29925 T/C 78.3/21.7 23 5  
 
      
       
1008 A/G 82.1/17.9 28 5 NDUFA3 
2307 T/G 87.7/10.8 65 7 NDUFA3 
3758 T/G 81.2/15.6 32 5 NDUFA3 
3764 T/G 89.5/10.5 38 4 NDUFA3 
6610 T/A 80.6/16.1 31 5 TFPT 
7260 C/A 88.5/11.5 139 16 TFPT 
18939 A/G 80.0/17.8 45 8 PRPF31 
23117 A/C 82.4/17.6 17 3 PRPF31 
23126 A/C 84.2/15.8 19 3 PRPF31 
23320 T/C 87.0/13.0 23 3 PRPF31 
Roche 454 
at 10% 
threshold 
23321 T/G 83.3/16.7 18 3 PRPF31 
 
      
 
Illumina GA 
at 10% 
threshold 
9141 G/A 85.5/14.5 4558 661 TFPT 
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Table S3. 
 
 
 
        ROCHE 454 ILLUMINA GA ABI SOLiD 
GENE 
Annotated 
SNPs 
Validated 
by 
Sanger 
Ref_seq 
position 
Ref. 
allele Alleles Frequencies Coverage 
Count 
of 2
nd
 
allele Alleles Frequencies Coverage 
Count 
of 2
nd
 
allele Alleles Frequencies Coverage 
Count 
of 2
nd
 
allele 
NDUFA3 rs254260  450 T G 99.9 1897  G 100.0 1632   G 99.7 12814   
NDUFA3 rs254259  646 T T/C 61.7/38.1 575 219 T/C 62.6/37.4 1919 718 T/C 50.8/49.1 8365 4110 
NDUFA4 rs2118214* yes 2286 G     G/T 71.4/28.5 2977 847 G/T 89.2/10.6 5450 575 
NDUFA3   2476 G G/A 59.4/40.4 636 257 G/A 56.4/43.4 3415 1483 G/A 56.9/43.0 21062 9066 
NDUFA3 rs254257  3268 A A/G 58.0/41.6 562 234 A/G 65.7/34.3 2643 906 A/G 55.1/44.8 22847 10240 
NDUFA3   3389 C C/T 61.2/38.8 619 240 C/T 61.4/38.5 1494 575 T/C 52.6/47.3 20754 9813 
NDUFA3 rs45595133  3754 T G/T 61.1/38.9 18 7 T/G 52.6/47.2 2243 1059 T/G 70.7/29.0 3615 1050 
NDUFA3 rs11878334  3853 T T/A 63.0/36.2 552 200 T/A 60.5/39.0 1650 643 T/A 60.8/38.9 16032 6235 
NDUFA3. 
(CDS) rs1061333 
 
4411 C C/T 52.2/47.8 813 389 C/T 58.9/41.1 1207 496 C/T 81.6/18.3 1706 312 
TFPT   5224 G G/T 62.5/37.1 774 287 G/T 63.5/36.0 1991 717 G/T 66.5/33.2 20108 6667 
TFPT rs56061812  5372 A A/G 68.2/31.8 676 215 A/G 64.7/35.3 3208 1131 A/G 52.1/47.9 34549 16539 
TFPT rs2118213  7341 G T 100.0 30  T 99.6 5319   T 99.3 6294   
TFPT rs12609379 yes 7661 G A/G 80.8/18.8 240 45 A/G 81.4/18.4 7484 1378 A/G 86.9/13.0 9359 1221 
TFPT rs254269  8128 G A 99.1 323  A 99.3 6154   A 99.1 10488   
TFPT rs60371156* yes 8337 T     T/A 87.2/12.5 4049 505     
TFPT  yes 8564 C G/C 70.1/29.9 616 184 G/C 81.2/18.6 14914 2778 G/C 76.7/23.2 9674 2245 
TFPT rs57911619 yes 9081 C G/C 60.9/39.1 192 75 G/C 77.7/22.1 5641 1248 G/C 82.8/16.9 3373 571 
PRPF31 rs4806711 yes 13432 A G/A 57.3/42.7 503 215 G/A 70.8/29.1 4507 1313 G/A 70.0/30.0 12653 3790 
PRPF31 rs35705606 yes 13761 A A/G 74.3/25.7 113 29 A/G 84.4/15.5 4462 691 A/G 85.1/14.9 11367 1691 
PRPF31 rs2668836 yes 14098 A A/C 69.4/30.6 468 143 A/C 80.8/18.9 5588 1056 A/C 75.7/24.1 9431 2273 
PRPF31 rs254277 yes 18785 G A 99.6 231  A 98.4 1480   A 96.3 3577   
PRPF31  yes 19678 T T/G 59.0/40.9 1116 456 T/G 60.1/39.5 2119 837 T/G 61.8/38.0 12695 4820 
PRPF31 rs59977379 yes 19705 A A/G 50.0/50.0 1051 525 A/G 58.9/41.1 2245 922 G/A 50.4/49.6 14174 7025 
PRPF31  yes 20006 C C/T 54.3/45.7 894 409 C/T 50.5/49.5 1846 913 C/T 50.3/49.7 9943 4938 
PRPF31 rs56220912 yes 20296 C C/G 57.0/42.9 994 426 G/C 52.4/47.3 1066 504 G/C 69.6/30.3 4504 1363 
PRPF31 rs254275 yes 20527 C G 99.5 409  G 100.0 1510   G 99.9 16010   
PRPF31 rs2303557 yes 21338 T C 100.0 879  C 100.0 665   C 99.9 3080   
PRPF31. 
(CDS) rs1058572 
yes 
21405 G G/A 58.6/41.3 1139 470 G/A 58.7/41.3 993 410 A/G 55.5/44.4 8681 3858 
PRPF31 rs56234781 yes 21703 G A/G 53.1/46.8 1186 555 G/A 51.0/48.8 1435 700 G/A 63.6/36.4 5138 1870 
PRPF31 rs33976447 yes 23127  C/A 86.2/13.8 65 9 C/A 52.7/47.1 831 391 C 99.3 539   
PRPF31  yes 23130  G/A 87.5/12.5 295 37 G/A 69.0/30.9 758 234 G 99.8 578   
PRPF31 rs254274 yes 23181 G A 99.3 584  A 99.5 1315   A 99.0 6044   
PRPF31 rs254273 yes 23788 A G 99.8 1235  G 99.6 1499   G 99.9 7961   
PRPF31 rs254272 yes 23938 T T/C 53.3/46.7 1399 653 T/C 60.8/39.1 2092 819 T/C 64.2/34.2 16475 5631 
PRPF31 rs10424816 yes 24449 C C/A 58.0/41.9 776 325 C/A 50.4/49.5 1847 914 A/C 59.7/40.1 9779 3925 
PRPF31  yes 24876 T T/G 60.1/39.6 675 267 T/G 57.5/42.3 2132 901 G/T 76.0/23.4 9364 2187 
PRPF31 rs254271 yes 24998 G G/C 57.7/42.3 943 399 G/C 53.2/46.7 1582 739 G/C 65.5/34.2 12638 4324 
PRPF31 rs10853869 yes 25338 G G/A 56.1/43.8 1229 538 A/G 50.2/49.6 3089 1533 G/A 55.4/44.4 20382 9048 
PRPF31  yes 25372 T T/C 83.2/16.5 636 105 T/C 54.7/45.2 2239 1013 T/C 60.2/39.7 15970 6348 
PRPF31 rs171703 yes 25619 T C 100.0 542  C 100.0 604   C 98.4 6125   
PRPF31 rs34990810 yes 25871 C T/C 58.5/41.5 388 161 T/C 54.4/45.5 794 361 T/C 70.2/29.7 6605 1964 
PRPF31 rs10417221* yes 26121 T     C 98.7 226   C 97.8 1963   
PRPF31 rs2668840 yes 26152 A G 100.0 115  G 99.6 810   G 99.9 12033   
PRPF31 rs667324 yes 26177 G A 98.6 143  A 99.6 764   A 99.7 10816   
PRPF31 rs2556367 yes 26332 G G/A 52.7/47.3 245 116 A/G 51.7/48.3 1711 826 G/A 52.0/48.0 10107 4847 
PRPF31 rs2576453 yes 26494 G A 100.0 295  A 99.6 726   A 99.5 19730   
PRPF31 rs608608 yes 26593 C G 99.7 298  G 99.6 687   G 99.6 14407   
PRPF31 rs655240 yes 26664 T C/T 79.7/20.3 138 28 C 99.6 978   C 99.8 11411   
 rs12150988  29568 C G/C 53.3/46.7 666 311 C/G 50.6/49.3 1901 938 C/G 54.4/45.4 15665 7107 
 rs2668838  30444 C T/C 71.6/28.4 95 27 T/C 51.7/48.1 1438 692 C/T 52.7/47.3 38101 18015 
   30583 A A/G 65.1/34.9 350 122 A/G 61.8/38.0 2567 976 A/G 61.8/38.1 32605 12422 
 rs254248  30795 A A/G 70.4/29.6 500 148 A/G 62.6/37.4 1769 661 A/G 54.5/45.4 20267 9200 
 rs4806715  30871 A C/A 58.0/41.3 460 190 A/C 62.2/37.7 2552 961 A/C 59.7/40.1 34714 13926 
  rs2668837  30965 C T/C 64.1/35.8 632 226 T/C 54.8/45.2 2192 990 T/C 52.0/48.0 22426 10757 
 
*, within homopolymeric sequence. 
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Table S4. 
 
 
 
Reference 
position 
 
Reference 
allele 
 
Allele 
variations 
 
Frequencies 
 
Coverage 
 
Count of 
2
nd
 allele 
 
Overlapping 
gene 
 
 
728 G G/- 64.4/35.6 407 145 NDUFA3, CDS 
775 C C/- 73.5/26.5 211 56 NDUFA3 
782 C C/- 65.1/34.9 195 68 NDUFA3 
1001 A A/- 56.1/37.8 180 68 NDUFA3 
1211 G G/- 51.4/47.5 183 87 NDUFA3 
1217 G G/- 76.4/23.6 165 39 NDUFA3 
1238 T - 42.0 143  NDUFA3 
1238 TT -- 39.2 143  NDUFA3 
1383 T T/- 71.4/28.6 84 24 NDUFA3 
1390 T T/- 78.8/21.2 52 11 NDUFA3 
1550 T T/- 74.3/24.9 237 59 NDUFA3 
2278 T -/T 51.6/43.2 190 82 NDUFA3 
2295 T T/- 76.8/20.6 155 32 NDUFA3 
3679 C C/- 63.6/35.6 225 80 NDUFA3 
3742 T T/- 79.2/20.0 125 25 NDUFA3 
3748 T -/T 48.1/39.4 104 41 NDUFA3 
3892 T T/- 67.8/29.9 515 154 NDUFA3 
4965 T -/T 56.3/38.1 446 170 TFPT 
5763 G G/- 75.0/24.6 741 182 TFPT, CDS 
6354 C C/- 69.9/30.1 501 151 TFPT 
6364 T T/- 61.6/38.0 484 184 TFPT 
6610 T -/T 48.0/47.5 1222 580 TFPT 
7261 AA -- 37.5 32  TFPT 
7261 A -/A 32.4/23.5 34 8 TFPT 
7272 A - 84.4 32  TFPT 
7541 C C/- 76.2/22.9 227 52 TFPT 
7933 G G/- 78.3/21.4 429 92 TFPT 
8326 A A/- 40.0/36.0 50 18 TFPT 
8326 AA AA/-- 31.9/21.3 47 10 TFPT 
8352 C C/- 75.3/24.7 85 21 TFPT 
9442 A A/- 75.3/24.7 81 20 TFPT 
9603 A -/A 44.3/39.2 79 31 TFPT 
9736 A -/A 59.7/37.3 67 25 TFPT 
9877 A A/- 34.6/23.1 26 6 TFPT 
9991 G G/- 79.2/20.8 274 57 TFPT 
10220 G G/- 79.3/20.7 188 39 TFPT 
10561 A A/- 64.7/34.0 153 52 TFPT 
10893 A A/- 71.7/27.4 329 90 TFPT 
11192 C C/- 69.9/29.8 302 90 TFPT 
11233 A -/A 42.2/33.2 211 70 TFPT 
11480 T T/- 59.9/36.3 284 103 TFPT 
12006 G G/- 74.5/25.0 200 50 TFPT 
12702 CTC CTC/--- 75.0/24.7 288 71 TFPT 
13063 C C/- 74.2/25.4 524 133 TFPT 
13513 T T/- 51.9/46.2 210 97 PRPF31 
13519 T -/T 62.0/34.0 200 68 PRPF31 
14563 A A/- 60.2/38.3 415 159 PRPF31 
14716 A A/- 48.9/39.4 94 37 PRPF31 
14735 A A/- 62.8/35.1 94 33 PRPF31 
14858 G G/- 68.8/30.5 311 95 PRPF31 
15305 AAA AAA/--- 23.8/23.8 42 10 PRPF31 
15474 A A/- 77.4/22.0 164 36 PRPF31 
16131 G G/- 77.8/21.9 465 102 PRPF31 
16370 T -/T 37.1/24.3 70 17 PRPF31 
16370 TT --/TT 23.2/20.3 69 14 PRPF31 
16599 T T/- 54.3/41.0 427 175 PRPF31 
17120 TTT TTT/--- 40.0/24.0 25 6 PRPF31 
17289 T T/- 71.8/25.1 529 133 PRPF31 
18396 T -/T 53.2/21.9 393 86 PRPF31 
18767 A -/A 46.2/43.6 117 51 PRPF31 
18925 AAA AAA/--- 21.7/20.8 106 22 PRPF31 
19573 G G/- 70.6/28.9 948 274 PRPF31 
21356 C C/- 74.4/25.5 1036 264 PRPF31 
22089 C C/- 74.7/25.1 427 107 PRPF31 
22302 C -/C 55.7/43.0 619 266 PRPF31 
22309 C C/- 75.5/23.8 608 145 PRPF31 
22961 A A/- 73.2/25.2 523 132 PRPF31 
23294 C C/- 63.1/36.9 179 66 PRPF31 
23314 T -/T 50.0/40.9 176 72 PRPF31 
23763 G G/- 62.9/34.9 1135 396 PRPF31 
23818 G G/- 78.8/20.9 1313 275 PRPF31 
23861 C C/- 66.5/33.1 1109 367 PRPF31 
24122 C C/- 73.7/25.7 992 255 PRPF31 
24741 A -/A 57.1/40.1 352 141 PRPF31 
24747 A -/A 56.3/42.6 350 149 PRPF31 
25184 G G/- 78.6/21.3 1277 272 PRPF31 
25474 G G/- 70.5/29.4 797 234 PRPF31 
25548 A -/A 69.1/30.4 573 174 PRPF31 
25613 G G/- 58.5/40.5 1204 488 PRPF31 
25671 C C/- 63.8/35.9 1224 439 PRPF31 
26120 CT -- 23.7 38  PRPF31 
26121 T - 60.5 38  PRPF31 
26406 C C/- 75.9/23.8 294 70 PRPF31 
26848 G G/- 70.5/29.2 359 105 PRPF31 
28297 AAA AAA/--- 21.1/21.1 90 19 PRPF31 
28297 AAAA ---- 23.5 85  PRPF31 
29326 T T/- 76.2/22.0 395 87 PRPF31, CDS 
30359 T T/- 46.2/20.9 91 19  
30672 C -/C 57.3/42.3 494 209  
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Project 2: Screening of the SNRNP200 gene in a cohort of dominant RP 
patients  
 
At the time of the study, one of the major limitations of NGS, was the complexity of testing 
many individuals at the same time. Sequencing arrays allow in fact physical separation of 
only a few samples, and the enrichment systems for targeting particular genomic regions had 
limited scalability. A still prohibitive solution for multiplexing was the addition of nucleotide 
barcodes during the library preparation step, which is a limiting step in terms of time and cost 
when dealing with many samples.  
We were confronted with this problem when we chose to test the SNRNP200 gene as a 
candidate for dominant RP in a cohort of 96 patients. The strategy that we experimented with 
for this screening involved the pooling of long-range PCR products targeting the gene from 
each patient and their simultaneous sequencing via NGS (Roche 454). This approach avoided 
the expensive procedure of barcoding and required instead a validation step consisting of the 
Sanger sequencing of individual samples only for particular exons in which a novel change 
was detected. This method led us to the identification of novel RP mutations in the hBRR2 
protein, and it proved to be more time and cost-effective than the classical method of 
sequencing single exons through the Sanger method. The results of this work were published 
as “Next generation sequencing of pooled samples reveals new SNRNP200 mutations 
associated with retinitis pigmentosa”, in Human Mutation journal, on February 2011. 
 
 
 
 
 
Candidate’s roles: 
• Preparation of samples for sequencing. 
• Planning and execution of the sequence analyses. 
• Downstream validation analyses by Sanger sequencing. 
• Writing of the manuscript. 
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with gradual reduction of the peripheral visual field with eventual development of tunnel vision and, in some 
cases, virtual total blindness. Early detection of this condition has been achieved by measuring retinal function by 
electroretinographic (ERG) testing (Berson, 1993), which represents the most reliable diagnostic tool for RP at all 
ages. Vitamin A supplementation has been reported to slow the course of this condition (Berson et al., 1993). This 
disorder, which affects almost 1 in 4000 people worldwide, is genetically diverse and can be inherited as an 
autosomal-dominant, autosomal-recessive, X-linked trait, and in rare cases also as a non-Mendelian trait (Hartong 
et al., 2006; Rivolta et al., 2002). 
By linkage mapping and candidate gene screening, more than 60 genes have been associated so far with non-
syndromic RP (RetNet database, http://www.sph.uth.tmc.edu/retnet/); however, mutations in these genes account 
for only about half of all reported cases (Hartong et al., 2006; Sullivan et al., 2006). Discovery of new causative 
genes by a candidate-functional approach is hampered by the labor intensive and costly methods of sequencing 
target genes in large numbers of patients. New and efficient methods of screening are therefore necessary to aid in 
the discovery of the remaining fraction of RP genes. In this context, the development of strategies based on "next-
generation," or ultra high-throughput DNA sequencing technologies, is starting to provide new tools to analyze 
panels of different genes in several patients and in a parallel fashion (Calvo et al., 2010; Daiger et al., 2010). 
Some twenty causative genes for autosomal dominant forms of RP (adRP) have been identified so far, including 
several genes encoding pre-mRNA splicing factors: PAP-1 (RP9) (Keen et al., 2002), PRPF31 (RP11) (Vithana et 
al., 2001), PRPF8 (RP13) (McKie et al., 2001), PRPF3 (RP18) (Chakarova et al., 2002), and SNRNP200 (RP33) 
(Li et al., 2010; Zhao et al., 2009).  
Splicing is a ubiquitous process by which introns are removed from pre-mRNA to form mature mRNA. The 
enzymatic reactions take place in the spliceosome, a supermolecular complex containing five small nuclear 
ribonucleoproteins (snRNP) and ~200 other proteins (Jurica and Moore, 2003). The SNRNP200 gene (or 
ASCC3L1; chromosome 2q11.2, MIM# 601664), encoding for the 200-kDa helicase hBrr2, is essential for the 
unwinding of the U4/U6 snRNP duplex, which is a key step in the catalytic activation of the spliceosome 
(Laggerbauer et al., 1998; Raghunathan and Guthrie, 1998). This protein is homologous to Brr2 from yeast and 
belongs to the DExD/H box protein family. It consists of two consecutive Hel308-like modules, each composed of 
a DExD/H box domain with ATPase activity and a Sec63 domain (Lauber et al., 1996; Pena et al., 2009; Zhang et 
al., 2009). Recently, two different mutations of hBrr2 have been found in two Chinese families with adRP that 
showed linkage to the RP33 locus (Li et al., 2010; Zhao et al., 2009; Zhao et al., 2006). These mutations, 
p.R1090L and p.S1087L, were identified following screening of candidate genes within the RP33 linkage interval 
and are both located in the first Sec63 domain. It has been shown that the corresponding mutations in yeast affect 
the helicase activity of Brr2 (Zhao et al., 2009). No other hBrr2 mutations have been identified and the prevalence 
of mutations in this gene among patients with adRP is yet unknown. No genetic analyses have been performed so 
far on large cohorts of patients or in families that were not pre-selected for segregation of the diseases with the 
SNRNP200 (RP33) genomic region. 
We present here the results of the screening of the SNRNP200 gene (45 exons, 44 introns) in 96 patients from 
adRP families with unknown molecular genetic cause, mostly composed of Caucasian individuals. To reduce the 
time and costs required to screen such a large gene in several patients with classical techniques, we used ultra 
high-throughput sequencing technology on pooled samples from multiple patients (Ingman and Gyllensten, 2009; 
Out et al., 2009). The potential advantages and the limitations of this method are evaluated. 
 
MATERIALS AND METHODS 
Patients and controls 
This study was carried out in accordance with the tenets of the Declaration of Helsinki and was approved by the 
Institutional Review Boards of the University of Lausanne and of Harvard Medical School and the Massachusetts 
Eye and Ear Infirmary, where the blood was collected and the patients were followed. Written informed consent 
was obtained from patients who participated in this study before they donated 10-30 ml of their blood for research. 
In addition to a regular ophthalmologic examination, our evaluation included ERG testing, performed as 
previously described (Berson et al., 1993). Patients were characterized as autosomal dominant if their families 
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showed evidence of transmission of retinitis pigmentosa over two consecutive generations in at least one branch 
with or without evidence of reduced penetrance in other branches. 
DNA from peripheral leukocytes was extracted from 191 unrelated patients with adRP. Ninety-six of these 
samples were used for screening with ultra high-throughput sequencing (UHTS), while the other 95 patients were 
analyzed only for those exons in which a mutation was confirmed after Sanger sequencing. Controls included 175 
individuals with no history of retinal degeneration, and included 80 subjects with normal ERG. In instances where 
control genomic DNA was insufficient for direct genetic screening, it was amplified by using a whole-genome 
amplification kit, following manufacturer’s instructions (REPLI-g Mini Kit, Qiagen, Venlo, The Netherlands). 
 
UHTS and sequence analysis 
The general workflow followed in this study is schematically illustrated in Figure 1. Specifically, the 
SNRNP200 gene (chromosome 2, nt. 96,940,074 to 96,971,297 of GenBank entry NC_000002.11) was amplified 
in the initial set of 96 patients by 4 overlapping long-range (LR) PCRs of 9,009 bp, 10,474 bp, 12,145 bp and 
5,594 bp in length, spanning in total an approximate 35-kb genomic region (nt. 96,937,041 to 96,972,001 of the 
same GenBank entry). Primers were those used in the work by Hinds et al. (Hinds et al., 2005), adapted in some 
instances to the region of interest (Supp. Table S1). PCR reactions were performed in a 10 µl final volume, 
including LA PCR Buffer II (TaKaRa, Otsu, Shiga, Japan), 4 mM of MgCl2, 1µM of each primer, 0.4 mM of 
dNTPs, and 1 U of TaKaRa LA Taq (TaKaRa), with slight modification in the cycling conditions suggested by the 
supplier. For the quantification of PCR products, we loaded 1 µl of each reaction (96 x 4 LR-PCRs) on E-Gel 48 
2% agarose gels (Invitrogen, Carlsbad, CA) and analyzed them by densitometry. We pooled equimolar PCR 
products, according to the measured intensity of the bands. To avoid over-representation of the overlapping 
regions after shotgun library preparation and sequencing, we chose to pool only fragments from non-overlapping 
LR-PCRs (fragment #1 pooled with fragment #3 and #2 with #4). Sequencing was performed with two runs of 
Roche 454 GS FLX Titanium, according to manufacturer’s protocols and by using a gasket that separated the two 
pools. All sequence analyses were carried out with the software package CLC Genomics Workbench (CLC bio, 
Aarhus, Denmark). Sequence reads were first trimmed and filtered according to their quality score and length 
(quality limit value set to 0.001, defined in the software manual; minimum length of a read set to 25 nt) and then 
assembled onto the reference sequence. We used default local-gapped alignment, allowing reads to align if they 
have at least 98% identity for more than 98% of their length. 
For detection of single-nucleotide substitutions, we applied the following restrictions on the sequence accuracy 
of the bases surrounding the variant to be called: within an 11-nt window, the average quality of the bases was set 
to 20 (PHRED score, corresponding to a base accuracy of 99%) and the maximum number of mismatches or indels 
accepted was 3 with respect to the reference sequence. We only considered calls having a minimal coverage of 
1,000 reads, corresponding to at least 5 reads per allele per patient and to twice the threshold previously indicated 
for confident detection of variants (Ingman and Gyllensten, 2009). Finally, to be considered reliable DNA variants, 
all detected changes had to be present independently in the two technical replicates, represented by the two runs of 
sequencing, with at least a 0.5% frequency (corresponding roughly to 1 variant allele over 192 alleles). 
Coordinates of detected DNA variants are given with respect to GenBank entry NM_014014.3, with +1 
corresponding to the A of the ATG initiation codon. 
 
Sanger sequencing and validation of mutations 
To validate the changes detected by UHTS, we individually analyzed by the Sanger method (Sanger et al., 
1977) the PCR products from each patient’s DNA for 4 exons (16, 25, 37, and 38) containing putative mutations 
on either long- or short-range PCR templates (Supp. Table S1 and Supp. Methods). In addition, we sequenced 
exons 4 and 31 to further ascertain the precision of the variants called by the UHTS procedure.  
Sequencing reactions were performed by mixing 5 Pl of previously-purified PCR products (ExoSAP-IT, USB, 
Cleveland, OH), 0.75 PM of primers and 1 µl of BigDye Terminator v1.1 Cycle Sequencing kit (Applied 
Biosystems, Foster City, CA), and run on a ABI-3130XLS sequencer (Applied Biosystems). 
To predict pathogenicity of amino acid substitutions we used both the PolyPhen (Ramensky et al., 2002) and 
MutPred (Li et al., 2009) algorithms. Possible mutations affecting splicing were tested with the NNSPLICE 0.9 
program (Reese et al., 1997). Protein sequences were aligned by using tools form the CLC Genomics Workbench. 
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RESULTS 
Sequencing 
We sequenced the SNRNP200 gene with the Roche 454 GS FLX Titanium instrument, as a pool of individually 
obtained LR-PCRs in 96 unrelated patients with adRP (4,320 exons, 4,224 introns, or ~3.5 Mb in total). We 
obtained in total ~2.3 million raw sequences of 314 nt in length on average. Following trimming and quality 
filtering procedures, 87% of them aligned to the reference sequence. The average base coverage obtained was 
about 7,500 fold, corresponding to ~40 sequences per single allele per patient in the pool, assuming an even 
representation of each sample. Ninety-six percent of the reference sequence was covered by at least 1,000 reads. 
 
Ascertainment of DNA variants 
We identified 79 DNA variants, including 33 annotated SNPs and 18 changes associated with homopolymeric 
stretches (i.e. AAAA…, CCCC…, etc.). Since these latter changes represent a well-known source of error for 
Roche 454 technology (Huse et al., 2007), they were immediately discarded from further analyses along with the 
identified known SNPs. Of the remainder variants, 21 were located within noncoding regions, 3 were predicted to 
produce isocoding changes, and 4 involved nonsynonymous changes. Putative isocoding changes were tested in 
silico for possible interference with the canonical splicing process, and none of them was predicted to be 
pathogenic. More specifically, the c.3315A>G (p.A1105) variant was in fact predicted to create a new donor site, 
but its associated likelihood score was not significant (0.43 out of 1.00). 
To confirm the presence of DNA variants and identify the actual carriers among the patients' DNA composing 
the pool, we sequenced all exons carrying nonsynonymous variants as well as p.A1105 by the Sanger method in 
individual DNA samples. Whenever a change could be confirmed, the screening of that particular exon (and of its 
intron vicinities) was extended to the genomes of 95 additional unrelated adRP patients (Table 1). 
In exon 16, the non-synonymous DNA change p.Y689C was confirmed by Sanger sequencing to be present 
heterozygously in one patient (Berman-Gund Laboratory patient ID: 001-107). Two missense variations, both 
affecting codon 681 (c.2041C>T and c.2042G>A, or p.R681C and p.R681H, respectively), were also identified by 
Sanger sequencing in two patients from the first cohort (IDs: 001-046, and 001-051). These variants were initially 
not detected by UHTS because they were present in the pool with frequency values that were below the 0.5% 
threshold and therefore can be considered as false negatives of the first method of screening. Sequencing of the 
second cohort allowed the identification of p.R681C in two additional unrelated patients (IDs: 001-061, and 001-
303), as well as the detection of two new DNA changes, p.V683L and c.2160+42C>T in two patients (IDs: 001-
485, and 001-346). None of these variants was present in 350 control chromosomes. 
In exon 25, the change p.S1087L, detected by UHTS with a frequency of 1.4%, was present in two patients 
from the first cohort (IDs: 001-085, and 001-212) and 1 patient of the second cohort (ID: 001-367). The isocoding 
change p.A1105 was also confirmed to be present in two patients, one in each cohort (IDs: 001-090, and 001-060). 
Again, these DNA variants were absent in controls. 
Sanger sequencing of the amplicons spanning exons 37 and 38 identified two false positives of the UHTS 
screening, p.F1717S and p.M1808V, both having a measured frequency corresponding exactly to the threshold 
value used in inclusion criteria. Alleles from SNPs rs772175 and rs78519182 were also confirmed to be present. 
 
Cosegregation analyses 
The p.S1087L mutation, found in 3 unrelated patients from our cohorts, was previously reported to be present in 
a family with adRP by Zhao et al. (Zhao et al., 2009). 
The 4 new missense changes detected in exon 16, p.R681C, p.R681H, p.V683L, and p.Y689C involved highly 
conserved residues (Figure 2A and B) and were all predicted to be deleterious by in silico analyses. Family 
members were only available from two probands carrying p.Y689C and p.R681C. In these pedigrees, both changes 
were present heterozygously in patients and absent in unaffected members, following the classical pattern of 
inheritance of alleles causing a dominant disease with complete penetrance (Figure 2C).  
The intronic change c.2160+42C>T, for which we also had other family members, did not co-segregate with the 
disease in the family and was therefore considered as non-pathogenic. 
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Table 1. SNRNP200 DNA variants in selected exons, detected by UHT and Sanger sequencing 
DNA change* Allele 
frequencies 
in the pool 
(%) 
Coverage Number 
of reads 
with 
allele  
Putative 
amino acid 
change 
Detected 
with 
UHTS 
Patients 
in the 1st 
cohort 
(Sanger) 
Patients 
in the 2nd 
cohort 
(Sanger) 
Controls Pathogenicity 
          
Exon 16          
c.2041C>T 99.6/0.4 10,627 44 p.R681C No (false 
negative) 
1 2 0 Likely 
c.2042G>A 99.9/0.1 10,656 10 p.R681H No (false 
negative) 
1 0 0 Likely 
c.2047G>T    p.V683L No 0 1 0 Undetermined 
c.2066A>G 99.3/0.7 9,677 69 p.Y689C Yes 1 0 0 Likely 
c.2160+42C>T    Intronic Yes 0 1 0 No  
          
Exon 25          
c.3260C>T 98.6/1.4 20,258 290 p.S1087L Yes 2 1 0 Confirmed 
c.3315A>G 99.1/0.9 17,203 153 p.A1105 Yes 1 1 0 Undetermined 
          
Exon 37          
c.5150T>C 99.5/0.5 12,064 65 p.F1717S Yes 
(false 
positive) 
0 ND ND No (not a real 
variant) 
c.5317C>T 
(rs772175) 
64.9/35.1 7,975 2,802  p.L1773 Yes 63 
(alleles) 
ND ND No 
c.5324-31G>C 
(rs78519182) 
98.0/2.0 7,553 149 Intronic Yes 3 ND ND No 
          
Exon 38          
c.5422A>G 99.5/0.5 9,409 51 p.M1808V Yes 
(false 
positive) 
0 ND ND No (not a real 
variant) 
 
With the exception of c.5317C>T, all changes were detected in a heterozygous state. * Nucleotide numbering reflects cDNA 
numbering with +1 corresponding to the A of the ATG translational initiation codon in the reference sequence NM_014014.3. 
ND, not determined. 
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Figure 2. Structure and sequence of the hBrr2 protein and mutation cosegregation analysis. A) Functional domains of 
hBrr2. Positions of the mutations found in this screening are indicated in red. B) Alignment of Brr2 protein sequences from 
human, dog, mouse, fish, fly, worm, plant, sea anemone, and yeast. Non-conserved residues are shaded; arrows indicate the 
residues affected by DNA changes detected in exon 16. C) Pedigrees segregating the p.Y689C (Berman-Gund Laboratory 
family ID: 5632) and p.R681C (family ID: 0270) mutations (M) are shown. Black and white symbols represent clinically 
affected and unaffected members, respectively. The question mark indicates an individual for whom clinical examination 
was not possible. Arrows indicate probands analyzed in the UHTS screening. 
 
Evaluation of variant detection specificity 
To test the performance of the pooling method adopted here, we re-analyzed the sequence obtained by UHTS 
for exons 4, 16, 25, 31, 37, and 38 in the initial set of 96 samples. Specifically, we ascertained the number of 
variants detected by using different frequency thresholds (0.1, 0.2, … 1.0%) and compared them with the results 
obtained by individual Sanger sequencing of such samples. The number of false positives increased as the 
threshold of detection decreased, following a negative exponential trend (Figure 3).  
 
DISCUSSION 
 
The SNRNP200 gene, encoding the splicing factor hBrr2, has been recently discovered by linkage analysis and 
molecular screening as a new autosomal dominant retinitis pigmentosa gene in two families from China. Two 
mutations were identified: p.S1087L and p.R1090L (Li et al., 2010; Zhao et al., 2009). Based on the evidence that 
hBrr2 is part of the same snRNP that includes PRPF31, PRPF3, and PRPF8, also involved in adRP, prior to the 
publication of these studies we screened this candidate sequence in a large cohort of unrelated patients from North 
America. Because of the elevated number of exons to be analyzed, we adopted previously published protocols 
consisting of the parallel sequencing of pooled and untagged DNA samples and evaluated them as potential 
methods for research on adRP, i.e. a rare disease with elevated genetic heterogeneity. 
Three out of 191 patients from our screening carried p.S1087L (c.3260C>T), located in the first Sec63 domain 
of the protein. These patients were of Mexican, French Canadian, and English/Irish descent, indicating either that 
this mutation represents a relatively early event in human history, or that nucleotide c.3260 is a mutational hotspot. 
Haplotype studies on other ethnic groups and extended cohorts of patients are needed to verify which one of these 
hypotheses is the correct one. 
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Figure 3. False positives identified as a function of different frequency thresholds. False positives 
were ascertained after Sanger sequencing of exonic DNA, covering in total ~3% of the entire 
SNRNP200 region sequenced by UHTS. Blue line: number of false positive variants detected in the 
assembly of all the sequences obtained by two sequencing runs. Pink line: false positives detected in 
both of the independent technical replicates. 
 
 
Importantly, we found 4 new missense variants in exon 16: p.R681C, p.R681H, p.V683L, and p.Y689C, which 
were present heterozygously in 6 patients and absent from 350 control chromosomes. Residues Arg681 and 
Tyr689 are phylogenetically very well conserved, and their replacement is predicted in silico to be damaging for 
the correct functioning of hBrr2. While both p.R681C and p.Y689C co-segregated with disease in the pedigrees 
analyzed, probands carrying p.R681H and p.V683L changes did not have other family members available for 
further genetic analyses. However, the p.R681H variation affects the very same conserved residue co-segregating 
with disease in the pedigree with p.R681C, strongly suggesting an association with RP. p.V683L was predicted to 
be possibly pathogenic by in silico analyses, involved a conserved amino acid, and was absent in the controls. In 
the absence of additional data (e.g. cosegregation) it is difficult to speculate at the present time whether it 
represents a rare benign variant or a true RP mutation. 
All the newly detected changes fall in the Brr2 protein region containing the first DExD-helicase domain, which 
has been demonstrated to be essential for the U4/U6 unwinding function in vivo and in vitro and for cell survival in 
yeast (Kim and Rossi, 1999; Raghunathan and Guthrie, 1998). The first of the two consecutive Hel308-like 
modules, consisting of a DExD/H domain and a Sec63 domain, shows the highest level of conservation among 
species, reflecting its importance at the functional level (Zhang et al., 2009). It is therefore remarkable that all 
adRP mutations in hBrr2 so far identified are located in this first Hel308-like module. We hypothesize that these 
new mutations, similar to the ones already described, would impair hBrr2 helicase/ATPase activity, leading to 
defects in spliceosome catalysis. 
Because of the high genetic heterogeneity displayed by RP, a very effective strategy for the identification of 
new disease genes consists in the screening of candidate genes in large cohorts of patients (Dryja, 1997). UHTS 
technologies (reviewed in (Metzker, 2010)) allow obtaining unprecedented amounts of DNA sequencing data, 
which makes them suitable for the screening of large genes. However, UHTS analysis of multiple samples is not a 
straightforward procedure, and unavoidably requires sample pooling to be economically sustainable. Current 
multiplexing procedures mostly rely on the addition of nucleotide barcodes to individual samples since the use of 
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physical separators does not grant sufficient parallelization (Craig et al., 2008; Lennon et al., 2010; Meyer et al., 
2008). Detection of sequence variants in multiple samples can also be achieved through sequencing a pool of non-
tagged DNA templates (for example PCR products covering the same gene) from different individuals and by 
ensuring an appropriate coverage in downstream UHTS procedures (Calvo et al., 2010; Ingman and Gyllensten, 
2009; Out et al., 2009). This approach bypasses the expensive and laborious procedure of barcoding multiple 
libraries, and can theoretically lead to identification of rare variants, the frequency of which is as low as 0.5% with 
respect to the pool. 
We followed this latter approach to analyze SNRNP200 for mutations. In our screening we detected an 
unexpectedly high number of both false positive and false negative calls, which could be ascertained only by 
Sanger sequencing. False positive calling of mismatches is a necessary drawback, since in our study we were 
considering very low frequency variations that could also be caused by sequencing or alignment errors. We could 
reduce them by considering only the subset of variations detected in two independent sequencing runs, as 
demonstrated also by our simulation experiments using variable thresholds and as indicated by the reduction of the 
number of DNA changes associated to homopolymeric stretches (from more than 100 to 18, data not shown). 
However, false positive calls could not be completely eliminated. Using a higher threshold of detection could 
correct the problem but would also hide potentially true signals (false negatives), especially for variants that could 
be penalized by uneven pooling of different PCRs products and/or unbalanced allelic amplification during pre-
sequencing procedures (Benaglio and Rivolta, 2010). In our specific case, we failed for example to identify two 
true changes, p.R681C and p.R681H, since they were present at a frequency that was below the theoretical limit of 
1 variant allele in 96 samples (0.4% and 0.1% respectively). While failure to detect the first change could be 
attributed to statistical fluctuation, the second false negative call is more likely to depend on the 
underrepresentation of this allele in the pool, probably prior to sequencing. However, correcting the underdetection 
of true positive calls through the mere operation of decreasing the threshold would also result in an exponential 
increase of noise generated by false positive calls, making the fine tuning of this procedure a subtle and rather 
empirical process. A practicable possibility in this context could consist in pooling fewer samples and in raising 
the threshold of detection proportionally. In our case, for example, pooling 48 samples instead of 96 would have 
allowed detecting a single allelic variation in 1% of the sequences (instead of 0.5%), allowing therefore to increase 
the detection rate while keeping the noise under control. 
The DNA screening strategy used in this work has proven to be extremely advantageous, especially if it is 
compared to the alternative option of individually sequencing all SNRNP200 exons in the several dozen patients 
and controls examined. Specifically, the triage operated by UHTS of pooled samples allowed reducing the number 
of exons to be analyzed by an order of magnitude (from 45 to 4). However, in contrast to classical exon-PCR 
analyses by Sanger sequencing or to UHTS of single samples, the results obtained have a stochastic component 
that depends heavily on the settings used.  
In conclusion, we identified new mutations in SNRNP200 and confirmed that adRP associated to hBrr2 
impairment is not limited to the Chinese population. Based on our data, the prevalence of SNRNP200-associated 
adRP seems to be rather high, since mutations were present in at least 4.2% (8 out of 191) of the screened patients. 
Considering that for 95 patients only 2 out of the 45 SNRNP200 exons were analyzed and that the UHTS pooling 
technique used generated a number of false negatives, this value could potentially be even higher, making 
mutations in this gene one of the most frequent causes of adRP in Caucasians. Furthermore, we also tested the use 
of next-generation sequencing technology on pooled and untagged samples, highlighting the advantages and the 
limitations of this methodology for DNA analyses involving many patients. Based on our work, we are persuaded 
that candidate gene screening for RP and other genetic diseases will greatly benefit from the high-throughput 
revolution in the very near future, but this will probably follow the development of automated and inexpensive 
procedures for genetic barcoding or other solutions for sample multiplexing. 
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SUPPORTING INFORMATION 
Supp. Table S1. Sequences of primers used for long-range (LR), regular (SR) and sequencing (Seq) PCRs 
 
Name Sequence (5'-3') 
LR_1.F ACAGAGAAGACTTTGTAGCTGGGGAAGA 
LR_1.R CAGCCCTGAAATAAACTATATATGAAACAAGG 
LR_2.F TGGTTTGGTCATGAGACCAGTGACCTG 
LR_2.R ACACAAAACACAGTCATTAAAGGCAGACACTG 
LR_3.F GCTGCTCTTCATCTTTACCTCTAAGAA 
LR_3.R TAAACATGACAGTATCTGGTTTCTGCTATCAA 
LR_4.F CTGGTAGCTGGCTTGGTCAGGTGTCAACTCAC 
LR_4.R TGATGGGGAGGTGGCCTTCTGGAAGTATCAG 
SR_ex16.F GTTTTAGAAGGGCCTTTGGG 
SR_ex16.R TTTTAATTTCTGTCAATCTTCCCC 
SR_ex25.F* ACCGTGTGTAGAGTGGCTCA 
SR_ex25.R* TTCCCATCAGACCCTTGG 
SR_ex37-38.F GCGTATTGTCCACCAGTGATG 
SR_ex37-38.R TCCTCGATGCTGATGCACTT 
Seq_ex4.F TCCTTTAGTTGTGGCATCAGC 
Seq_ex25.F GCCGCAGCACTCTTCTAATTGT 
Seq_ex31.R TTTGGAATAGGGCAGCAGGTAG 
Seq_ex37.F TTAGGTCTCACACAGGGACCATG 
* From Li et al, 2010. 
 
Supp. Methods 
Long-Range PCRs 
 
Reaction mix 
 
1x Buffer LA PCRTM Buffer II  
4 mM MgCl2 
1uM each primer 
0.4 mM each dNTP 
1 unit of LA TaqTM (TaKaRa) 
10 ul final volume 
 
 
 
Cycling conditions 
 
LR 1 
95˚C 5’(95˚C 30”, 67˚C 1’,68˚C 14’)x14, (95˚C 30”, 62˚C 1’,68˚C 14’)x16, 72˚C 10’ 
 
LR 2, 3, and 4 
94˚C 1’(98˚C 5”,68˚C 15’)x30, 72˚C 10’ 
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Regular PCRs 
 
Exon 16 
 
1x PCR Buffer  
2 mM MgCl2 
0.1 uM each primer 
0.2 mM each dNTP 
0.5 unit of HotStarTaq DNA Polymerase (Qiagen) 
20 ul final volume 
 
95˚C 15’(95˚C 30”, 56˚C 30”, 72˚C 1’)x35, 72˚C 10’ 
 
Exon 25  
 
1x PCR Buffer  
1.5 mM MgCl2 
0.1 uM each primer 
0.2 mM each dNTP 
1 unit of HotStarTaq DNA Polymerase 
25 ul final volume 
 
98˚C 8’(94˚C 30”, 56˚C 30”, 72˚C 1’) x5, (94˚C 30”, 54˚C 30”, 72˚C 1’)x5, (94˚C 30”, 52˚C 30”, 72˚C 1’)x15, 
(94˚C 30”, 50˚C 30”, 72˚C 1’)x15 72˚C 5’ 
 
Exons 37-38 
 
1x PCR Buffer  
0.5 mM MgCl2 
0.1 uM each primer 
0.2 mM each dNTP 
0.5 unit of HotStarTaq DNA Polymerase 
20 ul final volume 
 
95˚C 15’(95˚C 30”, 60˚C 30”, 72˚C 1’) x35, 72˚C 10’ 
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Project 3 (Review): Methods for genetic screening of multiple samples using 
targeted NGS 
 
We were invited to write a paper for a chapter of a book titled “Genomics III: Methods, 
Techniques and Applications”, edited by iConcept Press. The editors were interested in an 
extended version of the paper "Ultra High Throughput Sequencing in Human DNA Variation 
Detection: A Comparative Study on the NDUFA3-PRPF31 Region" (project 1), or other 
recent papers related to the book project. Since we were working on a new screening (that is 
described below, in project 4), and we had methodological materials from the previous one 
(project 2), we though it would be useful to perform a comparison of the two methods and 
discuss about their performances. This book chapter contains a detailed introduction in the 
form of a review of the methods used in NGS for targeted sequence enrichment and parallel 
analysis of multiple samples (multiplexing), with application in genetic screenings for 
Mendelian disorders. In the second part we reviewed the method already described in the 
paper of SNRNP200 screening (project 2), and compared it with the new one used for project 
4, consisting of a commercial method for the generation of multiple barcoded DNA libraries. 
The two strategies have been extensively dissected and discussed, providing useful 
recommendations for screenings projects. Additionally, two techniques for PCR product 
quantity normalization were evaluated. 
The work has been peer reviewed by two anonymous experts, with the same process as for 
journal publications. The PDF of the accepted version is freely available on the website 
(www.iconceptpress.com) since October 2102, while the hardcopy of the book is in press.  
 
 
 
 
Candidate’s roles: 
• Design of the paper. 
• Analysis of sequencing data. 
• Writing of the manuscript. 
• Corresponding author. 
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1    Introduction 
1.1    Next Generation Sequencing Technologies: an Overview  
Biological research has been revolutionized by the introduction of dideoxy DNA sequencing, developed by 
)UHGHULFN6DQJHUHWDOLQWKHODWHµV(Sanger et al., 1977). This technique, that essentially dominated the field 
of DNA analysis for the following 3 decades, was instrumental for the sequencing of the human genome in 
2004 (International Human Genome Consortium, 2004) and still is very heavily used. The succeeding advent 
and rapid development of the so-FDOOHG ³QH[W JHQHUDWLRQ´ RU ³XOWUD KLJK WKURXJKSXW´ VHTXHQFLQJ 1*6 RU
8+76 WHFKQRORJLHVXVKHUHG LQDQHUD LQZKLFKUHDGLQJDQRUJDQLVP¶VJHQRPHKDVDOPRVWEHFRPHDURXWLQH
practice. In addition to the sequencing of whole genomes, the development of different NGS methods and 
protocols has enabled a wide range of applications. The most used and best established ones are the sequencing 
of entire transcriptomes (RNA-seq), the sequencing of DNA from chromatin immunoprecipitation assays 
(ChIP-seq), DNA methylation profiling, and the analysis of genetic variations, especially in the field of medical 
genetics. 
The distinctive feature of next generation sequencing is the possibility of producing very high number of 
sequences (or reads) in a fast and cost-effective manner. The most used platforms are currently commercialized 
by Roche 454 (GS FLX and GS Junior), Illumina (HiSeq, Genome Analyzer and MiSeq), and Life 
Technologies (SOLiD System and Ion Torrent sequencers). Each platform is characterized by a combination of 
different strategies for template preparation, amplification and sequencing, which lead in all cases to the 
parallelization underlying the drastic drop of the per-base cost of sequencing. 
7HPSODWHSUHSDUDWLRQLVPRVWO\EDVHGRQD³VKRWJXQFORQLQJ´DSSURDFKXVHGWRVHTXHQFHORQJIUDJPHQWVRI
DNA) and includes the random shearing of the input DNA, usually through nebulization or sonication, 
IROORZHGE\WKHFORQDODPSOLILFDWLRQRIWKHIUDJPHQWVREWDLQHG³(PXOVLRQ3&5´IRUH[DPSOHLVWKe method of 
library amplification used by Roche 454, SOLiD, and Ion Torrent technologies. Fragments of DNA, ligated to 
universal adaptors, are captured and amplified on individual beads in a water-in-oil mixture (Metzker, 2010). 
The enriched beads are then fixed on a glass surface (SOLiD) or deposited into PicoTiterPlate (PTP) wells 
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(Roche 454). In the Illumina platforms, the enrichment step occurs on a glass slide, where high-density primers 
are attached, and clonally amplified clusters are produced from the templates.  
The sequencing reactions rely on different principles, based on either DNA polymerase or DNA ligase. 
Roche 454 uses pyrosequencing, in which the incorporation of complementary dNTPs results in the emission of 
photons (Margulies et al., 2005). The Illumina technology relies on a sequencing-by-synthesis approach, based 
on the cyclic incorporation of fluorescent nucleotides with reversible termination. Ion Torrent employs a similar 
approach, but uses non-modified dNTPs and a silicon chip that detects hydrogen ions released during each 
cycle of polymerization (Rothberg et al., 2011). In contrast to the previous methods, depending on the activity 
of DNA polymerase, SOLiD uses a ligase-based chemistry consisting of cycles of hybridization and ligation 
(McKernan et al., 2009).  
The sequences produced by NGS are first collected as raw images and then processed to generate a readable 
RXWSXWWKDWKDVWREHHLWKHUDOLJQHGWRDUHIHUHQFHJHQRPLFVHTXHQFHRUDVVHPEOHGWRIRUPD³GHQRYR´'1$
sequence. In all cases, assembly, mapping, and analysis of sequences require the use of dedicated software.  
Typically, NGS platforms produce reads of shorter length than those produced by Sanger sequencing, in the 
range of 50 to 400 nucleotides, depending on the platform. The throughput of these machines varies from 
several Megabases to hundreds of Gigabases per run and the time needed to produce such reads from a few 
hours to a few days. All of these features have to be taken into account and selected according to the desired 
output, in particular with respect to the desired coverage. The coverage is defined as the number of reads that 
LQWHUURJDWHDJLYHQ'1$EDVHDQGLQGLFDWHVKRZ³GHHSO\´DVDPSOHLVVHTXHQFHG$URXJKZD\WRHVWLPDWHWKH
average coverage of a sequencing experiment is to divide the total throughput (in base pairs) by the size of the 
DNA fragment that has to be sequenced. Sequencing redundancy, or high coverage, is necessary to reconstruct 
a correct sequence since NGS reads contain a higher proportion of errors than sequences obtained by the Sanger 
method and therefore every base has to be interrogated multiple times. In principle, the more accurate an 
instrument is, the less coverage is needed. Typical NGS errors are represented by an incorrect base call or small 
insertion and deletions. They can occur randomly or systematically in certain DNA regions that are more 
difficult to sequence, such as GC rich regions and homopolymeric stretches (i.e. TTTT..., AAAA..., etc) 
(Harismendy et al., 2009; Huse et al., 2007). 
NGS companies are putting constant effort into improving the accuracy, the throughputs, and the flexibility 
of their systems. It is therefore rather difficult to give a contemporary picture of their technical features, due to 
the continuing evolution of the technology and specialization of these instruments.  
1.2    Enrichment Strategies 
The analysis and interpretation of genome-wide sequencing results is currently a step behind the technology 
that produces them. For certain applications it is more interesting -and economically more convenient- to 
concentrate the study only to a limited part of the genome. In medical genetics, for example, it is still a common 
practice to screen for genetic variants only a limited number of genes (for example a genomic interval 
associated to an inheritable disease) or all the coding sequences of a genome (the so-called exome) (Gilissen et 
al., 2011). 
For this purpose, various strategies for enrichment of target DNA have been developed in recent years 
(Mamanova et al., 2010; Mertes et al., 2011). They can be divided mainly into PCR-, hybridization-, or 
circularization-based approaches. The choice of the enrichment strategy to be used depends on specific 
requirements of the project, and in particular on the target DNA size and the number of samples to be 
sequenced. 
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1.2.1    PC R-Based Enrichment Techniques 
Polymerase chain reaction (PCR) is certainly the most reliable method for target enrichment, due to its high 
specificity, sensitivity and reproducibility. However, while this technique is very well suited to capillary 
electrophoresis (Sanger) sequencing, in which each amplicon is directly and separately analyzed, it is not 
completely adapted to NGS approaches. In fact, to exploit the full throughput of NGS and to perform an 
analysis that is economically viable, many samples and amplicons must be run at the same time. As it will be 
detailed in the next paragraph (1.3), the sequencing of multiple samples is limited by the long time and the 
relatively high costs required for library preparation. Multiple amplicons may be obtained via multiplex PCRs 
or pooling of single-plex PCRs. In both cases, the danger is an uneven representation of the amplicons forming 
the pool. This can occur from unequal PCR efficiency across the various amplicons or from unbalanced pooling 
of the fragments. Both of these events, if present, are in general difficult to correct. The manual production of 
PCRs is feasible for less than a hundred thousand bases of target DNA by using standard PCRs of few hundred 
bases, or by using long range PCR (LR-PCR) of approximately 10 Kbases. For larger target regions, the 
workflow involving primers design, optimization of robust PCRs, and generation and pooling of the products 
becomes less time- and cost- effective.  
An automated solution for preparation of multiple PCRs (in this case standard PCRs) is provided by the 
RainStorm platform, produced by RainDance Technologies. In this system, emulsion-like PCR reactions occur 
as single-plexes in microdroplets, which are mechanically generated and assembled in a microfluidic system 
(Tewhey et al., 2009). Up to 20,000 primer pairs and corresponding number of reactions can be supported at the 
same time by this machine, which allows a relatively uniform enrichment of up to 10 Mb regions.  
Some PCR-based approaches allow the simultaneous generation of short PCRs and library preparations by 
means of the incorporation of sequencing adaptors to the PCR primers, which must amplify fragments shorter 
than the sequencing reads. The advantage of this strategy is to avoid the cleaning, pooling, and shotgun library 
preparation required for longer DNA fragments (Mertes et al., 2011)7KH)OXLGLJP³$FFHVV$UUD\6\VWHP´
employs this approach and allows, for example, the automatic preparation of 48 sample libraries using a 
microfluidic device that assembles and hosts 2,304 parallel separated PCR reactions.  
Finally, certain platforms, such as Illumina Miseq and Life Technologies IonTorrent PGM, provide panels of 
ready-to-use highly multiplexed short PCR reactions to amplify target regions ranging from 1 Kb to 1 Mb, for 
up to 96 samples.  
1.2.2    Hybrid Capture Enrichment Techniques 
To select larger DNA regions (from 1 to 50 Mb of cumulative sequence), the hybrid capture method is 
preferred to the PCR method for its simplicity and rapidity, rather than for its specificity. The principle of 
sequence capture is based on the hybridization of a shotgun library to complementary probes of 60-150 
nucleotides, designed to cover the target region. The hybridization reaction can occur in solution, or on a solid 
phase, where the probes are fixed on a microarray. The in-solution capture has the advantage of not requiring 
special equipment but a thermocycler, and of being more easily scalable. The main vendors of hybrid capture 
kits are NimbleGene (Roche) and Agilent; the first uses DNA probes, while the second longer RNA probes. 
The most used application of this technique is the enrichment of all the transcribed regions of the human 
genome, the so-called whole exome capture. One of the drawbacks of the hybrid capture method is the 
relatively high proportion of off-target and pseudogenes sequences, which have a negative effect on the 
coverage and the variant calling of the target region. 
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1.2.2    C ircularization-based enrichment techniques 
Another type of enrichment strategy is based on the use of custom molecular inversion probes (MIPsRU³JDS-
ILOO SDGORFN´ DGDSWHG IURP D 613 JHQRW\SLQJ SURWRFRO (Akhras et al., 2007). MIPs are synthetic DNA 
oligonucleotides that contain a common linker sequence flanked by two single-stranded sequences designed to 
anneal to two nonconsecutive parts of a genomic target region. Such a region can be of up to 191 bp in length 
(Turner et al., 2009) or 500 bp when using longer padlock probes (LPPs) (Shen et al., 2011). Once hybridized, 
the gap between the two specific sequences is filled by the DNA polymerase and closed by a ligase reaction. 
These circular products are then amplified by PCR with primers annealing to the common linker. Since this 
latter sequence contains NGS adaptors as well, ready-to sequence templates that do not require further steps for 
OLEUDU\ SUHSDUDWLRQ DUH SURGXFHG$ VOLJKWO\ GLIIHUHQW DSSURDFK LQYROYHV WKH XVH RI ³VHOHFWRU SUREHV´ZKLFK
differ from the previous one because the genomic DNA is first digested by restriction enzymes and the resulting 
fragments circularize after the hybridization to the probes (Dahl et al., 2007). The advantages of these capture 
methods include high specificity and reproducibility, the characteristic of being library-free, and low input 
DNA (Turner et al., 2009). Disadvantages are represented by a poorer uniformity of the captured targets and 
high initial costs of the probes (Mamanova et al., 2010). 
1.3    Multiplexing Strategies 
The number of samples that can be simultaneously sequenced and resolved represents an important issue in 
NGS. While capillary electrophoresis sequencing offers the highest degree of scalability, with hundreds of 
samples and Kilobases sequenced per run, NGS platforms easily produce Gigabases of sequences, but typically 
distributed among few samples or only one. The reason for this is mainly physical: a capillary electrophoresis 
sequencer contains a few dozen capillaries that can be used simultaneously; NGS reactions occur on array-like 
surfaces with almost no separation to host different samples. The ideal application for NGS is therefore the 
sequencing of large amounts of DNA from an individual sample (e.g. a genome or an exome). In case of 
targeted resequencing, a smaller sequencing throughput is required and this is obtained either by using lower 
VFDOHVHTXHQFHUVWKHYHU\QHZ³EHQFKWRSVHTXHQFHUV´OLNH,RQ7RUUHQW3*0,OOXPLQD0L6HTDQG5RFKH
GS Junior) or by distributing the sequencing capacity of a big platform across many samples, to be sequenced 
at the same time. If such samples correspond to non-overlapping DNA sequences (e.g. each sample is 
constituted by an individual PCR product, representative of a unique genomic region), sample/sequence 
identification is performed a posteriori, when reads are assembled or mapped. Conversely, if each sample is 
constituted by a PCR product that originates from the DNA of a given individual and pairs of primers targeting 
WKH VDPH '1$ UHJLRQ IRU DOO VDPSOHV ³PXOWLSOH[LQJ´ SURFHGXUHV DLPHG DW LGHQWLI\LQJ LQGLYLGXDO VDPSOHV
become necessary. Such multiplexing is achieved during library preparation, via a step in which a sequence of 
DNA of 4-8 nt (the so-called barcode), unique to each sample, is ligated to all DNA fragments composing the 
library (Craig et al., 2008; Smith et al., 2010). Multiple libraries are then pooled in equal amounts and 
sequenced at once, along with their barcodes. The identification of samples occurs after the sequencing, thanks 
to the information contained in the genetic barcode tags. 
Rather than technical, the real limitations of multiplexing are the high costs and the labor associated to 
sample preparation, which must be carried out separately for each sample in order to add individual nucleotide 
barcodes. As mentioned before, recent developments of PCR-based enrichment kits allow a greater automation 
in library preparation and a high level of multiplexing (up to 96 samples). However, this workflow is integrated 
for the moment only to low throughput sequencers (MiSeq, IonTorrent) or requires special equipment dedicated 
only to this process (Flugidim Access Array). Alternatively, other methods that do not require library 
preparation like MIPs can be appealing for processing many samples. Specifically, with MIPs barcodes can be 
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directly inserted in the primers that will amplify the captured sequences and the NGS adaptors (Akhras et al., 
2007). 
In case of recurrent genetic screenings performed on a same cohort of samples, a different strategy would be 
to initially tag the genomic DNA from different individuals with specific barcodes and NGS adaptor 
oligonucleotides, and then pool the barcoded fragments. Any downstream manipulation would be then 
performed on a single tube, which contains separable information of many individuals after the sequencing. 
This approach is available since the beginning of 2012 and is commercialized by PopulationGenetics, which 
also patented this workflow under the name of GenomePooling. In this approach, the regions of interest are 
extracted from the pool through specific primers and inverse simplex PCRs. Since they contain already both the 
individual barcode and sequences for NGS processing, they could be directly sequenced as a pool of samples 
(Casbon et al., 2011). If this technique demonstrates to have sensitivity and specificity comparable to other 
enrichment methods, it will represent a very powerful tool for genetic screenings via NGS.  
Many scientists have tried to bypass the step of individual barcoding by usLQJDVDVWUDWHJ\WKH³DQRQ\PRXV´
pooling (i.e. with no tagging nucleotides) of target DNA from different samples and the creation of a unique 
library for sequencing (Calvo et al., 2010; Lee et al., 2011; Otto et al., 2011; Out et al., 2009). Obviously, by 
this approach it is not possible to assign any direct relationship between reads and samples to which they 
belong, and further validations are required to track back the carrier of the variations via capillary sequencing or 
other methods. For some purposes, sample identification may not represent a primary necessity, for example if 
the aim of the project is to estimate the allele frequency of certain alleles in a population (Ingman & Gyllensten, 
2009). 
The mixed information contained in the results of such sequencing projects, in fact, must be interpreted 
based on the expected frequency of a single allele in a pool of chromosomes. For example, if 100 human 
samples have been pooled together, each autosomal allele will represent the 0.5% of the total sequence reads. In 
projects aiming at the identification of novel or rare variations (like disease causing mutations), the detection 
threshold of DNA changes must be therefore set at a frequency as low as 0.5%, depending on the number of 
individuals pooled together. For such experiments, it is important that the error rate of the sequencing platform 
does not exceed the expected frequency of one variation present in one individual. The risk is to produce many 
false positives, if the variant detection threshold is set too low, or false negatives, if this is set too high. This 
point will be elucidated in the following paragraphs through the description of a real example.  
Two main different ways of obtaining pooled libraries are to group samples before or after target enrichment. 
For example, in case of PCR-based enrichment, template DNA can be quantified, pooled and amplified in a 
unique reaction. Alternatively, PCR fragments must be generated for each samples and pooled in a second time. 
The first approach is by far quicker and cheaper, but on the other hand the second one allows assessing the 
product of each reaction and produce a more balanced pool across all different samples (Otto et al., 2011; Out 
et al., 2009).  
1.4    Genetic Screenings of Multiple Samples in Medical Genetics 
In medical genetics, the discovery of genes causing Mendelian diseases has been classically achieved through 
linkage analysis of families or through the screening of candidate genes in large cohorts of patients. Linkage 
analysis and sequencing of the genomic region harboring the mutation are very powerful techniques if large 
families are available. In absence of large families to study, the candidate gene approach can be chosen. The 
hypothesis that a gene may cause the disease, based on its biological relevance and other known data, is tested 
through the screening of many patients with the same disease. Nowadays, with high throughput sequencing 
being progressively more affordable, the use of the new technologies simplifies and accelerates the discovery 
process.  
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Before NGS technologies emerged, candidate gene sequencing for detection of disease causing mutations 
was carried out through the Sanger dideoxy method, which is still the gold-standard method for molecular 
diagnosis in many hereditary diseases. However, the high costs and time required for sequencing entire genes in 
many patients by this method forced many laboratories to apply cheaper screening techniques such as single-
strand conformation polymorphism (SSCP) and denaturing high-pressure liquid chromatography (DHPLC) 
prior to Sanger sequencing. NGS has the potential of substituting these procedures and offers a cost effective 
and accurate alternative to the Sanger method. The workflow of a NGS application is mostly defined by the 
enrichment and multiplexing strategies that are used, as described before. Successful examples include the use 
of commercial solutions such as the Raindance droplet-based multiplex PCR, or the Fluidigm microfluidic chip 
to test 86 known genes responsible for X-linked intellectual disability in 24 samples (Hu et al., 2009), or 3 
known familial hypercholesterolemia genes in 144 samples (Hollants et al., 2012). Others have developed in-
house methods to implement NGS in clinical diagnosis. For example, a pipeline based on a multiplex PCR 
enrichment step followed by a second PCR round to add sequencing adaptors was successfully applied to 
identify novel and known mutations in 3 genes responsible for the Marfan and Loeys-Dietz syndromes, in 87 
patients (Baetens et al., 2011). The anonymous pooling strategy described before was also proven to be 
efficient in mutation discovery (Benaglio et al., 2011; Calvo et al., 2010; Otto et al., 2011; Out et al., 2009). In 
general, based on published data, it appears that the majority of NGS efforts aimed at analyzing multiple 
patients at once have been devoted to molecular diagnosis of known disease-genes, rather than to the discovery 
of new genes. Furthermore, it seems that a uniformed protocol for sequencing a small target region in many 
patients is not yet present. 
Conversely, whole exome and genome sequencing are the most used and best-established strategies to 
discover new disease genes. Thanks to these approaches, discovery occurs through an unbiased analysis of the 
variants that are present in the entire genome or exome, in many cases helped by genotyping or sequencing 
information from family members. Whole exome or genome sequencing are more successful for discovering 
new genes associated with recessive conditions, since homozygous (or compound heterozygous) rare variations 
are less frequent in the genome with respect to heterozygous changes, and therefore are easier to identify and 
verify in terms of possible pathogenicity. 
In the cases presented below we applied the candidate gene approach to identify new mutations in a cohort of 
patients affected with autosomal dominant retinitis pigmentosa (adRP), a diseases leading to progressive retinal 
blindness. RP may be caused by mutations in more than 100 genes, each of them responsible for a small 
fraction of the cases (Hartong et al., 2006). Diagnostic screening of known mutations are performed by using an 
arrayed primer extension chip by Asper Biotech or, more recently, by NGS of known genes after solid-phase 
capture arrays enrichment (Neveling et al., 2011; Simpson et al., 2010). Because of the high genetic 
heterogeneity displayed by RP, a very effective strategy for the identification of new disease genes, which are 
calculated to account for almost the half of RP patients, consists in the screening of candidate genes in large 
cohorts of patients (Dryja, 1997). Also, due to this genetic heterogeneity, the screening of single genes in a 
cohort of patients is expected to identify only a few individuals who are positive for a particular mutation.  
We present two examples of single-gene screening in multiple patients (~100) using two different NGS 
strategies: the anonymous pooling approach and the tagged libraries pool approach. We chose long range PCR 
based methods, because of its high specificity, a crucial element to consider when many samples are processed 
together. 
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2    Anonymous Pooling Approach  
The method presented here was applied to screen for heterozygous mutations an RP-associated gene 
(SNRNP200) and allowed us identifying new likely pathogenic DNA variants (Benaglio et al., 2011). Because 
of the elevated number of exons to be analyzed (45), we adopted a protocol consisting in the parallel 
sequencing of pooled and untagged DNA samples and evaluated it as a potential method for studying rare 
diseases with elevated genetic heterogeneity, such as RP. We sequenced this gene with the Roche 454 GS FLX 
Titanium instrument, by using as template a pool of individually-obtained LR-PCRs from 96 unrelated patients 
with adRP, accounting for a total of 4,320 exons, 4,224 introns, or ~3.5 Mb. 
2.1    Exper imental Methodology 
2.1.1    Enrichment and Sequencing Method 
The candidate gene of interest was amplified in a cohort of 96 patients by 4 overlapping LR-PCRs of 5 to 12 
kbases in length, spanning in total approximately 35 contiguous kbases of the human genome. We quantified 
the resulting 384 PCR products by using pre-casted agarose gels and densitometry, before pooling them in 
equimolar amounts. Library preparation and sequencing was performed in agreement with the specific 
protocols for Roche 454 GS FLX Titanium. Two runs of such platform were performed. 
2.1.2    Sequence Analysis  
The analysis of the sequencing results was performed with the CLC Genomics Workbench software package 
(CLC bio, Denmark). We first polished the raw sequences by trimming the low-quality extremities of the reads 
and by eliminating the reads shorter than 25 nucleotides. Mapping was restricted to reads that could align to the 
reference sequence with at least 98% identity for more than 98% of their size. For reliable detection of single-
nucleotide substitutions, we considered only high quality reads of the assembly, in highly-covered regions. 
Specifically, we set a minimum of 99% average base call accuracy (or 20 PHRED score) and allowed a 
maximum of 3 mismatches or insertions/deletions, calculated on a region of eleven nucleotides spanning the 
called variant. The variation detection frequency threshold was set to 0.5% over a minimum of 1,000 reads, 
which corresponded roughly to the identification of one heterozygous change in a pool of 96 samples (192 
chromosomes), each allele being theoretically represented by at least 5 reads of relatively good quality. Finally, 
we used the information of the two independent sequencing runs as technical replicates and selected only DNA 
variants that were detected in both processes. Changes detected by UHTS were validated by sequencing 
LQGLYLGXDO 3&5 SURGXFWV IURP HDFK SDWLHQW¶V '1$ E\ FDSLOODU\ HOHFWURSKRUHVLV RQO\ IRU VHOHFWHG H[RQV
Moreover, if a likely pathogenic change could be confirmed, we screened for that particular change an 
additional cohort of 95 unrelated individuals presenting with the same disease. Potential effects of amino acid 
substitutions were evaluated by the web-based software PolyPhen (Ramensky et al., 2002), while the 
involvement of isocoding DNA changes on gene splicing was tested by using NNSPLICE (Reese et al., 1997). 
2.2    Results and Discussion 
Each run of Roche 454 FLX produced roughly 1.2 million raw sequences of 314 nt in size on average. After 
quality trimming and filtering, 87% of the raw reads aligned to the 35-kb reference sequence, producing an 
average base coverage of about 3,750 fold, with a minimum coverage of 500 reads for the 96% of the targeted 
region. If we assume that each sample is equally represented in the pool, we obtain a ~20x average coverage 
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per single allele per patient, which is in the range of coverage recommended for confident DNA analysis 
(Bentley et al., 2008; McKernan et al., 2009). 
The joint analysis of variant detection resulting from the two sequencing runs identified 79 DNA changes. 
We prioritized the analysis of candidate mutations according to the functional effect of such variations on the 
protein product of the gene. We therefore discarded all known polymorphisms (33), intronic and synonymous 
changes (24), and variations located within homopolymeric stretches (18), where pyrosequencing-based 
platforms are particularly prone to introduce errors (Huse et al., 2007) (Table 1). Validation of DNA changes 
by Sanger sequencing of individual DNA samples and the subsequent identification of the patient(s) carrying 
putative mutations was restricted to four non-synonymous substitutions, located in 4 different exons. 
 
 
# Variants Associated with homopolymers 
Annotated 
SNPs 
Intronic or 
non-coding Synonymous Nonsynonymous Total 
M erged  110 37 63 5 7 222 
Intersection 18 33 20 4 4 79 
Table 1: Number of single nucleotide variations identified in the pooled sequences with a 
frequency higher than 0.5%. Results obtained by either the assembly generated by merging the 
sequences of the two runs (Merged) or by retaining only those identified in both runs 
(Intersection - used in our experiment) are presented. 
Of the four putative missense mutations detected in both sequencing runs, only two were confirmed by 
Sanger sequencing. They had an allele frequency detected via NGS of 0.7% and 1.4%, corresponding to one 
and two actual carriers, respectively. The other two missense variations identified by NGS with a frequency of 
0.5% were false positives. Additionally, we identified two new missense variations through Sanger sequencing 
but not by NGS (false negatives). These variants, affecting the same codon, were initially not detected by NGS 
because they were present in the pool with frequency values that were below the 0.5% threshold (0.1% and 
0.4%) and therefore were not included in the list of candidate variants.  
These novel missense changes, were likely pathogenic mutations. Specifically, they involved highly 
conserved residues, were not detected in 350 control chromosomes, and were found in few additional unrelated 
patients after the screening of a second cohort. Moreover, for two of them the co-segregation of the DNA 
variant in the affected family members could be performed and was consistent with that of a pathogenic allele.  
In addition to the clinical relevance of these findings, this study gave us the possibility of exploring the 
anonymous pooling method and to point out its advantages and limitations. One marked limitation of our 
screening was the high rate of false positive and false negative variation calls with respect to the true signals. 
The reason for this was mainly attributable to the low frequency that we set for calling variants, which 
inevitably brought to detection of mismatches due to sequencing or mapping errors. 
To test the behavior of this method with respect to false positive discovery, we made a comparison between 
the number of variations detected by Sanger and NGS for 6 exons, covering in total ~3% of the entire gene. We 
were interested in ascertaining the number of false positives (i.e. variants detected by NGS but not by Sanger 
sequencing) at different thresholds of detection, ranging from a frequency of 0.1% to 2.0%. As predictable, 
false positives were detected in large amounts at low frequency thresholds. However, they were drastically 
reduced starting from a frequency threshold of 0.3% and virtually eliminated when such frequency was 1% or 
higher, according to an exponential curve (Figure 1).  
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Interestingly, we observed that the number of false positives was significantly lower when we counted only 
signals detected independently in both sequencing runs (i.e. the strategy that we adopted), with respect to 
merging the sequences obtained by the two runs. Similarly, we could also reduce by more than five folds the 
number of DNA changes that were present in homopolymeric stretches (Table 1), corresponding almost 
certainly to sequencing errors. 
 
 
 
F igure 1: False positive variants as a function of different detection thresholds. Variations that 
were identified in the pooled sequencing experiments (merged dataset or intersection of the two 
sequencing runs) but not in the Sanger sequencing of the corresponding exons were considered 
as false positives. The comparison was performed over 6 exons of the gene.  
Using higher thresholds of detection to correct the problem of false positives would also lead to the 
misidentification of potentially real variants, as we showed with our example. We could not in fact identify two 
true variations with an actual frequency of 0.4% and 0.1%, which were under the 0.5% limit that we chose for 
our analysis. While we can consider the first as a false negative (0.4%) because of stochastic deviation from the 
expected value, the second change (0.1%) was likely missed due to its underrepresentation with respect to the 
other alleles of the pool, rather than because of a sequencing error. This can happen for example when PCR 
products are pooled in an unbalanced quantity or when the two alleles from the same sample are differentially 
amplified due to the presence of a SNP near or inside the binding site of the PCR primers (Benaglio & Rivolta 
2010; Ikegawa et al., 2002). 
It seems therefore that the correct balance between low noise from false positive and sensitive detection of 
true variants is a fine process that cannot be predicted a priori. A feasible strategy to overcome this issue, also 
adopted in similar works (Calvo et al., 2010; Otto et al., 2011), is to pool a lower number of samples and 
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increase the detection frequency threshold consequently. For example, as it was showed by our simulation with 
different frequencies of detection, a marked improvement in specificity could be already observed at a 
frequency as low as 1%. This threshold could be used for variant detection of pools of 48 samples instead of 96 
and theoretically allow the identification of 1 allele out of 96 with a lower noise due to sequencing errors. 
To summarize, the DNA screening strategy presented here showed to be very efficient in finding new 
mutations, if compared to classical methods involving the individual sequencing and analysis of all the exons of 
a gene in hundreds of patients and controls. However, as a disadvantage with respect to classical exon-PCR 
analyses by Sanger sequencing or to UHTS of single samples, the results obtained with the pooled approach 
depend on stochastic variables that are difficult to control. The use of smaller pools of samples and more 
accurate sequencing platforms should almost certainly help increasing the efficiency of this method. 
3    Tagged L ibraries Pool Approach 
Given the risk of missing potential mutations experienced in the anonymous pooling approach, we decided to 
test a safer, although more expensive technique involving the pool of tagged libraries. Tagged libraries should 
reduce the number of false positive and negative changes because the analysis is performed individually for 
each sample. A higher detection threshold for variant detection can therefore be used, and areas of potential 
errors can be more easily identified in those presenting low coverage. The target DNA in this screening 
consisted in two candidate adRP genes of 51 and 20 kb in size, amplified by 5 and 2 LR-PCRs, respectively. In 
order to achieve the parallelization required for library preparation of 95 samples, we chose a transposase-based 
method of fragmentation, described below. Moreover, we run a pilot test to evaluate the fragmentation protocol, 
the conditions for normalization of LR-PCRs, and the feasibility of merging untagged samples in single library 
preparations. 
3.1    Exper imental Methodology 
3.1.1    Enrichment and Sequencing Method 
Similar to the previous screening, long range PCR products of ~10 kb in length were individually obtained to 
target and amplify two candidate genes in a cohort of patients. The total number of exons and introns analyzed 
was 43 and 41, respectively. Prior to the screening of 95 samples, we conducted a pilot experiment on 18 
libraries to test two methods of PCR product normalization. The first method, used for 8 samples, consisted in 
an approximate visual quantification of the 7 (5+2) long range PCRs on agarose gel and in an equimolar 
pooling that took into account their different PCR sizes. The PCR pools were subsequently purified and 
quantified. For 6 samples the purification and normalization of PCR products were performed with a 
commercial 96-well normalization plate (Invitrogen), which allows obtaining the same quantity of DNA for 
each product. Moreover, in the pilot test we wanted to assess the efficiency of variant detection when using the 
same barcode for multiple samples, in comparison with the results of individual sequencing. For this purpose, 
we included four libraries obtained by merging the pools of LR-PCRs from 2 or 4 samples, purified by the two 
methods just described (Figure 2). 
For each sample (pool of LR-PCRs), a library was obtained by using a commercial transposase-based kit 
(Nextera), starting from 50 ng of input DNA. The protocol consisted in two thermocycler reactions. In the first 
reaction, an enzyme fragments and tags the DNA by means RI DSSHQGHG WUDQVSRVRQ HQGV ³WDJPHQWDWLRQ´
After on-column purification of such product, a limited-cycle PCR is performed to add the barcoded adaptors, 
compatible with the sequencing platform. Eighteen different adaptors were used for the pilot study. After their 
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purification and quantification, the libraries were pooled together and run on one lane of Illumina GAII 
platform sequencer. 
 
F igure 2: Design of the pilot study. LR-PCRs from samples in red were pooled by WKH³PDQXDO
PHWKRG´ ZKLOH WKH RQHV in blue by the ³normalization PHWKRG´. We also merged two or four 
samples in order to test variant detection performance in non-tagged pools. 
)RUWKHDFWXDOVFUHHQLQJZHFKRVHWKHILUVWPHWKRGRIQRUPDOL]DWLRQ³PDQXDOPHWKRG´IRUUHDVRQVWKDWZLOO
be detailed below. Libraries were again prepared for each sample via the commercial tagmentation protocol 
(Nextera), using 48 different barcoded adaptors optimized to allow the highest difference in sequence also in 
case of miscalled bases (Meyer & Kircher 2010). The 48 libraries were individualy purified and quantified, and 
then pooled together and sequenced. The same procedure was repeated for another set of 47 samples, to 
complete the sequencing of 95 different samples.  
3.1.2    Sequence Analysis 
The resulting sequences for each sample, separated according to the barcode that identified them (but which is 
not considered in the mapping), were aligned to the human genomic reference sequence of the two target genes 
(71 kb). We considered only reads having at least 95% identity for the 95% of their length. For confident 
variation calling (single nucleotide substitutions and small insertions and deletions), we set the threshold of 
detection to at least 20% of reads having a different base with respect to the reference sequence, and having a 
minimum coverage of 15 reads. In the experiments of pooled samples, the detection thresholds were set to 15% 
and 8% in the 2-sample and 4-sample pools, respectively. 
3.2    Results and Discussion 
The global metrics resulting from the pilot run, as well as the two discovery runs, are summarized in Table 2.  
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 Run #0 (Pilot) Run #1 Run #2 
Instrument Illumina GAII Illumina Hiseq Illumina Hiseq 
Number of multiplexed samples 18* 48 47 
Number of Reads 22.7 M 143 M 149 M 
Read length 77 nt 51 nt 101 nt 
Average number of reads per sample 1.26 M 2.9 M 3.1 M 
Target DN A size 71 kb 71 kb 71 kb 
Total mapped reads 19 M (84%) 120 M (84%) 125 M (84%) 
Average number of mapped reads per sample 1 M 2.5 M 2.6 M 
Average base coverage per sample 1,140x  1,800x  3,900x  
Percentage of target DN A covered at least 
1000x  52% 80% 98% 
Percentage of target DN A covered at least 500x  87% 95% 100% 
Table 2: Summary of the results of the sequencing runs described in this section. (*) Eight 
samples were obtained by manual normalization of PCRs, 6 samples by commercial 
normalization, and 4 samples corresponded to the pools of untagged samples. 
3.2.1    Pilot Run 
The pilot run (one lane of Illumina GA II flow cell) produced a total of 22.7 million reads of 77 nt (1.7 Gbases) 
that could be assigned to a specific sample according to the index sequence. For each sample this resulted in 1.3 
million raw on average, with a standard deviation of 380,000; i.e. there was on average 25% variation between 
the number of reads assigned to each sample. This indicated that the libraries were pooled in a relatively 
balanced proportion and there was no major over-representation of a sample with respect to another. 
Due to the shorter length of the sequences produced by the Illumina with respect to the Roche 454 
sequencer, we decided neither to trim nor to filter the reads before the alignment process. Indeed, we observed 
that using trimmed or raw reads gave similar results in terms of percentage of mapped reads, even by using 
stringent parameters. We also confirmed that reads that did not align to the reference sequence were 
automatically discarded from the mapping, thus avoiding creating noise in subsequent variation detection. 
Nineteen millions reads (84%) aligned to the reference sequence of the two genes analyzed, with one million 
reads per sample on average. The percentage of reads that are used in a mapping procedure gives an indication 
of the accuracy of the platform (depending on the stringency of the used parameters), but it also reflects the 
specificity of the enrichment procedure. PCR enrichment results in general in high sequence specificity, if 
primers are well designed and no off-target amplification occurs. Nevertheless, for long range PCR it is often 
difficult to optimize robust conditions to specifically amplify DNA of different qualities and therefore failure 
rate of amplification is relatively high. For all experiments performed, we checked each PCR product on 
agarose gels and selected for sequencing only those displaying good quality of bands. Even though this 
procedure ensures in principle to have a high level of specificity in the final sequencing results, for very few 
samples we still had mapping percentages that were significantly below the average. For example, one sample 
of the pilot run produced only 39% of the reads mapping on the target genes, while 54% of them mapped to 
other chromosomes. Such aspecific enrichment was likely due to the lower yield of PCR amplification for 
certain DNA samples of inferior quality, rather than to environmental genomic contamination, which 
nonetheless cannot be excluded.  
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The average coverage per base per sample was about 1,000x, a very high figure for analysis of single 
samples. We were therefore confident that pooling a higher number of samples for the real screening would 
guarantee a sufficient coverage for these analyses.  
As mentioned, we also tested the efficiency of two different techniques for the normalization of PCR 
products before pooling (visual inspection vs. commercial normalization kit). The efficiency of these 
procedures was scored by using the coefficient of variation of the average coverages calculated for each long 
range PCR of one sample (i.e the standard deviation of the coverage of LR-PCRs divided by the mean of the 
average coverage of LR-PCRs). This value was on average 0.4 with no significant differences across the groups 
of samples normalized manually or by the commercial plates. In this latter system, the DNA is normalized 
according to the total amount of DNA, not to the number of molecules. Consequently, an equimolar 
normalization occurs only for DNA molecules of the same size, but not for long range PCR products of 
different sizes. When we then measured the coefficient of variation of the average coverage of a given long 
range PCR across different samples, we obtained indeed a slightly better level of normalization of products 
with the commercial respect to the manual method (mean coefficients of variation = 0.30 vs. 0.42). These 
concepts are more clearly represented in Figure 3, showing specifically that in the manual normalization 
method (panel A) the coverage of long range PCR products are almost randomly variable, despite the effort of 
visual quantification, while in the commercial normalization method (panel B) the coverage is more consistent 
across the same LR-PCRs but varies with an inverse proportion with respect to their size. Specifically, shorter 
fragments (such as fragment #3) tend to have a higher coverage than longer ones (e.g. fragments #2 and #4). 
From the same plots we can also observe peaks of higher coverage where contiguous LR-PCR fragments 
overlap and therefore artificially create DNA intervals having a higher number of copies. 
 
 
F igure 3: Coverage Plots. Base coverage values are represented for each point of the target 
regions that were amplified by the 7 LR-PCRs drawn at the top of the plots. The exact lengths of 
LR-PCRs are: 8.6, 12.2, 8.8, 11.6, 10.2, 10.3, and 9.7 kb. Panels on the left are examples form 
LR-PCRs that were pooled with the manual method, while those on the right show LR-PCRs 
normalized by the commercial kit.  
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Taken together, these observations indicate that there is no real advantage in using commercial 
normalization kits such as the one that we tested, especially if we consider that the coverage obtained with high 
throughput platforms is very high and allows a confident detection of variations also at depths that are inferior 
to the average. This said, for other applications such as detection of structural variants or copy number 
variations, in which the analysis of the local changes in coverage is important, it will be necessary to operate a 
reliable normalization step. 
Another element that we wanted to test was variant calling sensitivity in pooled samples. The rationale was 
the same as the one used in the previous experiment, i.e. to save on library preparation reagents by merging 
different samples into a unique library. Unlike in the previous project, we tried to pool only two or four samples 
together, instead of 96 (we had previously concluded that the main limitations of the test was lack of accuracy 
due to the high number of pooled samples). We also used a different sequencing platform (Illumina instead of 
Roche 454). To perform this new test we sequenced four samples separately and as a pool of 2 or 4 samples, 
and then compared whether there were any differences in the variants detected by the two sequencing 
strategies. Four samples were purified by using the normalization kit and four others by manual pooling (Fig. 
2). The results of such test are reported in Table 3, and examples of the output in Table 4. The minimum 
frequency of reads expected for one allelic change in a two-sample pool is 25% and in a four-sample pool is 
12.5%. Therefore, we set compatible thresholds of detection (15% and 8%) to take into account normal 
experimental fluctuations as well. When we compared the results obtained from single nucleotide substitution 
analyses, we observed that globally the values at which polymorphic alleles were detected in the pools were 
very close to the expected frequency (Table 4, examples 1 and 2). Some exceptions were however present and 
resulted to be due to an uneven pooling or to an unbalanced amplification of specific long range PCRs. When 
such events are particularly intense, false negative results tend to occur, and the effect is larger when the 
number of samples increases (Table 4, examples 3). For example, in the manual pool experiment with four 
samples, we observed that false negatives were almost exclusive of one particular sample, which was likely 
under-represented in the pool with respect to the other three. Conversely, unbalanced allelic amplification, 
which occurs when the two alleles are differentially amplified, is recognizable while analyzing the frequency of 
detection in individual samples. For instance, a clear indicator for this event is a substantial deviation from the 
50/50 proportion for heterozygous SNP alleles. False positive variations (Table 4, example 4) were also present 
with a frequency of detection immediately above the threshold, likely because of an effect of sub-optimal 
sequencing or mapping events. 
We performed the same analysis for the detection of small insertions and deletions, using the same 
parameters. The rate of false positives for detection of these variant resulted to be significantly higher. These 
errors, which consisted in the wrong incorporation of a base during sequencing, were especially localized in 
long DNA stretches of the same nucleotide, similar to the phenomenon observed with the Roche 454 sequencer. 
It seems therefore that Illumina platforms are as well sensitive to this problem, at least when insertions or 
deletions are considered.  
Based on all these observation, we concluded that the strategy of pooling samples might be an efficient 
technique; however, it does not guarantee perfect mutation detection, even when a few samples are pooled. 
Consequently, we chose to sequence individual samples as separate libraries for the screening of new candidate 
disease genes. 
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   Single Nucleotide Substitutions Small Insertions/Deletions 
 
Samples 
F requency 
of 
detection 
# 
Detected 
Variants  
# 
Expected 
Variants* 
# 
False 
+ 
# 
False 
- 
# 
Detected 
Variants  
# 
Expected 
Variants* 
# 
False 
+ 
# 
False 
- 
M
an
ua
l p
oo
lin
g A 20% 91    12    
B 20% 100    10    
C 20% 70    12    
D 20% 70    11    
A+B 15% 112 115 1 4 28 16 12 0 
A+B+C+D 8% 151 148 12 9 44 22 22 0 
N
or
m
al
iz
at
io
n 
po
ol
in
g 
E 20% 82    9    
F 20% 96    9    
G 20% 59    10    
H 20% 112    18    
E+F 15% 106 107 1 2 23 12 11 0 
E+F+G+H 8% 158 171 4 17 42 24 24 6 
Table 3: Number of variants identified in individual samples and in pools of two or four of them, 
using appropriate detection frequency thresholds for single alleles. (*)Expected variants were 
calculated as the sum of unique variants found in the individual samples used for the pools.  
Samples A lleles A lleles F requencies 
Read 
Count  
per A llele 
Coverage A lleles A lleles F requencies 
Read 
Count  
Per A llele 
Coverage 
 Example 1 Example 2 
A T/C 54.1/45.9 396/336 732 C/A 50.3/49.5 518/509 1029 
B T/C 51.1/48.9 393/376 769 C 99.9 1442 1444 
C T/C 50.9/49.1 556/536 1092 C 99.4 1108 1115 
D T/C 54.7/45.3 594/491 1085 C 99.9 999 1000 
A+B T/C 52.8/47.2 293/262 555 C/A 77.4/22.6 727/212 939 
A+B+C+D C/T 50.5/49.3 464/453 918 C/A 89.9/10.1 1118/126 1244 
 Example 3 (False Negative) Example 4 (False Positive) 
A A 100 692 692 T 100 677 677 
B A 100 575 575 T/C 98.5/1.5 535/8 543 
C A 99.8 633 634 T/C 99.3/0.7 550/4 554 
D A/G 54.3/45.7 238/200 438 T/C 99.1/0.9 422/4 426 
A+B A 99.7 664 666 T/C 88.5/11.0 554/69 626 
A+B+C+D A/G 93.1/6.9 471/35 506 T/C 87.5/12.4 474/67 542 
Table 4: Examples of SNP alleles detected in individual and pooled samples. The thresholds for 
variant detection are the same as in Table 3. In Example 1 all samples have the same 
heterozygous change, which was correctly detected with ~50% frequency in both pooled samples. 
In Example 2 one sample out of four carries a SNP that was detected at the corresponding 
frequency in the two-sample (~25%) and in the four-sample (~12.5%) pools. Example 3 shows a 
false negative: allele G of sample D was detected in the pooled sample at a lower frequency 
(6.9%, highlighted) than the detection threshold, set at 8%. Example 4 shows a false positive 
detection in the four-sample pool (highlighted), in which reads carrying likely a sequencing error 
were counted as carrying a variant, due to the lower frequency threshold set in the pooled sample.  
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3.2.2    Screening Runs 
The screening was performed with two lanes of Illumina Hiseq flowcells, each one processing 48 different 
samples that were multiplexed with barcoded adaptors. As reported in Table 2, each run yielded in total about 
150 million reads, almost 6 times higher than the ones obtained with previous version of the platform (GAII) 
for the pilot experiment. After mapping procedures, 84% of the reads aligned to the reference sequence of the 
two genes and produced an average coverage of about 2,000 and 4,000x for each sample of the first and the 
second run, respectively. This was largely due to the fact that in the first run reads were 51 nt long while in the 
second they were 101 nt long (Table 2). The coefficients of variation calculated over the average coverages of 
every LR-PCR were 0.46 and 0.38, respectively, indicating that PCRs were pooled with less than half a fold 
difference on average. If we consider the coefficient of variation of the average coverage for each sample, we 
obtain 0.23 and 0.16 for the first and second round, respectively, suggesting a good balance among samples.  
We then performed variant detection on every sample to look for candidate mutations. When we excluded all 
variants reported in dbSNP, a database of human polymorphisms, we obtained a list of 139 unique variants. We 
also excluded 48 changes that were judged to be in stretches of bad alignment or low coverage by visual 
inspection of the mapping. Among the remainder 91 novel variants, we did not find any good candidate 
mutations, for the main reason that they were almost all intronic changes with no obvious effects on splicing of 
the gene transcripts, as predicted by the program NNSPLICE. The only novel nonsynonymous substitution was 
also predicted by PolyPhen to be non-pathogenic. 
Although we could not identify any variants with possible implication in the disease that we were studying, 
we could get some insights on the sequencing methods that we selected for the screening of candidate disease 
genes. In particular, preparing many libraries in SDUDOOHOWKURXJKWKH³WDJPHQWDWLRQ´PHWKRGZDVSURYHQWREH
extremely fast (only a few hours needed to process 96 samples) and reliable. While at the time of this 
experiment reagents were still rather expensive (the cost was comparable to the one for normal library 
preparation via nebulization and size selection), their price is now starting to drop considerably, making 
screenings of few genes for many samples more affordable. This latter feature, together with the time 
effectiveness of such kits, renders the multiplexed barcode method a better choice with respect to the 
anonymous pooling screening. In fact, with a relatively limited amount of additional effort and, likely, of costs, 
the results produced by this new approach contain ready-to-use information for a complete panel of individuals, 
with minimal necessities of validation by additional methods. Moreover, if sufficient coverage and sequencing 
quality are ensured, false discovery rates should be in principle very low. 
The biggest limitations that we could observe about this approach, but which are nonetheless present in the 
anonymous pooling approach as well, are mainly related to long range PCR robustness and scalability. For our 
purpose, which was based on the sequencing of a small region for many samples, LR-PCR was the best choice 
for several reasons. It (i) allowed very specific amplification of the target region, (ii) required relatively few 
reactions to cover up to 100 kbases, (iii) included non-coding region, and (iv) could be achieved by using 
standard laboratory procedures and equipment. On the other hand, long range PCRs are not as robust as short 
range PCRs and are very sensitive to the quality of the template. Optimization of robust PCRs may require a 
certain effort, and even when the right conditions are found it is still possible to observe failure in amplification 
of certain DNAs, which must be re-amplified or discarded from the screening. The time and effort necessary to 
obtain a complete panel of LR-PCRs for many samples to be processed at once can be indeed relatively long 
with respect for example to enrichment by hybridization. Additionally, PCRs must be individually checked, 
pooled in equimolar amounts, cleaned and quantified before starting the library preparation. Automated or 
semi-automated PCR-based enrichment methods, such as the ones outlined in the Introduction, could offer an 
interesting alternative to overcome these issues.  
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4    Conclusions 
The two methods described in this chapter represent two different ways of addressing the scientific question of 
whether several patients affected by a specific disease carry pathogenic mutations in a given gene. Both 
approaches, the anonymous pooling and the tagged multiplexing, can lead to an answer. The first method is 
faster and cheaper, but provides positive answers only when mutations in a candidate gene have a relatively 
high frequency in the cohort that is analyzed. Furthermore, in case of negative results, it is not possible to rule 
out that the screening was poisoned by false negative events. Since the differences in costs and time required to 
perform the first vs. the second method are progressively diminishing, it may be worthier using tagged 
multiplexed libraries. Moreover, the rapid evolution of high throughput sequencing technologies and associated 
equipment is predicted to further facilitate the sequencing of many samples together. 
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Project 4: Screening of candidate splicing factors for mutations in adRP 
patients 
 
The results of the screening of SNRNP200 confirmed the association of the members of the 
tri-snRNP complex with autosomal dominat RP, and that candidate gene screening is still an 
effective tool for gene hunting in RP, even in the exome/genome sequencing era. This fact 
encouraged us to perform a second screening of other splicing factor genes (EFTUD2, 
PRPF4, NHP2L1 and AAR2) as novel candidate for adRP. The genes have been chosen based 
on their functional interaction with known genes of the tri-snRNP complex as documented in 
the literature. Since mutations in novel RP genes are expected to be very rare, a high number 
of patients with undiagnosed molecular cause is needed to add power to the screening. We 
expanded our adRP cohort used for the sequencing of SNRNP200 with additional samples 
shared by our collaborators from France (Christian Hamel, M.D.) and Spain (Carmen Ayuso, 
M.D.). We reached a total of 200 samples for the discovery-screening phase and about 100 
more for downstream validations. Following the methodological conclusions drawn in our 
previous publications, we adopted a similar NGS-based strategy using a pool of long-range 
PCRs as template, with the difference of using a high throughput commercial system for 
preparing barcoded libraries, by means of transposase reactions. This was used for the large 
genes, while for the genes composed of few exons we used capillary electrophoresis (Sanger) 
sequencing. The results did not reveal any plausible mutation linked to retinitis pigmentosa, 
although few confirmatory elements are missing. After their completion, the manuscript will 
be submitted to Molecular Vision or Ophthalmic Genetics, with minor modifications with 
respect to the following document.   
 
 
Candidate’s roles: 
• Design of the project. 
• Preparation of samples for sequencing: PCR enrichment and libraries preparation. 
• Planning and execution of the sequence analyses. 
• Downstream validation analyses by Sanger sequencing and other bioinformatic 
analyses. 
• Writing of the manuscript. 
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ABSTRACT 
Retinitis pigmentosa (RP) is a rare disease with heterogeneous genetic basis, characterized by 
the progressive degeneration of photoreceptors. Eleven percent of autosomal dominant RP 
(adRP) forms are caused by mutations in genes belonging to the tri-snRNP complex of the 
spliceosome. Although the exact mechanism by which splicing factor defects trigger specific 
photoreceptor death is not clear, their role in retinitis pigmentosa has been demonstrated by 
several genetic and biochemical studies. We sequenced four tri-snRNP splicing factor genes 
(EFTUD2, PRPF4, NHP2L1 and AAR2) previously not associated with RP in 200 adRP 
patients of European origin, to test their possible role in the disease. We took advantage of 
both classic Sanger sequencing and next generation sequencing methods to obtain accurate 
and cost-effective sequence data. The result of the screening revealed a few novel missense 
changes, whose role in the disease was not possible to verify. This suggests that the 
connection between splicing factors and RP is far from being obvious, and that recent 
advances in genome-wide sequencing might offer more unbiased approaches than candidate 
screening procedures to discover the remaining fraction of genes causing RP. 
  
INTRODUCTION 
The most common form of hereditary blindness is retinitis pigmentosa (RP), affecting 1 in 
4000 people worldwide. The disease typically begins with night blindness, due to early 
involvement of rod photoreceptors, and progresses with the reduction of visual field and 
eventual loss of central vision, as a result of later degeneration of cone photoreceptors [1]. 
Patients affected with RP display clinical heterogeneity with respect to age of onset, degree of 
severity, rate of progression and other secondary manifestations. These differences are partly 
explained by the different genes and mutations causing RP: to date, 56 genes have been 
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associated with non-syndromic RP, with about 3000 different mutations reported in total [2]. 
The inheritance mode is classically monogenic: dominant (~30-40%), recessive (~50-60%), x 
linked (5-15%), and a smaller fraction of non –Mendelian or complex inheritance [1]. 
Nevertheless, this genetic heterogeneity does not always determine differences in clinical 
manifestations, making it hard to assess clear genotype-phenotype correlation.  
The functions of RP genes can be very diverse: some genes are specific for retinal functions 
such as phototransduction and retinal metabolism; some others have a more general function 
in cell development and maintenance [3]. A particular category that exemplifies the 
complexity of the molecular genetics of RP is represented by a number of very conserved and 
ubiquitously expressed pre-mRNA splicing factors. Splicing consists of enzymatic reactions 
leading to the removal of introns from pre-mRNA to form mature mRNA. A macromolecular 
complex, referred to as the spliceosome, ensures the fidelity and the correct timing or these 
reactions. The spliceosome is composed of pre-mRNA, five small nuclear ribonucleoproteins 
(snRNP), U1, U2, U4/U6 and U5, and ~200 other proteins [4]. Spliceosome assembly is a 
dynamic, stepwise process: U1 snRNP first recognizes the 5’ splice site and U2 binds to the 
branch point; then U4/U6.U5 tri-snRNP complex is recruited and finally U1 and U4 are 
released, leading to catalytic activation [5]. 
To date, six splicing factors genes have been found to be mutated in adRP patients: PRPF8 
(RP13) [6], PRPF31 (RP11) [7], PRPF3 (RP18)[8], PAP-1 (RP9) [9], SNRNP200 (RP33) 
[10, 11] and PRPF6 [12].  These discoveries have been achieved through linkage analysis and 
positional cloning for the first two genes discovered (PRPF8 and PRPF31), followed by 
screening of other splicing factor genes in linkage intervals. All these genes have in common 
the high level of protein sequence conservation up to yeast, and their belonging to the 
U4/U6.U5 tri-snRNP complex. The growing evidences of a major role of these particular 
splicing factors suggested that also other partners of the complex could be meaningful 
candidate genes for adRP, which still includes about 50% of cases with unsolved genetic 
cause.  The role of the PRPF6 gene in adRP was found by such an approach, after screening 
its coding sequence in a cohort of 200 American patients [12]. 
Following this rationale, we screened four candidate genes (EFTUD2, PRPF4, NHP2L1 and 
AAR2) in 200 adRP patients with unknown molecular diagnosis and previously analyzed for 
mutations in the most common adRP genes or hotspots. These genes were selected based on 
their physical and/or functional interaction with known RP-linked splicing factors. EFTUD2 
encodes for an essential GTPase hSnu114, homolog of S. cerevisiae Snu114p, which forms a 
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stable complex with the SNRNP200 and PRPF8 products (i.e. hBrr2 and PRPF8) [13]. 
hSnu114 regulates hBrr2 at the dissociation step of U4 from U6 snRNAs and is also 
necessary for spliceosome disassembly after splicing [14]. Aar2p  (encoded by the AAR2 
gene) competes with hBrr2 in the binding of the C-terminal region of PRPF8 before the 
maturation of the U5 snRNP, supposedly regulating its assembly [15]. The 15.5-kDa protein 
(Snu13p in yeast), encoded by the NHP2L1 gene, binds to the 5!-stem-loop of U4 snRNA 
probably playing a role in the late phase of the spliceosome assembly [16]. Finally, PRPF4 
protein forms a complex with PRPF3 in the U4/U6 snRNP complex and its downregulation 
was found to induce photoreceptor defects in a Zebrafish model, similarly to PRPF31 [17, 
18]. 
For the genetic screening we took advantage of a method that combines classical exon-PCR 
for the small genes, and long-range PCR followed by next generation sequencing for the large 
ones (Table 1). The latter approach provides a cost- and time- effective alternative to the 
Sanger method and well adapts to routine genetic screenings in large sets of samples. 
 
METHODS 
Samples and patients 
The subjects analyzed in this cohort belong to three different collections of unrelated patients 
affected with autosomal dominant retinitis pigmentosa. One hundred ninety-one samples were 
collected and followed in the Massachusetts Eye and Ear Infirmary – Harvard Medical 
School; they are mostly American of European origin.  Fourty-seven were collected in Spain 
(Servicio de Genética, IIS Fundación Jiménez Díaz, Madrid) and 96 were from France 
(Service d'Ophtalmologie, Université et Hôpital de Montpellier). DNA was extracted from 
peripheral leukocytes and quantified. For technical reasons, not all these samples could 
undergo the complete screening, but all of them were used in case of validation of putative 
mutations. Control DNA samples were obtained from 95 individuals with no history of retinal 
degeneration and 96 unrelated healthy individuals aged between 34 and 92, purchased from 
the Coriell institute for medical research. All subjects provided written, informed consent and 
the study was conducted in adherence with the Declaration of Helsinki. 
 
Library preparation and next generation sequencing (NGS) 
Genes EFTUD2 and PRPF4 were sequenced by a long-range PCR (LR-PCRs) enrichment 
and next generation sequencing approach, using Illumina instruments (San Diego, CA). Five 
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and two LR-PCRs were generated to amplify the entire 51 and 20 kb regions of each gene, 
respectively, for a total of 71 kb targeted region. LR-PCRs were obtained individually for 
each sample using TaKaRa LA Taq polymerase (Takara Bio, Shiga, Japan) with GC buffer 
and 1 "M of the primers reported in Table S1. The following cycling conditions were used: 
94 °C for 1’ followed by 30 cycles at 98 °C for 5`` and 68 °C for 15’, and final extension of 
72 °C for 10’. For each sample, the 7 LR-PCRs were pooled into a single tube, after 
estimation of their quantity by agarose 1% gel visualization. They were subsequently purified 
using DNA Clean and Concentrator columns (Zymo Research, Orange, CA). Only the DNA 
samples from the three cohorts that yielded 7 clear PCR bands underwent NGS. 
Library preparation and sample barcoding were performed with the tagmentation method [19] 
using the Nextera DNA Sample Prep Kit (Epicentre, Madison, WI) and 48 barcodes adapted 
to Illumina platforms [20], following manufacturer instructions. Fourteen tagged samples 
were sequenced as a pool in one lane of the GAII instrument for testing purpose, after which 
two runs of Hiseq instrument (one lane) were used to sequence two different pools of 48 and 
47 barcoded samples each. After the integration of the Nextera products by Illumina 
Company, we processed 91 additional samples using the Nextera XT DNA Sample 
Preparation (Illumina) protocol, reagents and barcodes, and sequenced them as a unique pool 
by one Miseq instrument run. 
 
Analysis and variant calling of sequences from NGS 
We mapped the reads obtained from NGS to the reference sequence of the genes 
(GRCh37.p10 assembly) by the CLC genomics Workbench package, v. 5.5 (CLC bio, 
Aarhus, Denmark). The parameters were in a way that a read could align only if it had at least 
a 90% identity for the 90% of its length. A more relaxed setting (80% identity over 70% of its 
length) was also tried. Single nucleotide variant calling and small insertion and deletion 
calling was achieved by imposing a minimum frequency of discordant bases of 20%, with 
minimum coverage of 5 nucleotides and an average base quality of 20 Phred.  The analyses 
were performed as a batch for all individual samples (200) and the obtained variants were 
annotated with the hg19_snp137 track from the UCSC genome browser.  
 
Functional predictions of variant identified 
Missense changes were analyze by the online package PON-P, which integrates results of the 
most common prediction software including PolyPhen and SIFT [21]. The effect of intronic 
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changes was evaluated by the Shannon Human Splicing Pipeline implemented in the CLC 
software [22] and the NNSPLICE 0.9 algorithm [23]. 
 
Sanger sequencing and restriction analysis 
The genes NHP2L1 and AAR2 were screened by Sanger sequencing of the coding exons. PCR 
reactions were obtained by the GoTaq polymerase (Promega, Madison, WI) standard protocol 
and 0.25 "M of the primers reported in Table S2. Reactions were purified from excess 
primers and nucleotides by ExoSAP-IT (Affymetrics, Santa Clara, CA) and subjected to 
sequencing reactions using Big Dye V1.1 Terminator Kit (Applied Biosystems, Foster City, 
CA) and an ABI automated DNA sequencer (Applied Biosystems). Sequences were analyzed 
using the CLC Genomics Workbench. The same procedure was applied for the validation of 
novel changes in specific exons identified by NGS, cosegregation analysis and screening of 
controls and additional patients. Primers used for these purposes are also listed in Table S2. 
Controls and patients were tested using restriction enzymes when a particular nucleotide 
change abolished or created a restriction site. In particular exon 5 of PRPF4 was tested with 
MscI, exon 8 of EFTUD2 with HahI and exon 1 of NHP2L1 with MluI (New England 
Biolabs, Ipswich, MA). 
 
RESULTS 
NGS screening 
A total of 200 unrelated individuals diagnosed with adRP were screened for the genes 
EFTUD2 and PRPF4, in search for candidate mutations. Seventy-nine patients were from 
USA, 71 from France and 50 from Spain. The approach used to sequence these genes 
consisted of an enrichment step via LR-PCR, followed by multiplexed runs of NGS 
instruments. The analysis of the so-obtained reads involved firstly the alignment of such 
sequences to the reference genomic sequences of the targeted genes. Since different 
instruments were used, different samples had different coverage depths. Specifically, the 
samples sequenced using HiSeq had higher coverage with respect to the ones sequenced using 
MiSeq, due to the lower throughput and higher number of samples sequenced with the latter 
(Table S3). With the exception of a few samples, the targeted region was optimally covered 
for reliable variant calling. This consisted of the detection of both single nucleotide variations 
and small insertions and deletions by the CLC Genomics algorithm. After merging the results 
for each sample, we obtained a total figure of 1,195 variants identified, 591 of which are 
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known polymorphisms present at different frequencies in the analyzed cohort. By restricting 
the analysis to missense changes, we identified in total 6 variants, of which only 3 were novel 
(Table 2). 
Three different patients carried three different variants in PRPF4, of which 2 had an rs 
number and one was a false positive due to low coverage, as ascertained by Sanger 
sequencing. Although the DNA residue c.559C (NM_004697.3 – exon 5) is tagged by the 
rs187531407 number, the ccc>tcc (p.Pro187Ser) change was found only in two not validated 
1000Genomes reports. We could ascertain that one of these reports (low-coverage 
1000Genomes) was a false positive, after having retrieved and sequenced the DNA sample 
that was identified to carry this variant. Moreover the base change in the patient of our cohort 
is different: it is a ccc>gcc change, which is translated into p.Pro187Ala. The residue is fairly 
conserved across species and, according to predictions with different tools, the likelihood of 
pathogenicity is uncertain (Table 3). We followed up this change by analyzing controls and 
available relatives. Public databases, as well as sequencing of in-house controls, did not reveal 
the presence of this change. Neither it was found in the remaining, unscreened patients from 
our cohorts. The affected sibling (226-1953) also carried the same change, but other members 
were not available to check further the segregation. Since the base change is located 5 
nucleotides away from the exon-exon junction, we also checked if splicing of the exon could 
be affected. Bioinformatic prediction was negative and RT-PCR of patient’s cDNA (data not 
shown) did not reveal missplicing events. The lack of further information, the possible 
presence of polymorphism in the same codon and a not striking prediction of pathogenicity 
prevented us to make significant conclusions. 
Of the four missense changes found in the EFTUD2 gene, two were novel and present in 
single individuals: p.Arg220Cys and p.Ile80Leu (Table 2). The first one was confirmed by 
Sanger sequencing and predicted to be pathogenic by a number of prediction tools (Table 3). 
The residue is in fact much conserved, from human to yeast. The change was absent in public 
variation databases (dbSNP, 1000Genomes, exome variant server, 42 unlerated control 
individuals from Complete Genomics). Moreover it was absent in 150 controls tested in-
house and in the remaining patients from the cohort. Although we verified that patient’s 
healthy sister and son did not carry this change, the unavailability of other family members 
prevented us for further investigation of the variant.  The second change I80L was predicted 
to be a neutral change, based on conservation and strength of change and was not investigated 
further. 
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Since LR-PCR amplified both coding and non-coding regions of the target genes, we tested if 
any novel variant identified could affect sequences important for splicing signals also located 
in deep intronic regions. We analyzed 1,008 variants in both exons and introns of the 
EFTUD2 and PRPF4 genes with the Shannon Human Splicing Pipeline [22].  Only single 
nucleotide substitutions, but not insertions or deletion could be tested with this method. No 
change inactivated or reduced the strength of the natural splice sites. Four hundred thirty-four 
variants were predicted to modify in some way the sequence content information (defined 
with R) of cryptic splice sites. By filtering for variations that were not polymorphic and that 
resulted in the creation of a donor or acceptor splice site with greater strength than the natural 
splice site, only 5 variants were left (Table S4). Two of them were likely false positives 
because they were present only in one read out of 5-fold coverage. For the remaining three, 
other predictions were made using the NNSPLICE algorithm and did not agree with the one 
of the Shannon pipeline. In two cases the new cryptic splice sites were still weaker than the 
natural ones and in one case the already existing cryptic site was weakened by the change and 
not strengthen.  
Finally a second run of variant calling was performed on alignments obtained with less 
stringent criteria, in order to exclude the possibility of false negatives, due to too rigid 
mapping parameters. Such an analysis increased by two times the number of known SNPs 
identified (999 vs. 476) and by three times the number of non-reported changes (3752 vs. 
1195), indicating a gain in sensitivity, but also a loss in specificity (Table S5). In fact, when 
analyzing coding changes only, in addition to the variants found with the previous mappings, 
we obtained 8 false positives, all found in the same sample and localized in a stretch of 
wrongly aligned reads, as it was clear from inspection of the mapping. 
 
Sanger sequencing screening 
We selected two additional genes of the tri-snRNP complex to be screened by Sanger 
sequencing, in virtue of their small size. The gene NHP2L1 consists of two coding exons and 
two alternative 5’ UTR containing the start codon. The sequencing of the four exons in 320 
patients did not reveal anything significant but a novel change introducing an ATG start 
codon in the 5’ UTR, that was not found in the control population. This change was 
interesting because it creates an upstream open reading frame (uORF), whose effect would be 
to reduce the translation from the downstream, canonical ATG. However, this change did not 
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segregate with RP in the family. The sequence of AA2R gene was negative for novel 
variations. 
 
DISCUSSION 
The adRP-linked splicing proteins PRPF31, PRPF3, PRPF8, PRPF6, and hBrr2 are all 
components of the U4/U6.U5 tri-snRNP, suggesting that there is a common mechanism of 
pathogenesis in RP related to dysfunction of this complex. It has been shown that mutations 
in these proteins impair the assembly of tri-snRNP complex [24] [25] and/or affect catalytic 
activation of the spliceosome [26], leading to pre-mRNA splicing defects and eventually to 
cell death [27-29]. Mutations are thought to act through a haploinsufficiency mechanism 
because many of them either determine truncation and degradation of the protein and the 
transcript [30] or their instability and accumulation in Cajal bodies [27-29]. 
We wanted to investigate the hypothesis of the implication of other U4/U6.U5 tri-snRNP 
proteins in adRP by screening their DNA sequences in well-characterized cohorts of dominant 
patients who do not carry mutation in the most prevalent RP genes. We used an NGS-based 
approach that allowed a fast and parallel analysis of few candidate genes in a large set of 
patients, enabling in principle the identification of very rare mutations. The sequencing of the 
coding exons of the genes NHP2L1 and AAR2, and of exons and introns of EFTUD2 and 
PRPF4 revealed a few variants that could have an effect at the protein level and that were 
absent from the general population. Only the p.Arg220Cys missense in the EFTUD2 gene 
was predicted to be damaging but its putative pathogenicity could not be demonstrated. 
Moreover, during the course of this screening, the same gene has been linked by exome 
sequencing to another class of rare and sporadic congenital malformation syndromes, in 
particular to Mandibulofacial dysostosis with microcephaly (MIM 610536) [31, 32]. In these 
patients, mutations were de novo heterozygous missense, frameshift and null alleles. 
Although certain phenotypic variability was observed for EFTUD2 mutations [33], it seems 
that they impact early developmental stages and lead to much more dramatic phenotypes than 
RP. However, it cannot be excluded that other mutations may have milder effects and trigger 
the same photoreceptor cell death pathway as for the RP-linked splicing factors. The negative 
results for this and the other genes screened in this study, and the evidence that mutations in 
components of the tri-snRNP have role in other diseases indicate that their link to adRP is not 
straightforward. The implication of splicing factors in RP likely involves very subtle 
mechanisms in which RP mutations determine gradual accumulation of mild splicing defects, 
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which are less tolerated by photoreceptor cells, because of their higher demand of splicing 
[29]. It is therefore rather difficult to predict which ones of such proteins would be implied in 
RP and a candidate gene screening strategy may result inefficient to identifications of new 
adRP genes. Otherwise, gene-based approaches have proven to be very effective in the 
discovery of novel genes involved in RP [12, 34], especially in the early phases of RP genetic 
research. Conversely, in recent years the rate of discovery of novel genes has slowed down 
with respect to the previous 20 years, because unknown RP genes are increasingly rare and 
fewer families suitable for linkage analysis are available [2]. With the introduction of next 
generation sequencing it is no longer an issue to obtain genome-wide information of patients 
affected with Mendelian diseases and identification of the molecular cause can be achieved by 
an unbiased prioritization of mutations and/or by gene-driven hypothesis (i.e. by looking only 
at a large set of known or candidate genes). Powerful techniques such as exome sequencing 
have proven to be extremely useful in identification on novel mutations and genes, also in RP. 
However discoveries via exome sequencing have been obtained when analyzing recessive 
conditions or dominant diseases with no genetic heterogeneity. For a dominant disease with 
elevated genetic heterogeneity, the computational analysis and validation elements necessary 
to find significant association with heterozygous changes become more important [35]. 
Therefore, in autosomal dominant RP, the screening of many samples for candidate genes can 
still be a feasible option, provided that 1) strong candidate (possible deriving from animal or 
cellular model) are tested and 2) cohorts highly enriched in novel genes are screened. For 
these applications as well, next generation sequencing can offer useful strategies to perform 
targeted re-sequencing in a fast and comprehensive manner, such as the one adopted for this 
study.  
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TABLES 
 
Symbol Protein snRNP complex 
# 
exons Screening method 
# 
screened 
patients 
EFTUD2 Elongation factor Tu GTP binding 
domain containing 2- 116 kDa 
U5 
 
28 
 
Nextera-NGS 200 
PRPF4 PRP4 pre-mRNA processing factor 4 
homolog – 60kDa 
U4/U6  14 Nextera-NGS 200 
NHP2L1 NHP2 non-histone chromosome protein 
2-like 1- 15.5 kDa 
U4/U6.U5 4 Sanger 320 
AAR2 AAR2 splicing factor homolog U5 4 Sanger 100 
 
Table 1. Genes analyzed in this study and methods.  
 
 
Gene Sample count 
Genomic 
Position Coding region change Amino acid change DATABASE* 
Allele counts 
(M/m) 
EFTUD2 1 17:42953357 NM_004247.3:c.814A>G NP_004238.3:p.Thr272Ala rs150633454         541/497 
EFTUD2 1 17:42956968 NM_004247.3:c.658C>T NP_004238.3:p.Arg220Cys - 779/649 
EFTUD2 1 17:42963986 NM_004247.3:c.238A>C NP_004238.3:p.Ile80Leu - 292/292 
PRPF4 3 9:116049532 NM_004697.4:c.233A>G NP_004688.2:p.His78Arg rs1138958 - 
PRPF4 1 9:116053294 NM_004697.4:c.481G>A NP_004688.2:p.Glu161Lys - 4/1 (False +) 
PRPF4 1 9:116053770 NM_004697.4:c.559C>G NP_004688.2:p.Pro187Ala rs187531407 1139/1363 
 
Table 2. Variant output from NGS screening after filtering for aminoacidic changes. Genomic coordinates refer 
to assembly GRCh37.p10. Numbering of coding region starts at A of the ATG. *Human variation database 
search included dbSNP 137, 1000 Genome Project, Exome variant server, Complete Genomics control samples 
(52) and internal database of 500 exomes (CoLaus). 
 
 
Gene Origin Change 
Polyphen 
prediction 
based on 
alignment 
PON-P prediction Controls Segregation 
PRPF4 German p.Pro187Ala Probably damaging 
Unclassified, Probability 
of pathogenicity: 0.27 0/189 
Not 
conclusive 
EFTUD2 
American Indian- 
French 
Canadian/Irish 
p.Arg220Cys Probably damaging 
Pathogenic, Probability of 
pathogenicity: 0.91 0/150 
Not 
conclusive 
EFTUD2 - p.Ile80Leu Benign Neutral, Probability of pathogenicity: 0.02 NA 
Not 
available 
NHP2L1 Italian chr22:42078408 NM_005008.2:c.-46G>A   Creation of upstream out of frame ORF 
0/150 (and 
absent from 
database too) 
Negative 
 
 Table 3. Characterization of changes identified in the complete screening. Prediction of pathogenicity was made 
using public software of Polyphen [36] and PON-P [21]. Additional controls were performed.  
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SUPPLEMENTAL TABLES 
PRIMER NAME SEQUENCE 
EFTUD2_LR1_for CTCAGCCCTCCCCAGGCATTTAATACATAG 
EFTUD2_LR1_rev GCCAACCTCTTCCTTAAGAACACAAAACCC 
EFTUD2_LR2_for ATGGGGACAGGAAAGAAAGATGTCCCT 
EFTUD2_LR2_rev TCAAGGGGAAAATGTACACACCTGTCTCT 
EFTUD2_LR3_for CAATTGAGAGATGGAACACTTTGGCTAACCTT 
EFTUD2_LR3_rev TCTATTAGTAATTTCTGTGACCATGGGCATAG 
EFTUD2_LR4_for TACATGAGGGGAAACTATGCCCATGGTC 
EFTUD2_LR4_rev GACAAAGAATCTGGGAGAGACAGTCCCC 
EFTUD2_LR5_for ATTGTGCCATTGCTCTCCTTTTTGAGATGG 
EFTUD2_LR5_rev ATTAAGTTCTCCTGTTCTGGGCTCCACATC 
PRPF4_LR6_for TCCCTCATCTGTATCCTACTCTGCTGTTGT 
PRPF4_LR6_rev GTAATGAGGCTTGGAGAGGTGGACTCATTT 
PRPF4_LR7_for ACACAAAGCACTCTGTCACATTCTTGACAC 
PRPF4_LR7_rev CTTGAGCAAGTGTTTTTGGAGCCTGTTTTG 
 
Table S1. Primers used for long-range PCR 
 
PRIMER NAME SEQUENCE 
NHP2L1_Exon1-isoform1_for CATGTGAAGGAGACATACTC 
NHP2L1_Exon1-isoform1_rev GTGGGACCACTCATCTATAG 
NHP2L1_Exon1-isoform2_for TCAGCTGGAGTGCTAGAGTG 
NHP2L1_Exon1-isoform2_rev AAACAGACCGTGCGGCAAAG 
NHP2L1_Exon2 _for GCCATGGACTCAAATGGATG 
NHP2L1_Exon2_rev AGCCCATCAGCTTTAGCATC 
NHP2L1_Exon3 _for AAGTGGTCAGATTCAGGACG 
NHP2L1_Exon3_rev AAGGATGAAGGATGGCAGAG 
AAR2_Exon1_for GCTGTGAAGTGAGTGTCCTTGCAT 
AAR2_Exon1_rev AACTGCGGAAGCCCCACTCC 
AAR2_Exon2_for TGCCAGGCTCTGCAGGAGTGA 
AAR2_Exon2_rev AGGGAGAGGGTGGTACAGAGAGA 
AAR2_Exon3_for AGTCCTGCCCTAGCATCTCA 
AAR2_Exon3_rev ATGGGTACAGCCTCTTTGGC 
EFTUD2_exon8_for TCAAGTTCTCTGGCTCCCAG 
EFTUD2_exon8_rev GCGAGGAGGAAAGGGGATAT 
PRPF4_exon5-6_for GAATTCACCTTCCTTCTGGG 
PRPF4_exon5-6_rev CAGAGGTGAGCCAAAGTAG 
 
Table S2. Primers used for short range PCR and sequencing 
 
Instrument Multiplexed samples 
Read 
Length 
Number of 
reads 
Average per 
sample reads 
Average % 
mapping 
Average per 
sample 
coverage 
Illumina GA II 1 
lane 14 77 1,304,633 1,008,000 0.77 
2,383 
Hiseq 2000 1 lane 48 51 143,417,293 2,987,860 0.85 1,876 
Hiseq 2000 1 lane 47 101 148,691,083 3,163,640 0.84 3,826 
Miseq 
full 91 
200-250 
(paired) 31,690,692 348,249 0.90 
962 
Total samples 200      
 
Table S3. Summary of metrics of NGS screening runs and per sample statistics. 
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Gene Name EFTUD2 EFTUD2 EFTUD2 EFTUD2 PRPF4 
Chromosome 17 17 17 17 9 
Splice site coordinate 42939388 42954217 42963479 42938786 116041841 
Input variant T/A C/T G/C C/G T/G 
Ri-initial -13.32 -2.34 2.91 10.68 -2.09 
Ri-final 5.3 12.37 6.78 13.05 1.28 
!Ri 18.62 14.71 3.87 2.37 3.38 
Type DONOR ACCEPTOR DONOR ACCEPTOR DONOR 
Loc. of nearest nat. site 42940080 42953469 42963952 42937912 116041412 
Ri of nearest nat. site 3.21 10.16 4.74 3.3 -1.45 
Cryptic Ri relative to nat. GREATER GREATER GREATER GREATER GREATER 
Carriers 1 1 1 1 1 
Variant coverage  1 out of 4   1 out of 4 
Observations 
not concordant 
with NNSPLICE false positive  
not concordant 
with NNSPLICE 
not concordant 
with 
NNSPLICE false positive 
 
Table S4. Results of splice sites analysis using the Shannon Human Splicing Pipeline. Ri is a measure of the 
likelihood of a sequence to be used as acceptor or donor splice site. #Ri is the difference between the R value of 
a genomic coordinate in presence and in absence of the nucleotide variation. Nat.site is the closest natural splice 
site. 
 
 
 Used parameters Low stringency parameters 
Total variants 1195 3752 
Total variants <1% frequency 591 1928 
Tot SNPs 476 999 
Total nonsynonimous changes 6 14 
Tot nonsynonimous, non SNP change 3 11 
False positives 1 8 
 
Table S5. Total number of variants identified by two alignments with different mapping criteria. 
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Project 5. Study of possible mechanisms of incomplete penetrance of 
SNRNP200 mutations 
 
 
Incomplete penetrance is a phenomenon occurring most often in autosomal dominant diseases 
in which some of the members of a family segregating a mutation do not manifest the 
symptoms of the disease. Moreover, mutations can have variable expressivity determining 
differences in the presentation and in the severity of the symptoms. The causes for different 
penetrance and expressivity can be environmental, genetic or epigenetic. In retinitits 
pigmentosa there are very rare examples of incomplete penetrance, most of which are linked 
to mutations of the splicing factor gene PRPF31 and determined by genetic modifiers 
influencing its expression. A few reports have indicated that also mutations of other RP-
linked splicing factor genes can display this feature. Our collaborator Prof. Christian Hamel, 
MD, identified and examined a 4-generation French family with adRP and segregating the 
SNRNP200 p.R681C mutation, which was first reported in three patients from our screening 
(project 2). The mutation is transmitted from generation 1 to 4. However, carriers from the 2nd 
and 3rd generation are asymptomatic. We were involved in this study to find possible 
explanations for incomplete penetrance observed in this family by studying lymphoblastoid 
cell lines derived from family members. We also had clinical information and cell lines from 
SNRNP200 patients from our original paper, and included them in the analysis, to have better 
insight into SNRNP200 mutations at both clinical and, possibly, molecular levels. The results 
are still preliminary and need further experimental work. I presented them here in the form of 
an article for coherence with the rest of the thesis. We plan to complete the analysis and to 
submit a manuscript for publication by the end of year 2013. 
 
 
 
Candidate’s role 
• Patients’ lymphoblastoid cell lines immortalization and culture 
• Gene expression analysis by Real time PCR and Western Blot 
• Writing of the manuscript (except for the clinical parts, provided by Prof. Hamel) 
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ABSTRACT 
Retinitis pigmentosa (RP) is a genetically heterogeneous monogenic disease leading to 
progressive degeneration of the photoreceptor layer of the retina. Mutations in splicing factor 
genes contribute to a large proportion of autosomal dominant RP (adRP) cases. The gene 
SNRNP200 encodes a splicing factor protein of 200 kDa and has been linked to adRP by 
identification of several missense mutations. We identified for the first time a family 
segregating the SNRNP200 p.R681C mutation showing incomplete penetrance and intra-
familial variability with two severely affected members and one mildly affected, whose 
clinical phenotypes are reported in detail. The examination of other patients with SNRNP200 
mutations shows a picture of rather mild-variable phenotypes, consistent with previous 
literature. Molecular characterization of the mutation p.R681C in lymphoblastoid cell lines 
from patients reveals a decrease in SNRNP200 protein compared to controls. Further 
investigation on changes in SNRNP200 protein stability upon missense mutations might help 
to elucidate the mechanisms by which SNRNP200 mutations may determine variable RP 
phenotypes. 
 
INTRODUCTION 
Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal dystrophies affecting 
more than one million people worldwide [1]. Typically patients present with difficult dark 
adaptation and night blindness in adolescence, and loss of mid-peripheral and far-peripheral 
vision in young adulthood. Central vision may be eventually lost as well. The main hallmarks 
of RP at fundus examination are the presence of melanin deposits resembling bone spicule 
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released from the RPE, retinal atrophy and retinal arterioles attenuation. Electroretinography 
(ERG) is used for objective diagnosis of RP and monitoring of the progression of the disease. 
Another tool used to analyze retinal thickness and integrity especially in the macula is optical 
coherence tomography (OCT). Patients display a wide variability in the manifestations of the 
disease, including age of onset, rate of progression and fundus appearance [2]. Genetic factors 
heavily influence the outcome of this pathology. RP is caused by mutations in more than 50 
genes, which can be inherited most often as autosomal dominant, recessive or X-linked traits 
[3]. The genetic heterogeneity of RP also includes rather frequent cases of inter-individual 
variability, in which the same mutation may result in different expressivity of phenotype. 
Incomplete penetrance is far rarer, and is mostly observed in individuals carrying mutations in 
the second most common adRP gene, PRPF31, which encodes for a component of the pre-
mRNA spliceosome [4]. In PRPF31 families, incomplete penetrance is due to a differential 
mRNA expression between affected and asymptomatic carriers of mutations [5, 6]. Isolate 
reports of RP with incomplete penetrance have been described for other genes including RP1 
[7], PAP-1 [8] and PRPF8 [9], suggesting that the mechanisms of RP phenotype non-
penetrance are multiple and possibly related to splicing factor genes. 
The 200 kDa DExD/H-box RNA helicase hBrr2, encoded by the SNRNP200 gene, is another 
core component of the spliceosome complex, which was first linked to adRP in two different 
Chinese families [10, 11]. They segregated two different missense changes (p.S1087L and 
p.R1090L) which are located in the N-terminal Sec63-like domain and were shown to impair 
Brr2 helicase activity in yeast [10]. Later, four additional missense mutations (p.Y689C, 
p.R681C, p.R681H [12] and p.Q885E [13]) were identified in the first and more conserved of 
the two Hel308-like helicase domains. Although their effect at the molecular level have not 
been yet tested, their pathogenicity is strongly supported by segregation in families, 
conservation of the residues, absence of the changes in control population, and crystal 
structure models [13, 14]. At the clinical level, SNRNP200 mutations are usually associated 
with fully penetrant adRP with variable phenotypes and relatively late onsets [11, 13, 15]. 
 
MATERIALS AND METHODS 
Clinical and genetic assessment  
Patients R681C_1 to _5 were examined at the Centre of Reference for Genetic Sensory 
Diseases, in Montpellier, France, as described before [16]. Patients 001-303, 001-051, 001-
061, 001-367 and their relatives were ascertained at the Berman-Gund Laboratory, 
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Massachusetts Eye and Ear Infirmary – Harvard Medical School, according to procedures that 
were previously publushed [17]. Molecular diagnosis of patients R681C_1 to _5 was 
performed using primers to amplify coding and intron flanking sequences of exons 16 and 25 
of SNRNP200. The genetic analysis of patients 001-303, 001-051, 001-061, 001-367 and their 
relatives was performed in previous work [12]. All patients were enrolled in this project by 
signing written consent form. Our study was conducted in adherence with the tenets of the 
Declaration of Helsinki and approved by the Review Boards of our Institutions. 
 
Lymphoblastoid cell lines  
Lymphocytes from carriers of SNRNP200 mutations were isolated from 20 ml peripheral 
blood samples using Ficoll (GE Healthcare, Munich, Germany) gradient centrifugation and 
were immortalized with Epstein-Barr virus. Control lymphoblastoid cells were obtained from 
the Coriell repository. Cells were grown in T25 flasks in RPMI-1640 medium and GlutaMax 
(Life Technologies, Carlsbad, CA), supplemented with 1% of penicillin/streptomycin and 
10% fetal bovine serum (Life Technologies). Confluent cells (0.5-1 million cells/ml) were 
pelleted by centrifugation, washed with PBS buffer, and pelleted again for extraction of RNA 
or proteins. 
 
RNA extraction and cDNA Synthesis  
Ten million cells were lysed and homogenized with QIAshredder columns (Qiagen, Venlo, 
The Netherlands) and RNA was purified using RNeasy kit (Qiagen) and eluted in DHPC 
water. cDNA was synthesized from 2 "g of total RNA using PrimeScript RT-PCR Kit 
(Takara, Shiga, Japan) by priming with oligo dT and random hexamer oligonucleotides in a 
final volume of 20 microliters. 
 
Real-Time PCR  
The amplification of SNRNP200 transcripts for quantitative Real-Time PCR in patients and 
controls was performed with Sybr Green PCR Master Mix (Life Technologies) and the 
following primers: CTTCTCGGAGTCTCTGCTGG (sense) and 
TGAAGCACGTCATAGATGGG (antisense), spanning exons 35 and 36 (NM_014014.4). 
The housekeeping gene GAPDH for relative quantification was amplified by TaqMan 
Universal PCR Master Mix and a premix of primers and a VIC/MGB probe obtained by Life 
Technologies. Reactions were assembled with 1% of cDNA (~20 ng retrotranscribed RNA) in 
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a final volume of 20 "l. Forty cycles at 95°C for 15 sec and 60°C for 1 min, after an initial 
denaturation of 10 minutes at 95 °C were performed in an ABI PRISM 7500 Sequence 
Detector. mRNA expression of SNRNP200 was normalized with respect to GAPDH, and on 
the #Ct averages using the ##Ct method. 
 
Allelic imbalance assay with taqman probes 
To determine the specific amplification from the two alleles harboring the wild type base and 
the c.2041C>T (p.R681C) mutation, we designed the following probes: VIC-
CAACAGCTTCCGTCCAGTGC-MGB (wt), 6-FAM-CAACAGCTTCTGTCCAGTGC-
MGB (mut) and primers: CAAGGGTCTCTTTTACTTTG (sense), 
TCTGGAAACGCTTGATAGC (antisense) using the AlleleID software (Premier Biosoft, 
Palo Alto, CA) and synthesized by Life Technologies. The mutation is located close to the 
junction of exons 15 and 16, therefore the amplification products derive from cDNA only. To 
obtain templates of known concentration for the standard curve, we sub-cloned a 200 bp 
fragment encompassing the mutation, amplified from a patient (heterozygous for the change) 
with the following primers: TGCCACCCTACCCAACTATGA (sense), 
TCCAGCATGTTCCATGATTTTT (antisense). The PCR product was inserted by blunt 
ligation into a pcDNA3 vector cut with EcoRV. Transformed competent cells were selected 
by colony-PCR and plasmids were purified and measured by Nanodrop (Thermo Scientific). 
We selected two clones for which Sanger sequencing confirmed the insertion of a single copy 
of the PCR, harboring either the wt or the mutated allele. Optimized reactions for allelic 
expression discrimination consisted of 100 nM of each probe, 300 nM of each primer, 
TaqMan Universal PCR Master Mix, 5% cDNA or 0.04 ng of standard plasmid, in a final 
volume of 20 "l. Cycling conditions were the same as for the Syber Green reactions. Each 
sample was tested by three replicates consisting of different RNA extractions.  For the 
standard curve the wt and mutated plasmids were pooled at known ratios of 8:1, 4:1, 2:1, 1:1, 
1:2, 1:4 and 1:8. To calculate the relative amount of the wt allele versus the mutated one, we 
substitute the #Ct (CtalleleC-CtalleleT) to the equation obtained from the standard curve: Log2 
[c.2041C/T]= -0.592*#Ct +0.0634 (R2=0.986), as described in reference [18](Supplemental 
Figure 1). 
 
Protein extraction and Western blot 
Pelleted cells (~10 M) were lysed with 200-300 "l of lysis buffer (50mM Tris-HCl pH 7.6, 
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150 mM NaCl, 0.5% Triton and Protease Inhibitor Cocktail from Roche) in a rotating wheel 
at 4°C. After centrifugation at 10,000 rpm at 4°C, the supernatant was collected and 
quantified by the BCA Protein Assay (Thermo Scientific). Equal amounts of protein for each 
sample were loaded on a 6% acrylamide SDS page and transferred to nitrocellulose 
membrane. Proteins were revealed with HELIC2 (N-20) (Santa Cruz, sc-68563) and GAPDH 
(Ambion, 4300) or KIF3A (Abcam, ab11259) antibodies for normalization and revealed with 
LI-COR secondary fluorescent antibodies IRDye 800 anti goat and IRDye 680 anti mouse or 
rabbit, respectively. The bands were quantified using the program Image Studio (LI-COR 
Biosciences). 
 
RESULTS 
Clinical evaluation of adRP patients with SNRNP200 mutations  
By sequencing SNRP200 exons 16 and 25 (hotspots for known mutations), we identified the 
p.R681C substitution segregating in family RP617 over four generations. Of the five carriers 
of the mutation, only two siblings and their great-grandmother presented symptoms of RP 
(Figure 1).  
The elder of the two siblings (member #1 in the pedigree) was severely affected with first 
symptoms of night blindness appearing at age of 4 and attenuation of retinal vessels in fundus 
examination. Daylight activities and reading were normal. At the age of 7, her first visual 
field examination showed moderate narrowing of the isopter at 65-70° in temporal and 50-60° 
in nasal. At the age of 8, OCT showed a loss of photoreceptors outside the fovea. The full-
field ERG was highly decreased. No rod responses at dim blue stimulation were found and 
responses at the maximum white stimulations were at about 25% of the normal value. The 
photopic responses were also decreased at 50% of the normal amplitudes and the 30-Hz 
flickers, specific for cones, were at 20% of the normal amplitude. At the age of 13, there were 
no more scotopic responses and the 30-Hz flickers dropped to 5% of the normal amplitude. At 
the time of last examination (age of 14), her visual acuity was normal in each eye with a 
correction for astigmatism. She had no cataract. On fundus examination, the foveal reflex was 
altered and the peripheral retina lacked shining reflexes. A few spots of retinal atrophy and 
pigment deposits were visible in temporal mid periphery and retinal vessels were attenuated 
(Figure 2A-B). The peripheral visual field was moderately reduced in periphery (75° to 90° 
in temporal, 45 to 50° in nasal) but there was a large annular scotoma in midperiphery. On 
OCT, the IS/OS line (the junction between the inner segment and the outer segment of 
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photoreceptors) was present in the fovea, but it disappeared beyond the center. Foveal 
thickness was slightly increased, with a few cysts of macular edema. At the autofluorescence 
test, there was a ring of autofluorescence typical of retinitis pigmentosa. 
Her younger brother (member #2 in the pedigree) was mildly affected. The first visual field 
testing at 8 years old showed moderately decreased peripheral isopter at 70° in temporal and 
50° in nasal. The full-field ERG showed an attenuated rod response with the dim blue 
stimulation at about 60% of the normal value. The same values were observed after three 
years. The photopic responses were moderately decreased at 70-80% of the normal amplitude 
and the 30-Hz flickers were in the same order. At the age of 9, the visual field was better at 
85° temporal and 55° nasal. OCT showed that IS/OS line was present but it was attenuated in 
the periphery of the macula. At the time of last examination (age 12), his visual acuity was 
normal (20/20) in each eye with a correction for astigmatism. He had no cataract. The fundus 
showed slight depigmentation in the inferior retina but there were no spots of atrophy, no 
pigment deposits, no vessel attenuation and the macula was normal (Figure 2C-D). On OCT, 
there was no macular edema. The retinal autofluorescence was normal without macular ring 
of autofluorescence. 
The patients’ mother (member #3) and grandmother (member #4) were last seen at age of 28 
and 49, respectively. They did not have any symptoms of RP. Both had normal visual acuity 
with correction for astigmatism, and normal ocular pressure. The full-field ERG was strictly 
normal for all scotopic and photopic stimulations. In the grandmother, only the 30-Hz flickers 
showed slightly decreased responses. The mother had a normal fundus (Figure 3A-B), while 
the grandmother had few small spots of atrophy in infero-temporal in each eye, but there were 
no pigment deposits, and the maculae, the retinal vessels as well as the optic disc were normal 
(Figure 3C-D). On slit lamp examination she had a cataract beginning in infero-temporal in 
the right eye.  
The great-grandmother (member #5) was also a carrier of the p.R681C mutation and had a 
severe form of RP, with night blindness since infancy. At age of 18 years, she became aware 
of peripheral visual field defects and developed tunnel vision at the age of 70. She had 
cataract surgery at the age of 80. She also had an episode of acute glaucoma on the right eye 
at age 74. At the time of the examination (age 82), she could move only with the help of a 
stick and could not read. On examination, she had unoriented light perception of the right eye 
(because of acute glaucoma), and visual acuity was 1/20 on the left eye. The ocular pressure 
was normal at 13 mmHg in the right eye and at 18 mmHg on the left eye. The fundus showed 
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advanced retinitis pigmentosa with many pigment deposits and atrophy of the retina and 
choroid, mostly in pericentral regions (Figure 2E-F). The retinal vessels were very narrowed 
and the optic discs were waxy pale. There were small spots of foveal atrophy on both sides. A 
perifoveal ring of dark red-colored retina remained visible in both eyes. ERG was not 
performed because it would have been unresponsive. 
The clinical details of this family as well as of other patients from France with SNRNP200 
mutations are reported in Table 1. The clinical examination details from patients originally 
identified in our previous paper to carry SNRNP200 mutations, and used for expression 
studies are reported in Table 2. 
 
Expression analysis  
The molecular causes for incomplete penetrance are thought to derive from a different 
concentration of the disease gene product between affected and asymptomatic members, due 
to transcriptional regulation or modifier genes. We assessed by relative qPCR for possible 
expression differences between the members of family that are carrying the p.R681C 
mutation, as well as controls and unrelated patients carrying SNRNP200 mutations p.R681C 
(patients 001-303 and 001-061), p.R681H (001-061) and p.S1087L (001-367). As shown in 
Figure 4A, the mRNA level in lymphoblastoid cell lines was similar for all individual tested. 
We then wanted to investigate a possible mechanism of allelic expression imbalance, under 
the hypothesis that a different level of expression from the wild type and the mutated alleles 
in affected and non affected carriers could underlie the different phenotypic outcome of the 
members of the family segregating p.R681C mutation. We calculated the expression ratios of 
Brr2 transcripts from the wild type allele versus the mutated allele by using allele specific 
Taqman probes. No significant difference between expressions of the two alleles was 
observed in asymptomatic, in affected members of the family or in unrelated patients (Figure 
4B).  
We then tested the hBrr2 protein level by Western Blot. Three protein extractions from 
lymphoblastoid cell lines grown in same conditions were performed. Although different 
protein preparations gave some variability in the results, we consistently observed lower 
amounts of Brr2 protein at the steady-state in carriers of the mutation p.R681C with respect to 
carriers of the other two mutations (p.R681H and p.S1087L) and, to a certain extent, to 
controls. In the group of control cell lines there was in fact certain variability in the protein 
amount (Figure 5). Surprisingly, in one of the three protein extraction replicates, the cell lines 
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from the two asymptomatic members of the family had very low level of protein with respect 
to the other tested cell lines (Figure 6). 
 
DISCUSSION 
We report here for the first time that retinitis pigmentosa due to heterozygous p.Arg681Cys in 
SNRNP200 shows incomplete penetrance. The mutation segregates in a four-generation 
family with RP where mother and grandmother have no signs of retinitis pigmentosa, 
including normal ERG responses, while the great-grandmother her great granddaughter are 
severely affected. The great-grandson had moderate signs of retinal alteration and the 
decrease in ERG rod responses indicated a moderate loss of these photoreceptors. Yet, it is 
not certain whether these retinal alterations were progressing or not, in particular since there 
were no changes in ERG responses at a 3-year interval. In contrast, there were clearly signs of 
progressive disease in the great-grand daughter (ERG). 
In general the phenotype of SNRNP200 mutations reported so far and observed in the rest of 
the patients examined shows variability. The first description of a family with linkage to the 
RP33 locus, later identified to harbor the p.R1087L mutation, reports the diagnosis of 
dominant, fully penetrant RP, characterized by late onset of night blindness (16-18 years) and 
slow progression of the disease with variable phenotypes for both rods and cones vision [10, 
15]. The second family that was identified, also from China, segregated the p.R1090L 
mutation. Patients had an earlier onset, between 7 and 11 years, with typical progressive 
narrowing of the visual field, while central vision was relatively preserved [11]. These two 
mutations locate in the first (N-terminal) of the two Sec63-like domains of the hBrr2 protein, 
a region that is important for the interaction with the RNA and other proteins. The aminoacid 
substitutions were shown to decrease binding to RNA and to reduce Brr2’s helicase and 
ATPase activity in yeast [10, 14]. The last clinical report for SNRNP200-linked RP involves 
another Chinese family, segregating the p.Q885E mutation. Symptoms were more 
homogeneous within the patients of this family. Night blindness appeared between 10 to 15 
years of age and was followed by a gradual decline in visual acuity and peripheral visual field 
loss at the age of 40. Also, glaucoma was diagnosed in two individuals, in their 40s [13]. 
Incomplete penetrance is defined when individuals with a given mutation do not always 
present the clinical manifestation of the disease. A similar, but yet distinct phenomenon is 
variable expressivity, where the type or the severity of a phenotype varies in individuals with 
the same mutations [19]. In the case of the family presented in this report, both incomplete 
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penetrance and variable expressivity are present. It is also possible to hypothesize that a 
common mechanism explains both phenomena and that incomplete penetrance is the 
“mildest” extreme of a spectrum of phenotypes [20]. Glöcke and collaborators have recently 
published the results of a genetic screening of known RP genes, which reported also that 
SNRNP200 mutation p.S1087L was found in a patient and in the unaffected mother, 
indicating that incomplete penetrance can be a recurrent finding for different SNRNP200 
mutations [21]. It has to be remarked that, while for p.S1087L the authors provided a 
biochemical proof of the impairement of Brr2 activity in yeast, for p.R681C this evidence is 
missing. However, many genetic evidences support the causality of p.R681C for RP. It was 
found to cosegregate with RP in at least 5 families, it is absent in the general population, and 
it affects a very conserved residue. Moreover, Santos and coworkers provided recently a 
crystal structure of the two tandem helicase cassettes of human Brr2 protein where they 
highlighted the position of the residues that are mutated in RP. In particular, the cluster of 
residues R681, V683 and Y689, that we have found mutated in our first report, localize within 
a connecting domain in the first and more conserved helicase cassette, where they establish 
interdomain contacts, important for the stabilization of the folding [14]. In order to find clues 
to explain why we observed such divergent phenotypes in family RP612, we wanted to 
investigate whether there were any differences at the molecular level among carriers of the 
p.R681C mutation. 
Despite incomplete penetrance and variable expressivity have been observed for several 
genetic disorders, their causes have been scarcely understood, and are likely to differ from 
case to case and influenced by environmental factors as well. The fact that these events have 
been found mostly for dominant diseases may indicate that they are related to the dose of the 
gene product. Therefore epigenetic, transcriptional or translational regulation of gene 
expression is thought to be involved [19]. In the case of PRPF31, for example, incomplete 
penetrance is due to differential mRNA expression that has genetic origins, between affected 
and asymptomatic members of a family. A cis-acting modifier gene increases the expression 
of the wild type protein, which in asymptomatic individuals compensates for the loss of the 
mutated allele, rescuing the hemizygous condition derived from PRPF31 haploinsufficient 
mutations [5, 6, 22]. We first hypothesized that for SNRNP200 mutations the mechanism 
could be similar. We tested this hypothesis with Real-Time PCR but no appreciable 
differences were found among affected and asymptomatic members of the family that was 
studied, in lymphoblastoid cell lines. However, to find significant correlations, mRNA 
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expression analyses should be performed on a higher number of family members, an 
experiment that was not possible in this specific case. Since SNRNP200 mutations are 
missense and, unlike PRPF31 mutations, are not predicted in principle to result in reduced 
protein concentrations, a more plausible mechanism for incomplete penetrance would be a 
difference in the relative amounts of the wild type over the mutated transcript between 
affected and asymptomatic relatives. This was observed for example for BRCA1 and BRCA2 
mutations in familial breast cancer [18]. We could not see such a difference in our allelic 
imbalance expression assay. The sensitivity of this assay, constrained by the design of the 
probe, allowed to detect differences of more than 0.5-1 fold and not smaller, which would 
have been anyway of difficult interpretation in relation to the phenotype. We were then left to 
investigate possible differences in the total protein quantity. Although from our analysis it 
appears that hBrr2 protein has fluctuating concentrations in all cell lines that we analyzed, we 
could observe a certain reproducibility of the finding that p.R681C carriers have a decreased 
hBrr2 protein amount compared to other cell lines tested, including the ones from the carriers 
of p.R681H and p.S1087L mutations of the same gene. This may be in agreement with the 
structural role of the R681 residue in the conformational stability of the domain. The positive 
charge of arginine seems important to maintain this structural integrity and its disruption with 
a substitution by a non-polar aminoacid like cysteine, and maybe not by another positively 
charged aminoacid like histidine (as in the other mutation), might be detrimental for the 
stability of the whole protein. Since our analyses were performed at the steady-state, and may 
be confounded by a compensatory increase, we plan to confirm that the mutation causes 
indeed a reduction in protein stability by analyzing the protein after treatment with a 
translational inhibitor at different time points. The reason why in one instance it seems that 
asymptomatic carriers have even less protein than the affected relatives is difficult to interpret 
and further confirmatory experiments are needed to establish if there is a true difference or a 
stochastic finding, possibly due to the use of the particular antibody. Reduction or impairment 
in protein stability due to point mutations have been already indicated as a possible factor 
influencing the penetrance of mutations in different ocular diseases such as retinoblastoma 
(RB mutations) [23] primary congenital glaucoma (CYP1B1 mutations) [24], and also in 
retinitis pigmentosa (PRPF31 Ala216Pro mutation) [25]. The general hypothesis is that the 
protein derived from the hypomorphic allele would retain sufficient functionality to express 
the normal phenotype if concurrent factors are present. These factors can be of genetic nature, 
like compensatory variants in modifier genes or interacting protein partners or of 
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environmental origin, and their identification has proven to be challenging. By using novel 
whole genome sequencing approaches, it would be thinkable to perform genetic association 
analysis of non-penetrant p.R681C mutations, by focusing on sequence analysis of genes 
known to interact with hBrr2 or to play a role in retina development and pathogenesis. 
However, for this kind of study a larger number of non-penetrant p.R681C cases would be 
needed, and even in that case it is not sure that the cause for incomplete penetrance would be 
the same in all individuals. 
In conclusion, our analyses so far exclude the possibility that penetrance of the p.R681C 
mutation is due to mechanisms of regulation at the RNA level, although only the steady state 
was investigated. An explanation at the level of protein stability can be hypothesized, for 
which confirmatory experiments are needed.  
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FIGURES AND TABLES 
 
Figure 1. Pedigree of family RP612. The SNRNP200 mutation p.R681C segregates in the branch of the family 
with RP. A red number designates the members of the family analyzed for RNA and hBrr2 protein. 
 
Figure 2. Fundus appearance of 
affected family members. A-B) 
Fundus photographs of right (A) 
and left (B) eyes of patient#1, age 
of 14, severely affected, showing 
attenuation of the retinal vessels  
and moderate atrophy of the 
peripheral retina. Pigment 
deposits in periphery are shown 
by white arrows. C-D) Fundus 
photographs of right (C) and left 
(D) eyes of patient#2, brother of 
patient 1, age of 12 and with less 
severe RP. A slight discoloration 
of the inferior retina is present. 
The retinal vessels are normal and 
there are no pigment deposits. E-
F) Fundus photographs of right 
(E) and left (F) eyes of the great-
grandmother, aged 82, showing 
atrophy of the retina and choroid 
(white color of the fundus), many 
pigment deposits, extreme 
narrowing of retinal vessels and 
waxy color of the optic discs. The 
atrophic foveas (white arrows) are 
surrounded by a dark red ring of 
retina. 
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Figure 3. Fundus 
photographs of the 
unaffected carriers from 
the family. The right and left 
eyes of the mother, aged 28 
(A-B) and the grandmother, 
aged 49 (C-D) show a normal 
posterior pole. 
 
 
 
 
 
 
 
 
 
 
Figure 4. Expression analysis in lymphoblastoid cell lines from patients with SNRNP200 mutations. A) 
Relative qPCR of SNRNP200 transcript normalized on GAPDH expression and on the average expression. The 
values are an average of three experimets from different RNA extractions. Values are similar across patients, 
controls and asymptomatics. B) Taqman allelic imbalance assay from alleles c.2041T/C of SNRNP200 in carriers 
of the mutation p.R681C. The relative abundance of the transcript containing the wt over the mutated allele was 
calculated using a standard curve of cloned cDNA fragments at known proportions, as described in the method 
and in the supplemental Figure S1. All the samples showed roughly a 1:1 proportion of the two variants. (*) 
asymptomatic individuals. 
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Figure 5. hBrr2 protein in lymphoblastoid cell lines from patients with SNRNP200 mutations (I). Total 
protein extract form immortalized lymphoblasts were loaded in equal amount and revealed in western blot with 
Brr2 antibody (upper panel) and KIF3A antibody (middle panel). The relative densitometry quantification of the 
band is plotted in the panel at the bottom. (*) asymptomatic individuals. 
 
 
 
Figure 6. hBrr2 protein in lymphoblastoid cell lines from patients with SNRNP200 mutations (II). Total 
protein extract form immortalized lymphoblasts were loaded in equal amount and revealed in western blot with 
Brr2 antibody (upper panel) and GAPDH antibody (middle panel). The relative densitometry quantification of 
the band is plotted in the panel at the bottom. Carriers of the p.R681C mutation (samples 1 to 6) had reduced 
protein amount compared to carriers of p.R681H and p.S1087L (samples 7 and 8). The two asymptomatic 
members (samples 3 and 4) of the family and patient 01-303 show very low protein levels. (*) asymptomatic 
individuals. 
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SUPPLEMENTAL FIGURES 
 
 
Supplemental figure S1. Standard curve for allelic imbalance espression quantification. A) The panels from left 
to right show the amplification plots relative to the VIC Taqman probe, specifically recognizing the wt allele 
(c.2041C) in red, and the one from the FAM probe, recognizing the mutated allele (c.2041T) in black. From left 
to right plasmids containing cDNA from wt and mutated alleles are used at known ratios of 8:1, 4:1, 2:1, 1:1, 
1;2, 1:4, 1;8. The last panel represents four 10-fold serial dilutions of the 1:1 plasmid mix. B) Standard curve 
obtained from the Cts of panels A. The equation of the curve is displayed and used to calculate the relative 
expression of the two variants in the sample’s cDNA. C) Amplification plots obtained from the cDNA of the 
affected (1-2) and unaffected (3*-4*) family members, showing almost overlapping curves from VIC and FAM 
probes, indicating a similar abundance of the two variants in all the individuals tested. 
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Part II. 
Genome-wide association study of essential hypertension  
 
 
 
 
 
As a parallel project during my PhD training I have collaborated with a European consortium 
named HYPERGENES (www.hypergenes.eu), which aimed at the identification of novel 
genetic loci associated with essential hypertension by case-control genome-wide association 
studies. In this section I enclose the two publications that I contributed to, after presenting a 
general introduction to the subject and the main findings of the study. In the first paper, 
published on Hypertension in Sepetember 2012, we discovered a novel locus associated with 
hypertension in the promoter of the NOS3 gene and in the second one, to be published on 
Hypertension in November 2013, we proved the direct causality of the SNP in the 
susceptibility to hypertension.   
 
 
Candidate’s role: 
• Management and quality control of DNA samples received from partner Universities 
for genotyping (paper #1 and #2). 
• Array-based genotyping of a few thousands samples (paper #1 and #2). 
• Luciferase assay to validate the effect of the risk allele: plasmid construction, assay 
optimization, experiment on HEK293T cells (paper #2). 
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1. Hypertension and GWAS 
Cardiovascular diseases (CVDs) such as heart failure and stroke are the major cause of death 
in Western countries [100] and hypertension causes about half of cardiovascular mortality 
[101]. Essential (or primary) hypertension (EH) is defined by a systolic blood pressure (SBP) 
of more than 140 mmHg or diastolic blood pressure (DBP) of more than 90 mmHg, in which 
causes of secondary hypertension such as renal failure and aldosternonism are not present. EH 
accounts for the 95% of cases of hypertension [102]. The values of blood pressure that define 
hypertension are a cutoff at the right end of the normal distribution present in the general 
population (Fig. 1). Hypertension is a complex trait resulting from the interactions among 
multiple genetic variants and environmental factors such as diet, smoking and exercise. Some 
forms of familial hypertension caused by mutations in single genes also exist, but these 
monogenic forms represent only a minority [103]. It was estimated by several studies that 
genetic factors contribute to 31-68% of blood pressure variance [104], but the identification 
of common variants with small effect is much more difficult than identification of rare 
variants with high penetrance and large effect on the phenotype. In the past 10 years the entire 
sequence of the human genome and a catalogue of its variants across different individuals and 
populations have been made available. This has been possible thanks to the effort of many 
groups participating to the International HapMap project [105] and the Human Genome 
Project [74]. As a consequence of this advancement and together with the development of 
high-throughput genotyping platforms, the genetic risk factors for many common diseases 
including hypertension have been identified [106].  
 
Figure 1. Normal distributions of SBP (left) and DBP (right) in the general population. Modified from [107]. 
Genome-wide association studies (GWAS) are used to find statistical association between 
common genetic variations and complex traits by comparing the genotypes of many 
individuals with different phenotypes. There are two types of GWAS: one is based on the 
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comparison of allele frequencies between individuals with a disease and matched control 
individuals (case-control study), while in the other type the phenotype is a quantitative trait 
that can be measured as a continuum within a population sample. High-density microarrays 
are used to genotype thousands of individuals for hundreds of thousands common SNPs 
spread over the whole genome. In fact, to reach the statistical power necessary to find 
genome-wide significant associations, and correct for the elevated number of independent 
tests, the sample size needs to be in the order of several thousand subjects [108]. The power 
of a GWAS increases with the number of individuals and SNPs tested. Some of the terms and 
the concepts frequently used in GWAS are explained in Table 1. 
Term Explanation 
Bonferroni 
correction 
Adjustment of the threshold of statistical significance in GWAS to limit the discovery of 
false positive results. Bonferroni correction divides the standard P = 0.05 by the number of 
statistical tests performed or, in GWAS, the number of variants being tested. Thus, for P = 
0.05 and 106 variants tested, only associations of P < 5 x 10-8 are considered statistically 
significant. 
Genetic risk 
score 
A method to assess the combined effect of multiple variants that are individually associated 
with a disease. Scores are calculated by summing the number of alleles associated with 
increased disease risk. Top GWAS hits for a given condition are often used to identify the 
variants included in a genetic risk score. 
Manhattan 
plot 
A visual representation of GWAS results. Points graphed on a Manhattan plot represent P 
values for individual tests for association between a variant and the condition or trait of 
interest. The most important feature of the Manhattan plot is the presence of peaks formed by 
multiple points; this suggests a strong association at a particular locus. 
Meta-
analysis 
A statistical method that combines results from multiple independent studies of the same 
condition. Meta-analyses of GWAS are used to increase sample size and boost statistical 
power to detect associations for variants of small effect. 
Q-Q plot 
A visual tool in which P values observed in GWAS are plotted against the expected P values 
derived from a !2 distribution. If the majority of observed P values deviate from expected P 
values, some artifact is likely inflating the significance of observed associations and must be 
adjusted in the GWAS regression model. 
Statistical 
power 
The probability of identifying statistically significant associations considering the desired 
significance threshold (i.e. P = 0.05), sample size, frequency of genetic variants in the 
general population, and frequency that specific variants are observed in cases. Well-powered 
GWAS require thousands of participants to detect associations between common variants 
with low effect size. Often, the power in GWAS is increased by meta-analysis of multiple 
GWAS that have studied the same phenotype. 
       Table 1. Glossary of main terms used in GWAS. Taken from [108]. 
 
Due to its high phenotypic heterogeneity, which is influenced by many factors including age, 
ethnicity, weight, diet, contractile state of the hearth and vascular tone, the genetic dissection 
of hypertension has progressed at a slower pace with respect to other common diseases. 
Nevertheless, in the last few years GWAS analyzing blood pressure as a continuous trait and 
by case-control design have identified about 40 loci robustly associated with it [103]. Some 
associated variants have been found near genes involved in important processes of regulation 
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of blood pressure including of the oxide-natriuretic signaling pathway (NOS3, NPPA-NPPB, 
GUCY1A3-GUCY1B3), vascular and endothelial function (SH2B3, CSK, GNAS–EDN3, 
ATP2B1, LSP1/TNNT3, CACNB2), renal electrolyte balance (MTHFR, AGT, NPR3, UMOD) 
and aldosterone synthesis (CYP17A1). Some of these and other genes have been also found in 
Mendelian diseases and syndromes involving blood pressure [109]. Moreover, many of them 
were confirmed by meta-analyses and by large-scale association analysis of variants in 
candidate cardiovascular genes [110]. However, the evidence that many associated genes do 
not have a direct function in blood pressure regulation and that some of the most obvious 
candidate for hypertension have not been found near associated SNPs, indicate that less 
intuitive pathways of regulation constitute the genetic basis of hypertension. 
A recognized limitation of the GWAS approach is that although statistically convincing 
associations have been identified for many conditions, in most of cases we lack the biological 
explanation for why a genomic interval associates with a complex trait [111]. The associated 
SNPs are often only proxies for variants lying in a same linkage disequilibrium (LD) block, 
among which the actual variants causing the observed phenotypic variability are hidden. The 
identification of causative variants affecting the phenotype is a complex task and involves the 
functional prediction of all possible SNPs in LD with the associated loci. In some cases the 
functional SNPs may directly affect the sequence of a protein by non-synonymous 
substitutions or truncating variants. However, it is largely agreed that the causative variants 
underlying GWAS signals have a regulatory function rather than coding. This hypothesis is 
supported also by the results of recent genome annotation efforts of the Encyclopedia of DNA 
Elements (ENCODE), which showed that GWAS SNPs were enriched in regions functionally 
labeled as enhancers, promoters, and transcription factor binding sites [112].  
Another unforeseen limitation of GWAS is that although many genomic markers have been 
associated with a trait, they can explain only a small fraction of the variance of a quantitative 
trait or have low odd ratios for binary traits. As a consequence of this, most of the SNPs that 
have so far been found associated with common diseases have little predictive value and little 
clinical utility [113]. In particular, for hypertension, the aggregate common variants 
associated with blood pressure explain only the 3% of the phenotypic variance [103]. The 
concept of “missing heritability” refers to all genetic variation that was estimated to underlie 
common heritable diseases, and has not been uncovered yet. Genetic variants that are not 
usually captured with GWAS have been indicated as possible contributors to the missing 
heritability. They include rare variants, which are not in LD with the SNPs used for 
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genotyping, and structural variations such as copy number variants (CNVs- insertions and 
deletions) or copy neutral variations (inversions or translocations) [114]. Moreover, the lack 
of precise phenotypic information for a large number of individuals and of a measure of 
environmental effects are likely to contribute to our limit in understanding the molecular 
causes of complex diseases. 
Current and future GWAS are aiming to overcome these drawbacks by different approaches. 
One of this is to analyze more accurate phenotypes through extensive clinical examination, or 
to evaluate more intermediate and molecular phenotypes, like gene expression in eQTLs 
association studies. Another one is to employ next generation sequencing to identify in an 
unbiased way rare variants, which may have a greater effect size. Additionally, targeted NGS 
can be applied for the identification of the actual causing variants among an associated 
genomic locus.  
2. The “HYPERGENES” study 
The design of the GWAS performed by the HYPERGENES consortium consisted of a case-
control study organized in two stages. The strategy adopted to reduce the limitations 
explained above was to enroll extreme cases (DBP>90 mmHg and SPB>140 mmHg or under 
antihypertensive treatment before the age of 50) and controls (DBP <85 mmHg and SBP 
<135 at least until 55 years and never treated for hypertension) from extensively characterized 
cohorts followed up for many years in Europe. This determined a relatively small sample size, 
but had the aim to increase the discovery power by avoiding the effects of misclassifications 
biases. In the first phase of the study (discovery phase), 1865 cases and 1750 controls were 
analyzed for 1 million SNPs each. At the time of this study the 1M-SNPs chip from Illumina 
was the densest array used for GWAS and its use had a positive effect on statistical power. 
This was followed by a validation step where other 1385 cases and 1246 controls were 
genotyped for only 15 thousands SNPs including the top results of the discovery phase and 
variants in candidate genes for hypertension. Only one marker showed an association of 
genome-wide significance with hypertension and was the T allele (<10% MAF) of the 
rs3918226 SNP in the promoter of the endothelial nitric oxide synthase gene (NOS3), a 
relevant protein for cardiovascular homeostasis and blood pressure regulation. The use of 
genotyping array with high number of markers played an important role in the discovery 
because this SNP was not included in arrays used in previous studies and, being in a region of 
low LD, was not possible to impute from genotypes of lesser dense arrays. Interestingly, the 
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polymorphism is located close to a predicted binding site for transcription factors important 
for NOS3 expression, suggesting that the two alleles might result in a different transcription 
factor binding site (TFBS) strength and consequently to differential gene expression. 
There are few cases in GWAS where the discovered associated variants have a direct effect 
on relevant gene products, and are thus likely to be the actual variants responsible for the 
association to the trait. The NOS3 polymorphism rs3918226 is one of these exceptions. In the 
follow up study in fact we could prove this causality using three different methods: i) targeted 
resequencing, ii) luciferase assay and iii) population study.  
For the fine mapping of the NOS3 locus, aiming at discovering other possible candidate 
causal variants, a 140-kb genomic area was re-sequenced by targeted high throughput 
sequencing in 44 hypertensive patients and 48 healthy controls from the HYPERGENES 
cohort. Two haplotypes including the risk allele were identified and one of it, about 27 kb 
long, was significantly more presents in patients than controls. However, the haplotype did 
not confer a higher association P value than rs3918226 alone. Five novel variants were 
located in the region of linkage disequilibrium upstream of rs3918226 but their annotation did 
not suggest any functional role. This indicated that rs3918226 was the closest marker 
responsible for the association signal. A direct evidence of the effect of the risk allele (T) on 
transcription with respect to the major one (C) was given by luciferase reporter assays in 
human cell lines (HeLa and HEK293T cells). The eNOS promoter containing variant T 
determined a significant reduction (20-40%) of transcription with respect to the C allele.  
Finally, a population study confirmed that the T allele present in homozygosis increased the 
risk of developing high blood pressure with age. Specifically, in a longitudinal study (7.6 
years median of follow up) using blood pressure as a continuous phenotype in 2722 randomly 
recruited Europeans, systolic and diastolic blood pressures increased 5.9 and 4.8 mmHg more 
in TT homozygotes than in C allele carriers.  Moreover, the hazard study on individuals that 
among the cohort developed hypertension (692) indicated that carriers of TT genotype had a 
two-fold risk of developing hypertension compared to the other genotypes.  
3. eNOS and hypertension 
Nitric oxide (NO) is a radical gas and in mammals is an important cellular signaling molecule 
involved in many processes. It is produced from L-arginine, oxygen and NADPH by three 
different nitric oxide synthase enzymes in different cells: nNOS (NOS1) in neurons, inducible 
iNOS (NOS2) in machrophages and eNOS (NOS3) in endothelial cells [115]. The role of NO 
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and eNOS in cardiovascular system is well known, as well as its implications in vascular 
disorders such as atherosclerosis and hypertension. NO biosynthesis is stimulated by various 
mechanical or humoral factors to induce vasodilatation [116] (Fig. 2). When diffusing to 
adjacent smooth muscle cells, NO stimulates the guanilate cyclase to form cyclic GMP, which 
will ultimately lead to relaxation of muscle cells and vasodilation. In addition, NO released 
from the endothelium to the lumen of the vessel has other functions, including the reduction 
of platelet aggregation and neutrophil adhesion to the endothelium, inhibition of vascular 
smooth muscle cell proliferation, and stimulation of angiogenesis. A decrease in nitric oxide 
synthesis produces an increase in blood pressure, as it was seen for example when introduding 
inhibitory L-arginine analogous in humans [117]. Moreover, it has been shown that in 
knockout mice for eNOS, acetylcholine-induced vascular relaxation is absent and mice are 
hypertensive [118]. Several genetic association studies have been addressing the role of 
genetic variants of eNOS in cardiovascular disease and other polymorphisms have been 
associated with a higher risk of hypertension [119]. Our work identified and characterized a 
novel susceptibility locus, consolidating the role of eNOS in cardiovascular risk in 
perspective of future therapeutic actions.  
 
 
 
Figure 2. Scheme of nitric oxide pathway. Picture taken from [120]. 
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Abstract—Essential hypertension is a multifactorial disorder and is the main risk factor for renal and cardiovascular
complications. The research on the genetics of hypertension has been frustrated by the small predictive value of the discovered
genetic variants. The HYPERGENES Project investigated associations between genetic variants and essential hypertension
pursuing a 2-stage study by recruiting cases and controls from extensively characterized cohorts recruited over many years
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in different European regions. The discovery phase consisted of 1865 cases and 1750 controls genotyped with 1M Illumina
array. Best hits were followed up in a validation panel of 1385 cases and 1246 controls that were genotyped with a custom
array of 14 055 markers. We identified a new hypertension susceptibility locus (rs3918226) in the promoter region of the
endothelial NO synthase gene (odds ratio: 1.54 [95% CI: 1.37–1.73]; combined P!2.58 ! 10"13). A meta-analysis, using other
in silico/de novo genotyping data for a total of 21 714 subjects, resulted in an overall odds ratio of 1.34 (95% CI: 1.25–1.44;
P!1.032 ! 10"14). The quantitative analysis on a population-based sample revealed an effect size of 1.91 (95% CI: 0.16–3.66)
for systolic and 1.40 (95% CI: 0.25–2.55) for diastolic blood pressure. We identified in silico a potential binding site for ETS
transcription factors directly next to rs3918226, suggesting a potential modulation of endothelial NO synthase expression.
Biological evidence links endothelial NO synthase with hypertension, because it is a critical mediator of cardiovascular
homeostasis and blood pressure control via vascular tone regulation. This finding supports the hypothesis that there may be
a causal genetic variation at this locus. (Hypertension. 2012;59:248-255.) ● Online Data Supplement
Key Words: genetic epidemiology # risk factors # genetics association studies # NO # essential hypertension
Essential hypertension (EH) is a clinical condition affect-ing a large proportion (25% to 30%) of the adult
population and is a major risk factor for cardiovascular and
renal diseases.1,2 It is a complex trait influenced by multiple
susceptibility genes, environmental, and lifestyle factors and
their interactions.3 In the last years, huge efforts have been
performed in recruiting and genotyping tens of thousands of
individuals and meta-analyzing dozens of cross-sectional,
population-based studies. In spite of this, the research on the
genetics of EH has been frustrated by the small predictive
value of the discovered genetic variants and by the fact that
these variants explain a small proportion of the phenotypic
variation.4–13 EH is a late-onset disease and, therefore, the
small discovered effect sizes could in part be because of the
effect of misclassification, sample selection bias, and inap-
propriate phenotyping of cases and controls.9,14,15 The selec-
tion of cases and controls may have important effects on the
results, because misclassification bias can lead to loss of
power. For common traits, such as EH, this bias can be
remedied by defining more stringent selection criteria, by
recruiting hypernormal controls and adopting a more strin-
gent case definition.14,15
The HYPERGENES Project pursued a 2-stage study to
investigate novel genetic determinants of EH. Cases and controls
were recruited from extensively characterized cohorts over many
years in different European regions using standardized clinical
ascertainment. Particular care was devoted to control selection.
A large proportion of the sample has been followed for 5 to 10
years after DNA collection, allowing for the exclusion of
controls that developed hypertension at a later age, thereby
defining the hypernormal controls.
Methods
Study Population
Cases and controls were recruited from extensively characterized
cohorts using standardized clinical ascertainment, collected over many
years in different European regions (balanced within North Europe,
continental Italy, and Sardinia). The inclusion criteria are described in
the Methods (S1) section of the online Data Supplement (available at
http://hyper.ahajournals.org). To perform a genetic association with
continuous blood pressure (BP) phenotypes, we considered 2 additional
cohorts (FLEMENGHO-EPOGH, n!1514, and Wandsworth Heart &
Stroke Study, n!306, see Methods [S2] of the online Data Supplement)
that provided population-based data. Description of the different sam-
ples is reported in the Methods S2 section.
Genotyping and Imputation
Genotyping details are shown in Methods S3 through S6 of the online
Data Supplement. Briefly, in the discovery phase, the samples were
genotyped using the Illumina 1M-Duo array, and the imputation was
performed with MACH16 using as reference the 1000 Genomes haplo-
types (release June 2010; Method S3). To validate and fine map the
genes found associated with EH in discovery phase, an Illumina custom
chip of 14 055 markers was created starting from the list of best-
associated and of candidate single nucleotide polymorphisms (SNPs)
based on a priori biological knowledge (Methods S4 and S5). For the
replication stage, we used the in silico data of rs3918226 from
Anglo-Scandinavian Cardiac Outcomes Trial/AIBIII/NBS, BRIGHT,
EPIC Turin, HYPEST, and NORDIL/MDC studies (Methods S6).
Statistical Analysis
All of the quality controls and statistical analyses were performed in
accordance with the protocols written by Anderson et al17 and Clarke
et al18 (Methods S7 through S9). We tested each SNP for association
with hypertension using a logistic regression under an additive model
with adjustment for sex and for the first 10 principal components.
Combined analysis for discovery, validation, and replication results
was conducted using METAL.19 The quantitative effect of
rs3918226 on systolic BP and diastolic BP was tested on 2 additional
population-based cohorts (Methods S2). Moreover, we tested for
multiplicative interaction between rs3918226 and the most plausible
interactive partners of the endothelial NO synthase (eNOS) gene,
actin genes and heat shock protein (HSP) 90 genes (Methods S9).
The quantitative effect of rs3918226 on systolic BP and diastolic BP
has been tested on 2 additional population-based cohorts
(FLEMENGHO-EPOGH and Wandsworth Heart & Stroke Study,
see Methods S2). The recognition sequences for transcription factors
in the eNOS region were searched using TRANSFAC20,21 and the
TFSEARCH database22 (Methods S10).
Results
A classic 2-stage case-control strategy was used with a
discovery phase of 1865 cases and 1750 controls (2294 males
and 1321 females), all genotyped on the Illumina 1M Duo
chip. The sample consisted of an ethnically diverse popula-
tion (25.06% North Europeans, 38.70% Sardinians, and
36.24% continental Italy subjects). The discovery phase was
followed by a validation phase of an additional 1385 cases
and 1246 controls (1417 males and 1214 females). According
to ethnicity, the validation sample was composed of 1262
North Europeans (47.97%), 788 Sardinians (29.95%), and
581 continental Italians (22.08%). Tables S1 and S2 (avail-
able in the online Data Supplement) show the demographic
characteristics and baseline measures.
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Principal component analysis of the genotype data were
carried out to find the major axes of variation used as
covariates to correct for population stratification.23 The dis-
covery samples in the principal component map showed 3
(roughly) equal-sized distinct clusters corresponding with the
3 main ethnic groups, as expected from the study design
(Figure S1). All of the association analyses were adjusted for
the ancestry principal components and sex by including them
as covariates in the logistic regression model. In addition,
genomic control correction was applied (because genomic
inflation factor was 1.04). In the discovery phase, 90 SNPs
(57% intragenic) with P value!1 ! 10"4 were identified after
genomic control (Figure S2 and Table S4). The most prom-
ising SNPs were genotyped in the validation samples using an
Illumina Infinium Custom chip. The meta-analysis of the
discovery and validation data revealed SNP rs3918226 to be
associated with EH in whites, reaching a Pcombined of
2.58 ! 10"13 and odds ratio (OR) of 1.54 per T allele (95% CI:
1.37–1.73) under an additive model (Figure 1 and Table 1 and
Figure S4). Estimated ORs in the discovery and validation
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Figure 1. Local Manhattan plot for the NOS3 (endothelial NO synthase) region. Each circle represents a single nucleotide polymorphism
(SNP), its y coordinate is the "log10 association P value for hypertension, and the x coordinate represents the physical position on the chro-
mosome (on build 36, hg18). When replication data were available, the combined P value was used, otherwise the discovery P value was
used. Circles are filled with colors according to the linkage disequilibrium (LD; r2) between the given SNP and the lead SNP (rs3918266, violet
square). Blue line indicates the recombination rate. The second best hit with P value 2.46E-6 in the discovery stage (named chr7:150 314 954
according to the 1000 Genome Project) was imputed based on the 1000 Genomes haplotypes (release June 2010), and its imputation quality
was very high (r2-hat#0.94). In validation stage, the imputation quality was very low (r2-hat#0.17).
Table 1. Meta-Analysis Results for the Top SNPs in the HYPERGENES Study
Marker Name Chr Position
Effect/
Other Allele Gene
OR
Discovery
P
Discovery
OR
Validation
P
Validation
OR
Combined CI Combined
Inverse Variance-
Weighted P Combined
Z Score
P Combined
rs3918226 7 150321109 T/C NOS3 1.425 4.81E-06 1.71 2.55E-09 1.538 1.372–1.726 1.98E-13 2.58E-13
rs341408 15 58928982 G/A RORA 0.786 1.74E-06 0.956 4.29E-01 0.856 0.79–0.92 3.98E-05 2.79E-05
rs4976593 5 167710021 G/A WWC1 1.27 3.75E-06 1.045 4.60E-01 1.169 1.08–1.26 6.64E-05 5.29E-05
rs631208 16 9307225 G/A RP11-473I1.1 0.798 8.09E-06 0.951 3.84E-01 0.862 0.80–0.93 8.89E-05 6.36E-05
rs7907270 10 78550949 G/A KCNMA1 1.27 2.35E-06 0.989 8.53E-01 1.141 1.06–1.23 5.75E-04 4.25E-04
rs10519080 15 58925751 G/A RORA 1.369 5.79E-06 0.979 7.95E-01 1.187 1.07–1.31 1.09E-03 8.49E-04
rs1406891 6 161107070 G/A PLG 1.251 3.99E-06 0.949 3.50E-01 1.112 1.03–1.19 3.87E-03 2.97E-03
rs783182 6 161088538 G/A PLG 0.797 2.95E-06 1.068 2.42E-01 0.902 0.84–0.97 5.31E-03 4.15E-03
rs1084656 6 161101282 C/A PLG 1.243 6.67E-06 0.936 2.39E-01 1.103 1.03–1.18 7.66E-03 6.35E-03
rs783145 6 161072439 G/A PLG 0.788 8.53E-07 1.102 8.45E-02 0.909 0.84–0.98 9.27E-03 6.85E-03
rs1247558 6 161110189 G/A PLG 1.24 8.30E-06 0.932 2.14E-01 1.100 1.02–1.18 9.42E-03 7.93E-03
The table shows association results (OR and P values) for discovery and for validation samples and for the combined analysis (both inverse variance weighting and
z score meta-analysis). P values and ORs with the associated 95% CIs have been calculated under an additive model using logistic regression adjusted for sex and
principal components. To retrieve information about single nucleotide polymorphisms and their genomic context (the nearest gene) we used the hg18 (National Center
for Biotechnology Information 36) assembly. OR indicates odds ratio; P, P values; CI, confidence interval; Chr, chromosome; SNP, single nucleotide polymorphism.
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samples were consistent across the different white popula-
tions of the HYPERGENES sample (Figure S5).
The polymorphism rs3918226 maps to the promoter region
of the eNOS gene (!665 C"T, NOS3).24,25 The T-allele
frequencies in the present study are 13.8% in cases and 8.9%
in controls. SNP rs3918226 is monomorphic in the nonwhite
HYPERGENES samples (Wandsworth Heart & Stroke Study
cohort) and African and Asian HapMap samples. The second
best hit chr7:150,314,954 (G/A SNP, minor allele frequency
of A allele#3%) with P value 2.46 ! 10!6 and OR 2.25 was
imputed based on the 1000 Genomes haplotypes (release June
2010); its imputation quality was very high (r2-hat#0.94).
Unfortunately we could not replicate the observation in
validation because of low imputation quality. An additional 7
SNPs within eNOS gene showed significant P values
(1 ! 10!3$P$1 ! 10!5): rs2853792 (intronic, Pcom-
bined#7.76 ! 10!5), rs1549758 (coding, Pcombined#3.32 ! 10!4),
rs1800779 (intronic, Pcombined#1.16 ! 10!3), rs6951150 (in-
tergenic, Pcombined#1.64 ! 10!3), rs743507 (intronic, Pcom-
bined#1.76 ! 10!3), rs1800780 (intronic, Pcombined#1.96 ! 10!3),
and rs1800783 (intronic, Pcombined#2.89 ! 10!3; Figure 1).
Table 1 shows also other significant SNPs with P values
between 1 ! 10!3 and 1 ! 10!5 mapping different genes as
calcium-activated potassium channel subunit !-1 (KCNMA1),
plasminogen (PLG), retinoid-related orphan receptor-!
(RORA), and WW domain-containing protein 1 (WWC1).
Moreover, the signals of SNPs presented previously in
literature are in our study in the same direction as the original
studies,5,6,8 showing evidence of a marginally significant
association in HYPERGENES (Table S5).
We meta-analyzed rs3918226 using in silico data from
Anglo-Scandinavian Cardiac Outcomes Trial/AIBIII/NBS,
BRIGHT, EPIC-Turin, HYPEST, and NORDIL/MDC sam-
ples (Methods S2 and S6), resulting in an overall OR of 1.34
per T allele (95% CI: 1.25–1.44; Pcombined#1.032 ! 10!14;
Table 2 and Figure 2) for a total of 21 714 subjects. Because
case and control definitions differed between HYPERGENES
and the in silico replication samples, the ORs are not directly
comparable. In our study, the P value of heterogeneity
calculated for HYPERGENES samples is 0.13. It decreased
slightly but remained nonsignificant, as expected, when
EPIC-Turin was also considered together in the meta-analysis
Table 2. In Silico Meta-Analysis Results for rs3918226 (T/C, Effect Allele/Other Allele)
Variable Study Sample Size OR SE 95% CI P
HYPERGENES samples HYPERGENES discovery 3596 1.43 0.11 1.224–1.657 4.81E-06
HYPERGENES validation 2610 1.71 0.155 1.440–2.049 2.55E-09
Combined analysis HYPERGENES 6206 1.54 0.038 1.372–1.726 2.58E-13
Replication samples ASCOT/AIBIII/NBS 4049 1.06 0.092 0.895–1.256 4.97E-01
BRIGHT 3641 1.39 0.126 1.168–1.663 2.32E-04
EPIC Turin 2714 1.28 0.126 1.050–1.551 1.44E-02
HYPEST 1204 1.13 0.236 0.754–1.705 5.45E-01
NORDIL/MDC 3900 1.25 0.124 1.030–1.519 2.40E-02
Combined Analysis of Replication Samples 15 508 1.23 0.056 1.125–1.344 6.50E-06
Meta-analysis 21 714 1.34* 1.248–1.437† 1.032E-14‡ 6.198E-16§
Top section shows association results (odds ratios, SEs, CIs, and P values) for discovery, validation, and combined analysis of the HYPERGENES samples. Middle
section shows results for ASCOT/AIBIII/NBS, BRIGHT, Epic Turin, HYPEST, and NORDIL/MDC studies and combined analysis of replication in silico samples. Bottom
section shows meta-analysis results for all of the samples using both the z score and inverse variance-weighted P value methods.
*Data are OR combined.
†Data are 95% CI combined.
‡Data are combined P (z score).
§Data are combined P (inverse variance weighted).
Study
Hypergenes discovery
Hypergenes validation
ASCOT AIBIII NBS
BRIGHT
OR (95% CI)           Weight %
1.43 (1.224-1.657)          16.56
1.71 (1.440-2.049)          12.02
1.06 (0.895-1.256)          18.65
1.39 (1.168-1.663)          16.77
EPIC Turin
HYPEST
NORDIL MDC
Overall
1.28 (1.050-1.551)          12.50
1.13 (0.754-1.705)            5.54
1.25 (1.030-1.519)          17.96
1.34 (1.248-1.437)          100
0                     1                     2
Figure 2. Forest plot of meta-analysis between
HYPERGENES Discovery, HYPERGENES Valida-
tion, ASCOT/AIBIII/NBS, BRIGHT, EPIC Turin,
HYPEST, and NORDIL/MDC studies. The squares
and the horizontal lines correspond with the odds
ratio (OR) and 95% CI of each study; the size of
squares is proportional to weights (also shown as
percentage); and the dotted line and the diamond
represent the overall combined OR and 95% CI.
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(P!0.092), because the recruitment criteria for cases and
controls were identical. Conversely, the heterogeneity in-
creased significantly (P!0.005) when HYPERGENES sam-
ples were meta-analyzed with all of the other samples
(Anglo-Scandinavian Cardiac Outcomes Trial/AIBIII/NBS,
BRIGHT, HYPEST, and NORDIL/MDC).
Moreover, we tested for epistatic multiplicative interactions
between eNOS rs3918226 and all of the available polymor-
phisms in genes known to be involved in targeting and regulat-
ing the overall availability of eNOS at the cell membrane26–28:
actin genes (ACTA1, ACTA2, ACTB, ACTG1, and
ACTG2)29,30 and HSP90 genes (HSP90AA1, HSP90AA2, and
HSP90AB1).26 Nominally significant interactions were ob-
served between rs3918226 and rs13447427 (P!1.34 ! 10"3) in
actin-! gene (ACTB), rs7503750 (P!1.57 ! 10"3) in actin-"1
(ACTG1), and rs4922796 and rs17309979 (P!3.47 ! 10"3,
P!4.88 ! 10"3) in HSP-#2 (HSP90AA2; Table S6). When con-
trolling for multiple testing, these interactions remained signifi-
cant at a false discovery rate of 20%.
The quantitative analysis confirmed the qualitative obser-
vation. In fact, the ! coefficient of the regression between
systolic BP or diastolic BP with rs3918226 is, respectively,
1.91 (95% CI: 0.16–3.66) and 1.40 (95% CI: 0.25–2.55) per
T allele. The coefficient is the effect size on BP in millimeter
of mercury per coded allele based on an additive genetic
model. The BP distribution according to rs3918226 genotype
is shown in Table S7.
Because rs3918226 maps to the promoter region of eNOS,
we tested whether it may fall into a regulatory binding site.
Using the PATCH algorithm of TRANSFAC database,21 we
characterized a putative binding site for transcription factors
of the ETS family directly next to rs3918226. The ETS family
members are present in endothelial cells and participated in
activation of the eNOS promoter.31 Using the TFSEARCH
tool,22 we confirmed this finding with a score of 87.3.
We also tested the degree of evolutionary conservation of
rs3918226 locus in primates and placental mammals using
the conservation track of the University of California, Santa
Cruz genome browser. Figure S6 shows that the region in
which rs3918226 lies is conserved from placental mammals
to primates.
Discussion
EH is a complex clinical condition representing the main risk
factor responsible for renal and cardiovascular complications.
The HYPERGENES Project investigated undiscovered asso-
ciations between genetic variants and EH pursuing a 2-stage
study by recruiting cases and controls from extensively
characterized cohorts recruited in different European regions.
We discovered rs3918226 in the promoter region of the eNOS
gene to be significantly associated with hypertension (OR: 1.54
[95% CI: 1.37–1.73]; P!2.58 ! 10"13). The result was con-
firmed by meta-analyzing in silico data for a total of 21714
subjects (OR: 1.34 [95% CI: 1.25–1.44]; P!1.032 ! 10"14). We
observed heterogeneity in the findings of meta-analysis
(P!0.005 for Q test of heterogeneity) that could be attributed to
both different sample sizes and recruitment criteria not directly
comparable between HYPERGENES and the in silico replica-
tion samples (Figure 2).
The quantitative effect of rs3918226 was also estimated in
continuous BP phenotypes, resulting in a !-coefficient of 1.91
for systolic BP and 1.40 for diastolic BP, despite the low P
values of the regression probably because of the low sample size.
This finding reinforces the observation on the qualitative
phenotype.
We identified a potential transcription factor binding site for
the ETS family domain directly next to rs3918226. The mem-
bers of ETS family, as ETS-1 and ELF-1, are essential factors
for the activation of the eNOS promoter.31 This suggests that, by
affecting transcription factor–binding affinity, rs3918226 might
modulate the transcription of the eNOS gene.
It is also worth noting that the region in which rs3918226
lies is conserved from placental mammals to primates. We
propose rs3918226 as a novel susceptibility SNP, because
among the genomewide association studies so far published,
this is the first that points to eNOS: the novelty of the
rs39118226 finding is that the association between eNOS and
hypertension has been found in whites using a genomewide
association study approach.
The use of the Illumina 1M array and Human CVD
BeadArray was crucial in detecting the association, because
rs3918226 is not present on other commercial arrays.32 Other
than being poorly covered by other genotyping platforms, the
region has a relatively high recombination rate toward the
coding region (Figure 1). This has resulted in low linkage
disequilibrium with markers present on older platforms (eg,
rsq-hat #0.2 for Affy500K platform). These facts largely
limited the potential to replicate our finding using data from
other genomewide association studies samples, almost all of
which relied on older platforms.
Indeed, eNOS has been found inconsistently associated
with hypertension with several underpowered candidate gene
studies, many of which only focused on a few variants with
relatively small numbers of cases and controls compared with
the large sample sizes of genomewide association studies.
Positive studies were substantially on Asian cohorts,33–35
whereas the majority were negative in whites, as summarized
in a recent meta-analysis.36 The polymorphisms studied in our
white sample G894T (rs1799983) and T-786C (rs2070744)
did not reach genomewide significant association with hyper-
tension. If looked with candidate gene threshold, the P value
and the sample size of the present study by far outnumber all
of the other published so far. rs1799983 was associated with
EH with a P value of 2.63$10"3 (OR!1.038) and rs2070744
with a P value of 6.42$10"4 (OR!1.04), as shown in Table
S8. To summarize, the ORs are clinically irrelevant. We
underline the low linkage disequilibrium between rs3918226
and rs1799983 (R2!0.16) and rs2070744 (R2!0.17), sug-
gesting that these 2 SNPs are independent from rs3918226
and do not have any additional effect on the phenotype.
There is considerable biological evidence linking eNOS with
hypertension and hypertension-associated cardiovascular target
organ damage.37 eNOS, which catalyzes the synthesis of NO by
vascular endothelium, is responsible for the vasodilator tone that
is fundamental for the regulation of BP. Furthermore, eNOS is a
critical mediator of cardiovascular homeostasis through regula-
tion of blood vessels diameter and of the maintenance of an
antiproliferative and antiapoptotic environment.
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Because NO is highly active, it cannot be stored inside
producing cells. Indeed, eNOS signaling capacity must be
controlled, at least in part, by regulating its targeting from Golgi
apparatus to plasma membrane by its compartmentalization
within the plasma membrane and by its later internalization from
the plasma membrane to the cytoplasm. eNOS is a dually
acylated peripheral membrane protein that is targeted to endo-
thelial plasmalemmal caveolae through an interaction with the
caveolae structural protein, caveolin 1 (Cav1).26,27 Cav1 inhibi-
tion of eNOS is lessened by calmodulin (Calm) causing disso-
ciation of eNOS from caveolin. This regulatory mechanism is
further altered by HSP90,27 which binds to eNOS and facilitates
displacement of Cav1 by Calm. Moreover, eNOS directly
interacts with actin cytoskeleton.29 Recently, Kondrikov et al30
added that !-actin is associated with the eNOS oxygenase
domain increasing eNOS activity and NO production. To ex-
plore such a pathway, we tested the interaction between the
discovered eNOS SNP and its most plausible interactive part-
ners. We observed nominally significant interactions between
rs3918226 and rs13447427 in ACTB, rs7503750 in ACTG1, and
rs4922796 and rs17309979 in the HSP90AA2 gene.
In conclusion, with a stringent case-control design and a
population-based study, we identified a novel hypertension
susceptibility locus in the promoter region of eNOS with a
relatively high effect size. Our finding could provide new
insights into the mechanism of vascular regulation and could
help in better understanding the genetics of EH. Furthermore,
we believe that this indication can be useful to guide fine
mapping or sequencing efforts to single out causal variants.
Perspectives
Further investigations and high-throughput sequencing of
region of interest will help to identify the real causal variant
and to clarify the functional role of eNOS in EH.
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Hypertension is a chronic age-related disease influenced by a large number of genetic and environmental fac-
tors, lifestyle, and their interaction.1 Hypertension affects 
an estimated 25% to 35% of the world’s population and 
>60% of the elderly.1–3 In 2001, hypertension caused 8 mil-
lion deaths worldwide, representing 14% of global mortal-
ity.4 High blood pressure (BP) is the main driver of ischemic 
heart disease and stroke3,4 and substantially exceeds the 
contribution of the 2 other main modifiable risk factors, 
hypercholesterolemia and smoking, to the global burden of 
noncommunicable disease.4 Several genome-wide associa-
tion studies (GWAS) identified a number of single-nucleo-
tide polymorphisms (SNPs), all with a small effect on BP.5,6 
In view of the impact of BP as a continuous risk factor, small 
genetic effects might entail substantial effects on morbidity 
and mortality.1,3
Using GWAS in a case–control design,7 we recently 
identified rs3918226 as a new hypertension susceptibility 
Abstract—A case–control study revealed association between hypertension and rs3918226 in the endothelial nitric oxide 
synthase (eNOS) gene promoter (minor/major allele, T/C allele). We aimed at substantiating these preliminary findings 
by target sequencing, cell experiments, and a population study. We sequenced the 140-kb genomic area encompassing 
the eNOS gene. In HeLa and HEK293T cells transfected with the eNOS promoter carrying either the T or the C allele, we 
quantified transcription by luciferase assay. In 2722 randomly recruited Europeans (53.0% women; mean age 40.1 years), 
we studied blood pressure change and incidence of hypertension in relation to rs3918226, using multivariable-adjusted 
models. Sequencing confirmed rs3918226, a binding site of E-twenty six transcription factors, as the single nucleotide 
polymorphism most closely associated with hypertension. In T compared with C transfected cells, eNOS promoter 
activity was from 20% to 40% (P<0.01) lower. In the population, systolic/diastolic blood pressure increased over 7.6 
years (median) by 9.7/6.8 mm Hg in 28 TT homozygotes and by 3.8/1.9 mm Hg in 2694 C allele carriers (P≤0.0004). The 
blood pressure rise was 5.9 mm Hg systolic (confidence interval [CI], 0.6–11.1; P=0.028) and 4.8 mm Hg diastolic (CI, 
1.5–8.2; P=0.0046) greater in TT homozygotes, with no differences between the CT and CC genotypes (P≥0.90). Among 
2013 participants normotensive at baseline, 692 (34.4%) developed hypertension. The hazard ratio and attributable 
risk associated with TT homozygosity were 2.04 (CI, 1.24–3.37; P=0.0054) and 51.0%, respectively. In conclusion, 
rs3918226 in the eNOS promoter tags a hypertension susceptibility locus, TT homozygosity being associated with lesser 
transcription and higher risk of hypertension.   (Hypertension. 2013;62:844-852.) s Online Data Supplement
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locus. This locus lays in the promoter of the endothelial 
nitric oxide synthase (eNOS) gene, which encodes the 
enzyme that produces nitric oxide, a strong vasodilator 
with a key role in the regulation of systemic vascular resis-
tance. GWAS usually points to genomic regions of inter-
est in relation to a trait, but seldom directly identifies the 
causal or functional variant. In the present study, we aimed 
at consolidating the role of eNOS as a hypertension suscep-
tibility gene by fine mapping the DNA sequence tagged by 
rs3918226, by studying the transcriptional functionality of 
the rs3918226 alleles in vitro, and by relating the change in 
BP over time to rs3918226 in a randomly recruited popula-
tion sample.
Methods
Target Sequencing
From the HYPERGENES study,7 we selected 44 hypertensive patients 
carrying ≥1 T allele and 48 healthy controls homozygous for the C 
allele. Analyses of the genetic data confirmed that all patients and 
controls were of continental Italian descent. We sequenced a 140-kb 
DNA region of chromosome,7 which, in addition to eNOS, included 
KCNH2 mapping upstream and 6 genes mapping downstream: 
ATG9B, ABCB8, ACCN3, CDK5, SLC4A2, and FASTK. Detailed 
information on the DNA sequencing methods and an accompany-
ing glossary are available in the online-only Data Supplement. We 
sequenced indexed and multiplexed samples in a paired-end proto-
col implemented on an Illumina GAIIX platform (Illumina Inc, San 
Diego, CA).
Paired-end raw reads were checked for their quality using FastQC, 
version 0.10.0 (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc) and PrinSeq, version 0.19.4 (http://edwards.sdsu.edu/cgi-
bin/prinseq/prinseq.cgi). Reads were aligned to the human refer-
ence genome (hg19; UCSC assembly; February 2009) using BWA. 
SAMtools, Picard (http://picard.sourceforge.net), and Genome 
Analysis Toolkit (GATK) were used to handle the reads and for 
postalignment quality control checks. Multisamples variant call was 
performed by GATK, and quality filters were applied to variant call. 
Only variants with high SNP quality score were evaluated and anno-
tated with Annovar software for type and impact on the gene product 
(http://www.openbioinformatics.org/annovar).
We imputed missing genotypes based on the HYPERGENES 
results with MiniMac, a low memory, computationally efficient 
implementation of the MaCH algorithm,8,9 using as reference panel 
the 1000 Genome Database, released in June 2011. We tested im-
puted SNPs with high quality (mean R2, 0.91; SD, ±0.11) for associa-
tion with hypertension, using logistic regression as implemented in 
Mach2dat8,9 with adjustments applied for sex and the first 10 signifi-
cant principal components.
Luciferase Reporter Assays
We obtained the pGL2-eNOS promoter-luciferase plasmid, carry-
ing the C allele of rs3918226, from Addgene (plasmid 19297; http://
www.addgene.org) and constructed the T allele by site-directed 
mutagenesis (see Expanded Methods available in online-only Data 
Supplement). We transfected HeLa cells in 4 independent experi-
ments and each construct was tested in triplicate. HEK293T cells 
were transfected in 3 independent experiments and each construct 
was tested in duplicate. We compared luciferase reporter activities 
between the C and T alleles by Student t test.
Population Study
Study Participants
Recruitment for the Flemish Study on Environment, Genes, 
and Health Outcomes (FLEMENGHO) started in 1985.10,11 
From August 1985 to November 1990, a random sample of the 
households living in a geographically defined area of Northern 
Belgium was investigated with the goal to recruit an equal num-
ber of participants in each of 6 strata by sex and age (20–39, 
40–59, and ≥60 years). All household members aged ≥20 years 
were invited, provided that the quota of their sex–age group 
had not yet been satisfied. From June 1996 until January 2004, 
recruitment of families continued using the former participants 
(1985–1990) as index persons and also including teenagers. The 
participants were repeatedly followed up. In all study phases, 
we used the same standardized methods to measure BP and to 
administer questionnaires.10,11 The European Project on Genes 
in Hypertension (EPOGH) recruited participants from 1999 
to 2001.11,12 The EPOGH investigators received training at the 
Studies Coordinating Centre in Leuven, Belgium, and applied 
the same protocol, questionnaires, and follow-up procedures, 
as used in FLEMENGHO. Questionnaires were translated from 
Dutch and English into Czech, Italian, Polish, and Russian and 
back-translated into Dutch and English to ensure that all ques-
tions kept the same meaning in all languages. The last follow-up 
examination took place from 2005 to 2008 in FLEMENGHO11 
and from 2006 to 2008 in EPOGH.11 Both studies complied with 
the Helsinki Declaration for investigation of human subjects.13 
Each local institutional review board approved the study protocol. 
Participants gave written informed consent.
Measurements
At baseline and follow-up, experienced observers measured each 
participant’s anthropometric characteristics and BP and admin-
istered the standardized questionnaire to collect information on 
medical history, smoking and drinking habits, and use of medica-
tions, including BP-lowering drugs, contraceptive pill intake, and 
hormonal replacement therapy. At each contact, BP was the aver-
age of 5 consecutive auscultatory readings in the sitting position 
(see Expanded Methods available in online-only Data Supplement). 
Digit and number preference was checked at 6-month intervals.12 
Hypertension was an untreated BP of ≥140 mm Hg systolic, or 90 
mm Hg diastolic, or use of antihypertensive drugs. For adolescents 
(n=33), we used the thresholds specified by the European Society 
of Hypertension, which are stratified by sex, age, and height per-
centiles.14 Body mass index was weight in kilograms divided by the 
square of height in meters.
Datasets for Analysis
From 3785 subjects who initially agreed to participate in 
FLEMENGHO (n=2593) and EPOGH (n=1192), 53 participants were 
excluded because the baseline BP measurements were missing, leav-
ing 3732 subjects with a full set of required baseline measurements. 
Of these, 2981 subjects participated in ≥1 follow-up examination. We 
additionally excluded 259 participants from analysis because the BP 
measurements were missing (n=32) or their DNA was of bad quality 
(n=227). Thus, the blood pressure cohort used to study change in BP 
included 2722 participants (Figure 1). Changes in BP during follow-
up were calculated as the last minus the baseline BP. The hyperten-
sion cohort used to study the incidence of hypertension encompassed 
2013 participants, who were normotensive at baseline (Figure 1). We 
censored subjects from further analysis after occurrence of the first 
diagnosis of hypertension.
Statistical Analysis
For database management and statistical analysis, we used SAS 
software, version 9.3 (SAS Institute Inc, Cary, NC). Between-group 
comparisons of means, medians, proportions, and Kaplan–Meier 
survival functions relied on the standard normal z test or ANOVA, 
Kruskal–Wallis ANOVA or Fisher exact test, and the log-rank test, 
respectively. We applied McNemar test to evaluate changes over time 
in categorical variables. We computed 95% confidence intervals (CIs) 
of rates as R±1.96×√(R/T), where R and T are the rate and the denom-
inator used to calculate the rate.
We studied the association between change in BP and the 
rs39188226 genotypes, using mixed models with indicator vari-
ables (0,1). Multivariable-adjusted models with BP changes as 
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dependent variables accounted for cohort, sex, age, baseline BP, 
follow-up duration, baseline and follow-up body mass index, in-
take of female sex hormones or nonsteroidal antiinflammatory 
drugs at baseline and follow-up, and 3 indicator variables coding 
for antihypertensive drug intake (starting or stopping treatment be-
tween baseline and follow-up and remaining on treatment). A sen-
sitivity analysis additionally accounted for family clusters modeled 
as a random effect.
To study the incidence of hypertension, we applied Cox regres-
sion adjusted for the same covariables as in the continuous analyses. 
We checked the proportional hazards assumption by the Kolmogorov 
supremum test. To account for family clusters, we used the PROC 
SURVIVAL procedure of the SUDAAN 10.01 software (Research 
Triangle Institute, NC). We computed the positive predictive value of 
TT homozygosity as (R×D)/([G/100]×[R–1]+1), where R is the mul-
tivariable-adjusted hazard ratio, D is the incidence of hypertension in 
the whole population (34.5%), and G is the prevalence of TT homo-
zygosity (1.09%).15 The attributable risk is given by ([R–1]×100)/R 
and the population-attributable risk by ([G/100]×[R–1]×100)/([G/10
0]×[R–1]+1).15
Results
Target Sequencing
In 44 hypertensive patients and 48 healthy controls, we cap-
tured 91% (SD, 6) of the targeted genomic region with a 
63-fold amplification above the genomic background. In 
each sample, the region of interest was covered on average 
20 times with mapping and base quality scores of ≥20 and 17, 
respectively.
We identified 338 variants, of which 15 were nonsynony-
mous; 23 synonymous; 23 and 8 in the 3′ UTR and 5′ UTR, 
respectively; 198 intronic; and 71 intergenic. Among the 338 
variants, 277 were already annotated in dbSNP135 (Table 
S1 in the online-only Data Supplement) and 61 were novel 
variants (Table S2). We had genotyped 76 of 277 annotated 
SNPs in the HYPERGENES GWAS, using the Illumina 1M 
array.7 The genotype concordance rate between the 2 tech-
nologies was high (r2=≈0.988). Of the 61 novel SNPs, 55 
heterozygous variants were rare, only present in a single 
subject. Table S3 lists the 6 other novel variants. Of these, 3 
were intronic in KCNH2 (1 homozygous in 1 subject and 2 
other heterozygous in 2 and 4 individuals). One variant was 
intergenic, mapping ≈3 kb from KCNH2 and 9.5 kb from 
eNOS (3 heterozygotes). One was intronic in eNOS (2 het-
erozygotes). One was intronic in ABCB8 (9 heterozygotes 
and 1 homozygote).
The haplotype analysis appears in page S5 and Figure S1. 
Five novel variants were located in a region of linkage dis-
equilibrium upstream of rs3918226. Their annotation did not 
suggest any functional role (Table S3). We, therefore, did not 
consider them in further analyses. Variants imputed in the 
entire HYPERGENES study population with a probability 
value of ≤10–3 appear in Table S4. rs3918226 remained the 
SNP most closely associated with hypertension.
Luciferase Reporter Assays
SNP rs3918226 is located in the promoter region of eNOS. 
Compared with the C allele, the risk-carrying T allele was 
associated with lower transcriptional activity of the eNOS 
gene ranging from ≈20% (P<0.0001) when tested in HeLa 
cells (Figure 2A) to ≈40% (P<0.01) in HEK293T cells 
(Figure 2B).
Population Study
Characteristics of the Participants
The Table lists the characteristics of the participants by 
cohort and rs3918226 genotype. The blood pressure cohort 
(n=2722) included 1442 (53.0%) women and 55 (2.0%) dia-
betic patients. All participants were white Europeans. Age 
averaged 40.7 years (range 19.5–83.5). At baseline, 709 
(26.1%) participants had hypertension, of whom 322 (45.4%) 
were on antihypertensive drug treatment. The hypertension 
cohort consisted of 2013 participants, who were normoten-
sive at baseline (Table). In 3 groups of unrelated participants 
(n=717), randomly selected from the blood pressure cohort, 
FLEMENGHO EPOGH
Baseline (1985-2002)
Invited 3324
Participated 2593 (78.0%)
Baseline (1999-2001)
Invited 1721
Participated 1192 (69.3%)
Full set of required baseline
measurements 3732
Died 194
Critically 10
Moved 142
Follow-up
Invited 3386
Participated 2981 (88.0%)
Missing BP 32
Degraded DNA 227
Excluded
HT at baseline 709
Hypertension cohort
Followed up for 
hypertension 2013
2722
BP cohort
Missing BP 5Missing BP 48 Baseline
Follow-Up
Figure 1. Flow diagram of participants. The blood 
pressure cohort and hypertension cohort refer 
to participants used to study changes in blood 
pressure and the incidence of hypertension over 
follow-up, respectively.
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the frequencies of the rs3918226 genotypes did not deviate 
from Hardy–Weinberg equilibrium (0.19<P<0.99). The gen-
otype and allele frequencies were equally distributed across 
cohorts (P=0.67; Table S6).
Cross-sectional Analyses of the Blood Pressure Cohort
At baseline (Table), systolic BP was similar across the 
rs3918226 genotypes (P=0.42), but TT homozygotes had 
higher (P=0.030) diastolic BP than C allele carriers. At fol-
low-up (Table), systolic (P=0.012) and diastolic (P=0.0002) 
BPs were higher in TT homozygotes than in C allele carriers. 
The differences in baseline and follow-up systolic and dia-
stolic BPs between the CT and CC genotypes were not statis-
tically significant (P≥0.23; Table). With adjustments applied 
for cohort, sex, age, body mass index, and antihypertensive 
drug intake, baseline (P=0.035) and follow-up (P=0.0007) 
diastolic BPs and follow-up systolic BP (P=0.038), but not 
baseline systolic BP (P=0.48), remained higher in TT homo-
zygotes than in C allele carriers.
Blood Pressure Cohort
Follow-up data were available at 1, 2, or ≥3 occasions in 
1269, 459, and 994 participants, respectively. Median follow-
up was slightly longer (P=0.053) in TT homozygotes (10.4 
years; interquartile range [IQR], 7.2–14.0) than in C allele 
carriers (7.6 years; IQR, 6.1–12.3; Table). In multivariable-
adjusted analyses (see Methods) of the BP changes over 
follow-up (Figure 3), systolic BP increased 9.7 mm Hg (CI, 
4.2–15.1; P=0.0005) in TT homozygotes and by 3.9 mm Hg 
(CI, 1.8–5.9; P=0.0003), 3.8 mm Hg (CI, 2.1–5.4; P<0.0001), 
and 3.8 mm Hg (CI, 2.1–5.4; P<0.0001) in CT heterozygotes, 
CC homozygotes, and C allele carriers, respectively. Diastolic 
BP increased by 6.8 mm Hg (CI, 3.3–10.3; P<0.0001) in TT 
homozygotes and by 2.0 mm Hg (CI, 0.6–3.3; P=0.0036), 
1.9 mm Hg (CI, 0.9–3.0; P=0.0004), and 1.9 mm Hg (CI, 
0.9–3.0; P=0.0004) in CT heterozygotes, CC homozygotes, 
and C allele carriers, respectively. Systolic BP increased 5.8 
mm Hg (CI, 0.4–11.2; P=0.034) and 5.9 mm Hg (CI, 0.7–11.1; 
P=0.028) more in TT homozygotes than in CT heterozygotes 
and CC homozygotes. Similarly, diastolic BP increased 4.8 
mm Hg (CI, 1.4–8.3; P=0.0062) and 4.8 mm Hg (CI, 1.5–8.2; 
P=0.0046) more in TT homozygotes than in CT and CC geno-
type carriers. Furthermore, the BP increases were 5.9 mm Hg 
systolic (CI, 0.6–11.1; P=0.028) and 4.8 mm Hg diastolic 
(CI, 1.5–8.2; P=0.0046) greater in TT homozygotes than in 
C allele carriers. In models additionally accounting for family 
clusters, the effect sizes were 5.3 mm Hg systolic (CI, –0.5 
to 11.2; P=0.071) and 3.1 mm Hg diastolic (CI, –0.6 to 6.8; 
P=0.097). The interactions between the TT genotype and sex 
or age were not significant (P≥0.66).
Hypertension Cohort
Follow-up data were available at 1, 2, or ≥3 contacts in 874, 
351, and 788 participants, respectively. The median duration 
of follow-up (7.1 years; IQR, 5.5–10.4) was similar (P=0.18) 
among the rs3918226 genotypes (Table). In the entire cohort, 
692 participants developed hypertension, of whom 216 
(31.2%) were on antihypertensive drug treatment at the least 
follow-up visit. In 476 untreated patients (68.8%), the diag-
nosis of hypertension relied on thresholds being exceeded for 
systolic or diastolic BP or both in 171 (35.9%), 166 (34.9%), 
and 139 (29.2%) patients, respectively. The TT genotype con-
ferred a higher risk of hypertension compared with the CT 
and CC genotypes (P≤0.011) or C allele carriers (P=0.003), 
with no difference between the C allele–carrying genotypes 
(P=0.55; Figure 4). Expressed per 1000 person-years of 
follow-up, incidence rates of hypertension were 40.6 cases 
(CI, 37.6–43.6) in the entire hypertension cohort, 86.8 (CI, 
44.3–129.3) in TT homozygotes, 43.7 (CI, 35.8–51.6) in CT 
heterozygotes, 39.4 (CI, 36.1–42.7) in CC homozygotes, and 
40.1 (CI, 37.1–43.1) in C allele carriers. In multivariable-
adjusted Cox regression (Figure 5), the hazard ratios asso-
ciated with the TT homozygosity were 2.04 (CI, 1.23–3.37; 
P=0.0056), 2.06 (CI, 1.21–3.50; P=0.0075), and 2.04 (CI, 
1.24–3.37; P=0.0054) compared with CT heterozygotes, CC 
homozygotes, and C allele carriers. In an analysis adjusted 
for family clusters, the hazard ratio expressing the risk of 
hypertension in TT homozygotes versus C allele carriers was 
2.4 (CI, 1.20–3.46; P=0.0082). All Cox models complied 
with the proportional hazards assumption. The positive pre-
dictive values, attributable risk, and population-attributable 
risk associated with TT homozygosity were 69.3%, 51.0%, 
and 1.1%, respectively.
Discussion
The key finding of the present study was that rs3918226 in 
the eNOS promoter tags a hypertension susceptibility locus, 
TT homozygosity being associated with lesser transcription 
of the gene product and a 2-fold higher risk of hyperten-
sion. Our current findings confirm the previously reported 
HYPERGENES case–control study.7 The discovery phase of 
this project7 involved 1865 hypertensive patients and 1750 
controls, who were genotyped with a Illumina 1M array. 
The validation study included 1385 cases and 1246 con-
trols, who were genotyped with a 14-K Illumina Infinium 
custom array. HYPERGENES showed that rs3918226 
in the eNOS gene promoter (–665 C>T) tags a hyperten-
sion susceptibility locus.7 The odds ratio associated with 
the T allele was 1.54 (CI, 1.37–1.73; P=2.58×10–13). In a 
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Figure 2. Luciferase activity in transfected cells. Luciferase 
activity was measured in HeLa cells (A) and HEK293T cells (B) 
transfected with constructs carrying the C or T allele. HeLa 
cells were transfected in 4 independent experiments and 
each construct was tested in triplicate. HEK293T cells were 
transfected in 3 independent experiments and each construct 
was tested in duplicate. Plus-minus values are mean±SE. 
Compared with the C allele, the risk-carrying T allele was 
associated with a ≈20% lower (P<0.0001) transcriptional activity 
of the eNOS gene in HeLa cells and with a ≈40% lower (P<0.01) 
transcriptional activity in HEK293T cells.
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meta-analysis, using both in silico and de novo genotyp-
ing data in 21 714 subjects, the odds ratio was 1.34 (CI, 
1.25–1.44; P=1.03×10–14).7 In the current study, using BP as 
a continuous phenotype in a randomly recruited European 
population sample followed up for 7.6 years (median), sys-
tolic and diastolic BPs increased 5.9 and 4.8 mm Hg more in 
TT homozygotes than in C allele carriers.
Fine mapping the eNOS genomic region in hypertensive 
patients and healthy controls and imputing approaches in the 
whole HYPERGENES cohort using 1000 Genome Database 
released in 2011 as reference further validated rs3918226 as 
the SNP most closely associated with hypertension. Of 61 
novel variants discovered in the genomic area of interest, 55 
were singletons with very low minor allele frequency (<0.5%), 
and 5 were located in a region of linkage disequilibrium and 
were not functional. The remaining newly discovered variant 
in the ABCB8 gene located downstream of rs3918226 and was 
not genotyped in the HYPERGENES sample, because it could 
not have been tagged by rs3918226 in view of the high recom-
bination rate in this genomic region.
Table.  Characteristics of Participants by Cohort
Characteristic
Blood Pressure Cohort Hypertension Cohort
TT CT CC TT CT CC
Number of subjects (%) 28 (1.0) 411 (15.1) 2283 (83.9) 22 (1.1) 300 (14.9) 1691 (84.0)
Median follow-up,  
y (IQR)
10.4 (7.2–14.0) 8.4 (6.4–14.1) 7.4 (6.0–12.0) 7.2 (4.6–10.8) 7.2 (5.9–10.0) 7.0 (5.7–9.4)
Number (%) with characteristic
  FLEMENGHO 19 (67.9) 287 (69.8) 1612 (70.6) 17 (77.3) 221 (73.7) 1256 (74.3)
  EPOGH 9 (32.1) 124 (30.2) 671 (29.4) 5 (22.7) 79 (26.3) 435 (25.7)
  Women 10 (35.7) 214 (52.1) 1218 (53.4) 8 (36.4) 165 (55.0) 918 (54.3)
Baseline
  Hypertension 6 (21.4) 111 (27.0) 592 (25.9) … … …
  Antihypertensive 
treatment
2 (7.1) 51 (12.4) 269 (11.8) … … …
  Use of female sex 
hormones
2 (7.1) 47 (11.4) 208 (9.1) 2 (9.1) 42 (14.0) 182 (10.8)
  Use of NSAID 3 (10.7) 53 (12.9) 326 (14.3) 3 (13.6) 39 (13.0) 232 (13.7)
Follow-up
  Hypertension 20 (71.4)†¶ 191 (46.5)¶ 973 (42.6)¶ 16 (72.7)‡ 118 (39.3) 558 (33.0)
  Antihypertensive 
treatment
10 (35.7)‖ 118 (28.7)¶ 617 (27.0)¶ 2 (9.1) 38 (12.7) 176 (10.4)
  Use of female sex 
hormones
1 (3.6) 19 (4.6)¶ 112 (4.9)¶ 1 (4.6) 22 (7.3)‖ 112 (6.6)§
  Use of NSAID 3 (10.7) 56 (13.6) 334 (14.6) 3 (13.6) 28 (9.3)§ 182 (10.8)‖
Mean (SD) characteristic
  Baseline
   Age, y 41.9 (16.0) 40.5 (14.9) 40.7 (15.1) 37.0 (14.3) 37.2 (13.8) 37.3 (14.2)
   Body mass index, 
kg/m2
25.8 (5.0) 25.7 (4.5) 25.4 (4.5) 25.4 (5.3) 24.7 (4.0) 24.4 (4.0)
   Systolic pressure, 
mm Hg
128.6 (20.7) 126.1 (17.2) 125.3 (17.2) 121.5 (12.2) 118.8 (10.6) 118.4 (10.5)
   Diastolic 
pressure, mm Hg
81.8 (9.4)* 77.8 (11.4) 77.2 (11.1) 80.2 (8.8)‡ 73.8 (8.0) 73.3 (8.3)
  Follow-up
   Age, y 52.8 (15.1)¶ 51.0 (16.4)¶ 50.1 (16.6)¶ 45.4 (14.7)¶ 46.2 (15.0)¶ 45.6 (15.2)¶
   Body mass index, 
kg/m2
27.4 (5.6)‖ 26.9 (5.0)¶ 26.7 (7.0)¶ 26.9 (4.9)¶ 26.0 (4.7)¶ 25.9 (7.4)¶
   Systolic pressure, 
mm Hg
138.4 (18.1)*‖ 130.6 (17.8)¶ 129.5 (18.3)¶ 136.7 (17.6)‡¶ 126.1 (15.4)¶ 125.1 (15.1)¶
   Diastolic 
pressure, mm Hg
87.5 (10.2)‡‖ 80.5 (11.2)¶ 79.8 (10.5)¶ 90.6 (11.5)‡¶ 79.5 (10.9)¶ 79.0 (10.3)¶
Blood pressure cohort and hypertension cohort refer to participants used to study the changes in blood pressure over follow-up and the incidence of hypertension, 
respectively. Blood pressure was the average of 5 consecutive readings at a single visit. FLEMENGHO indicates Flemish Study on Environment, Genes, and Health 
Outcomes, EPOGH, European Project of Genes in Hypertension; IQR, interquartile range; and NSAID, nonsteroidal antiinflammatory drugs. Significance of the difference 
with TT genotype: *P≤0.05; †P≤0.01; ‡P≤0.001; significance of the difference with baseline: §P≤0.05; ‖P≤0.01; ¶P≤0.001.
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In our initial report,7 we tested whether rs3918226 falls into 
a regulatory binding site. Using the PATCH algorithm of the 
TRANSFAC database16 and the TFSEARCH software17 (score 
87.37), we characterized a putative binding site for transcription 
factors of the ETS (E-twenty six) family only 1 nucleotide away 
from rs3918226. The members of the ETS family, ETS-1 and 
ELF-1, are present in endothelial cells and are essential for the 
activation of the eNOS promoter.18 We then hypothesized that 
rs3918226 maps in an open chromatin region. Indeed, DNaseI 
and FAIRE (Formaldehyde-Assisted Isolation of Regulatory 
Elements) experiments in HUVEC (Human Umbilical Vein 
Endothelial Cells) cells from ENCODE show significant sig-
nals around rs3918226 either for DNaseI (P=1.9e−10) or FAIRE 
(P=5e−7). Moreover, methylation and acetylation histone marks 
(H3K4ME1 and H3K27Ac) provide signals above the 98th 
percentile in the same region.
In our current study, we consolidated our previous results7 
in transfected HeLa and HEK293T cells showing that the T 
allele, which is the risk factor for hypertension, is associated 
with a significant reduction of eNOS transcription compared 
with the C allele. We hypothesize that this can impair endo-
thelial NO production in vivo. Luizon et al19 reported that 
the rs3918226 polymorphism does not affect plasma nitrite 
levels in 181 healthy self-reported blacks. However, Luizon 
et al’s results are difficult to interpret, because rs3918226, 
according to HapMap data, is not polymorphic in blacks. We, 
therefore, presume a substantial admixture with whites in 
this black study population. The T allele frequency was only 
0.04.19 Thus, the low frequency of the risk-conferring T allele 
and the small sample size probably render a correct estima-
tion of T allele effect on plasma nitrite levels impossible.20
In mammals, NO can be generated by 3 different isoforms 
of the enzyme NO synthase, referred to as neuronal nNOS 
(NOS1), inducible iNOS (NOS2) produced by macrophages, 
and endothelial eNOS (NOS3).21 The human eNOS gene spans 
21 kb with 26 exons on chromosome 7q35–q36. Blockade of 
NO synthesis with inhibitory L-arginine analogues leads to 
peripheral vasoconstriction and a rise in BP.22–24 Genetically 
engineered mice with disrupted eNOS are hypertensive and 
have no endothelium-derived relaxant activity.25 The physi-
ologically most important determinants for the continuous 
generation of NO and thus the regulation of local blood flow 
are fluid shear stress and pulsatile stretch.26 NO dilates all 
types of blood vessels by stimulating soluble guanyl cyclase 
and increasing the cGMP concentration in smooth muscle 
cells.22 eNOS is not only a physiological vasodilator but also 
conveys vascular protection in several ways.21,22 NO released 
toward the vascular lumen is a potent inhibitor of platelet 
aggregation and adhesion to the vascular wall and prevents 
the release of platelet-derived growth factors that stimulate 
smooth muscle proliferation. NO decreases the expression of 
chemoattractant protein MCP-1 (Monocyte chemoattractant 
protein) and of a number of surface adhesion molecules and 
inhibits leukocyte adhesion to vascular endothelium and leu-
kocyte migration into the vascular wall. This offers protection 
against the early phases of atherosclerosis.22 The decreased 
endothelial permeability, the reduced influx of lipoproteins 
into the vascular wall, and the inhibition of low-density 
lipoprotein oxidation contribute to the antiatherosclerotic 
properties of eNOS-derived NO. Finally, NO inhibits DNA 
synthesis and proliferation of vascular smooth muscle cells 
as well as smooth muscle cell migration, thereby protecting 
against the later stages of atherogenesis.22
Given the central role of eNOS in cardiovascular regulation, 
several previous studies addressed the association between 
hypertension or cardiovascular disease and genetic variation 
in eNOS. Niu and Qi27 published a meta-analysis of 3 widely 
investigated polymorphisms, G894T (rs1799983) in exon 7, 
4b/a in intron 4, and T–786C (rs2070744) in the promoter in 
relation to hypertension, published in English and Chinese. 
Overall comparison between allele 894T and 894G across all 
studies (cases/controls: 19 284/26 003) yielded an increased 
risk of hypertension, amounting to 16% overall, 32% in 
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Figure 3. Association between blood pressure 
(BP) change (∆) and rs3918226 genotype. The 
estimates were adjusted for cohort, sex, age, 
baseline BP, follow-up duration, baseline and 
follow-up body mass index, intake of female sex 
hormones or nonsteroidal antiinflammatory drugs 
at baseline and follow-up, and 3 indicator variables 
coding for antihypertensive drug intake (starting or 
stopping treatment between baseline and follow-
up and remaining on treatment). Plotted values 
are mean±SE (values given) for systolic (A) and 
diastolic (B) BP. Probability values denote the 
significance of the difference with the TT genotype.
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Figure 4. Incidence of hypertension according to rs3918226 
genotype. pa and pr refer to the significance of the log-rank test 
according to an additive (TT vs TC vs CC) or a recessive model 
(TT vs C allele carriers).
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Asians, and 40% in Chinese. The risk associated with the 
4a versus 4b allele was 29% overall and 42% in Asians. For 
T–786C, ethnicity-stratified analyses suggested that in whites 
the risk of hypertension was 25% and 69% higher in carriers 
of the –786C allele and the –786CC genotype, respectively.27 
Moreover, the T allele of T–786C polymorphism is a predis-
posing factor to coronary spasm and reduces the eNOS pro-
moter activity.28
The candidate gene and GWAS studies published so far on 
hypertension6 identified 47 distinct genetic variants robustly 
associated with BP, but collectively these variants explained 
only a few percent of the heritability of BP. HYPERGENES 
was the first GWAS to identify rs3918226 (C–685T) as a 
hypertension susceptibility locus.7 An international consor-
tium applied a gene-centric assay in an independent discov-
ery sample of 25 118 individuals that combined hypertensive 
case–control and general population samples and followed 
up 10 suggestive SNPs in a further 59 349 individuals.6 An 
analysis of combined discovery and follow-up data iden-
tified rs3918226 (T/C: 0.08/0.92) as being significantly 
(2.2×10–9) associated with diastolic BP. The effect size per 
–690T allele was +0.78 mm Hg (SE, 0.21; P=9.5×10–5).6 The 
recent GWAS of systolic and diastolic BP performed by the 
International Consortium for Genome-Wide Association 
Studies (ICBP) used a multi-stage design in 200 000 indi-
viduals of European descent.29 Overall, the eNOS region 
was poorly covered in this study. Genotyping had been 
performed in most of the cohorts with arrays older that the 
Illumina 1M, which do not include rs3918226. Moreover, 
imputation was done using the HapMap panel as reference 
that does not include rs3918226. In the ICBP data set,29 a 
SNP mapping 779 bp from rs3918226, rs1800783 (position 
150689397), shows a high D′ (1.000) but a low R-sq (0.141) 
with rs3918226. Because of the low R-sq, allele frequencies 
are different, and rs1800783 cannot be considered a proxy of 
rs3918226. In GenHAT,30 the hazard ratio for the primary end 
point, fatal coronary heart disease, and nonfatal myocardial 
infarction in T allele versus CC genotype carriers was 1.12 
(CI, 1.00–1.26; P=0.048). Conen et al31 analyzed 3 SNPs in 
the eNOS gene (rs3918226, rs1800779, and rs1799983) in 
18 436 white women enrolled in the Women’s Health Study. 
The participants were all health professionals and normoten-
sive at baseline. BP was self-reported. Over 9.8 years, 29.6% 
of the women developed hypertension. The hazard ratios for 
the eNOS polymorphisms were 1.01 (CI, 0.97–1.06), 1.06 
(CI, 0.99–1.14), and 1.05 (CI, 1.01–1.09), respectively.31 
Progression of BP across 3 increasing categories was not 
associated with the eNOS polymorphisms, but follow-up 
for this soft end point was only 4 years. Seidlerová et al32 
reported a pilot study examining the association between 
arterial properties and the rs3918226 polymorphism in 101 
untreated volunteers. Among 31 smokers, carriers of the 
mutated T allele (n=8) had a marginally higher aortic pulse 
wave velocity (10.0 versus 8.7 m/s; P=0.051) and a higher 
aortic augmentation index (172 versus 153%; P=0.024). 
Seidlerová et al32 hypothesized that pending confirmation 
in a larger study genetic modulation of intermediate arterial 
phenotypes might lead to higher BP.
Taking into account our current findings and the literature, 
the C to T substitution at position –690 in the eNOS promoter 
strongly complies with the Bradford Hill criteria33 as a cause 
of hypertension. The association is strong,6,7,27 consistent 
across studies,6,7,27 and specific for hypertension- or hyper-
tension-related complications.6,7,27,30 The current study estab-
lished temporality and provided a possible mechanism adding 
to the plausibility. Some studies, but not ours, suggested a 
dose effect based on the number of T alleles.6,27
Perspectives
We demonstrated that TT homozygosity at the rs3918226 
locus in the eNOS gene promoter enhances the age-related 
increase in BP and increases the risk of hypertension, prob-
ably by reducing the transcriptional activity of the eNOS 
gene. The implications of our current findings span both the 
prevention and treatment of hypertension and its associated 
cardiovascular complications. The prevalence of TT homozy-
gosity is low, explaining why the population-attributable risk 
for hypertension is only 1.1%. However, the attributable risk 
in TT homozygotes is 51.0%. Combined with other genetic 
markers, the rs3918226 polymorphism might, therefore, con-
tribute to the stratification of cardiovascular risk. Our find-
ings also support pharmacological interference with the NO 
signaling pathway. In GenHAT,30 amlodipine, compared with 
lisinopril, was more effective in the prevention of stroke in 
minor allele carriers (hazard ratios CT+TT versus CC: 0.49 
versus 0.85; P=0.04). Overall, amlodipine reduced systolic 
BP 1.2 mm Hg more than lisinopril.34 Stroke is the compli-
cation of hypertension that is most closely linked to the BP 
level.1 Moreover, amlodipine enhances endothelial NO avail-
ability via stimulation of NO formation35 and by prolong-
ing the NO half-life through antioxidative properties.35,36 
Recently developed compounds act downstream in the NO 
signaling pathway by inhibition of cGMP-specific phospho-
diesterase type 537 or by stimulation (haem-dependent) or 
activation (NO- and haem-independent) of soluble guanylate 
cyclase activity.38 Further clinical research should establish 
whether eNOS might be a target for preventive or therapeutic 
intervention.
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Figure 5. Hazard ratios for hypertension associated 
with TT homozygosity compared with the CT or CC 
genotypes or C allele carriers. The hazard ratios 
were adjusted as in the continuous analyses of the 
blood pressure changes (see Figure 3). Probability 
values denote the significance of the difference 
with the TT genotype.
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What Is New?
ڇ In the general population, TT homozygosity at the rs3918226 locus (mi-
nor/major allele, T/C allele) in the eNOS gene promoter enhances the 
age-related increase in blood pressure and increases the risk of hyper-
tension. Sequencing confirmed rs3918226, a binding site of E-twenty six 
transcription factors, as the SNP most closely associated with hyperten-
sion. In luciferase reporter assays, the risk-carrying T allele was associ-
ated with a 20% to 40% lower transcriptional activity than the C allele.
What Is Relevant?
ڇThe prevalence of TT homozygosity is low, explaining why the population-
attributable risk for hypertension is only 1.1%. However, the  attributable 
risk in TT homozygotes is 51.0%. Combined with other genetic markers, 
the rs3918226 polymorphism might, therefore, contribute to the strati-
fication of cardiovascular risk. Further clinical research should establish 
whether eNOS might be a target for preventive or therapeutic interven-
tion.
Summary
rs3918226 in the eNOS promoter tags a hypertension susceptibility 
locus, TT homozygosity being associated with lesser transcription 
and higher risk of hypertension.
Novelty and Significance
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DISCUSSION 
 
 
 
The years during which the experimental work for this thesis was made coincided with the 
most extraordinary technological change that occurred to medical genetics since decades. 
Next generation sequencing transformed all aspects of DNA investigations, starting from the 
sequencing of small genomes to the sequencing of human genomes and molecular diagnostics 
of inheritable disease. More specifically, I started working on this project during the early 
phases of implementation of NGS in molecular genetics research. In our first NGS-related 
work, we were interested in exploring the use of different NGS platforms (from Roche, 
Illumina and Life Technologies) for the sequencing of simple targets. A mutation in an 
intronic repetitive element of PRPF31, representing an obstacle for both classic sequencing 
methods and NGS, was chosen as a test case. We showed that all NGS platforms are powerful 
tools for molecular geneticist to identify rare and common DNA variants, even in case of 
more complex sequences. Moreover, we highlighted the features of different NGS platforms 
to be considered in re-sequencing projects. In particular, the identification of variants in 
repetitive elements was facilitated by the use of longer reads, such as the ones produced by 
Roche 454 Technology. Sequencing of repetitive regions has been a long lasting problem for 
finishing the sequence of genomes in many organisms, and has not been completely solved 
yet. In the human genome, for example, highly repetitive regions like centromeres, telomeres 
and Y chromosome are still scarcely covered and annotated [121, 122]. To correct the 
ambiguity of non-unique alignment of identical short reads on reference genomes, the use of 
paired-end reads and of specific bioinformatic tools have provided some help [123]. One of 
the most used strategies, especially for variant detection, is to simply ignore reads that map to 
multiple locations, with the awareness that only non-redundant sequences can be analyzed. In 
exome sequencing, for example, repetitive regions are not captured, limiting the efficacy of 
this methodology for comprehensive variant analysis. The homozygous 353 bp Alu inserion in 
the RP gene MAK, for example, has been identified by exome sequencing only due to a 
fortunate coincidence and because two different sequencing platforms were used [98]. 
Another recent example is the discovery of a single cytosine insertion in the gene MUC1 
causing the dominant rare disease medullary cystic kidney disease type 1 [124]. Despite 
linkage analysis clearly pointed to a defined locus, whole-exome (WES), sequence-capture 
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and whole-genome sequencing (WGS) of several patients failed to identify the causative 
mutation. Only by cloning, Sanger sequencing and de novo assembly of the specific gene it 
was possible to reconstruct the polymorphic repetitive element, a VNTR, where the mutation 
lied. Interestingly, this scenario is very similar to our original case of PRPF31, although the 
polymorphic number of repeats in PRPF31 was smaller (6-7) than in MUC1 (>30). The 
problem of repeats is still topical and should not be underestimated when analyzing whole 
genome or exome sequences, which often result in no candidate genes or mutation relevant 
for a particular disease. 
Despite this and other limitations, WES or WGS are very powerful tools to discover new 
genes causing Mendelian diseases, including RP and especially for conditions that have 
recessive inheritance [81]. The constant plummeting of their costs allowed them to gradually 
substitute almost all other genetic approaches for research and diagnostic. However, for the 
study of dominant retinitis pigmentosa, we decided to use a “classic” candidate gene approach 
and not WES/WGS because: i) WES/WGS are less effective in the identification of dominant 
mutations in heterogeneous diseases, due to the high number of novel hetherozygous variants 
present at the genomic scale in each individual, ii) the cost was still too high to be applied to a 
elevated number of patients and their family members, iii) the candidate gene approach is an 
effective tool for discovering new genes in heterogeneous diseases such as RP [125]. We 
therefore performed NGS-based screenings of multiple samples to sequence candidate 
splicing factor genes in well-characterized cohorts of patients with adRP. From a 
methodological point of view, the main challenge was to adapt NGS procedures to multiple 
samples processing. For the first gene to screen, SNRNP200, as a cost-effective solution we 
sequenced all target PCRs from all the patients as a single library, thus avoiding the costs of 
many sequencing library preparations. This method required the development of downstream 
analysis and validation by Sanger sequencing, aimed at distinguishing true mutations from 
false positives, the latter being very frequent with the Roche 454 pipeline used in our analysis. 
Following the commercialization of cheaper and more scalable library preparation solutions 
(such as the “Nextera” kit), for screening of the second set of candidate splicing factor genes 
(EFTUD2, PRPF4) we sequenced PCRs from all samples by individual barcoded library 
preparations. This procedure allowed obtaining results that were less poisoned by false 
positive and negative discoveries. Overall, the approaches used in our screenings proved to be 
cost- and time-effective solutions for gene analysis in many samples. Both procedures 
allowed exploiting the full capacity of modern NGS sequencers and obtaining reliable results 
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for molecular analysis, especially when individual library preps were used. However, since 
the generation of many long-range PCRs is a rather tedious and low-throughput procedure, 
other enrichment methods such as micro-droplet PCR [126], microfluidic arrays-based PCRs 
[127] or molecular inversion probes [128] can be now used for faster and more scalable 
custom target selection. 
Screening of these splicing factor genes confirmed SNRNP200 as a novel RP gene, which was 
identified by other authors in two different families [38] [37]. Our study highlighted the 
effectiveness of screening large cohorts of patients with NGS to identify new RP genes and to 
enrich the mutational panel of disease genes, important also for diagnostics. Conversely, the 
genes analyzed in the second round of sequencing (EFTUD2, PRPF4, NHP2L1 and AAR2) 
did not bear any pathogenic variant to be linked to RP, likely because these genes are not 
indeed causing RP or mutations are too rare to be identified by screening a small number of 
cohorts. WES and WGS are more expensive alternatives to candidate gene screenings and 
present the advantage to be hypothesis-free. However, applying these methods on large 
cohorts of patients has higher necessities than single candidate gene sequencing. For example, 
mutations in known genes have to be excluded in order to be cost-effective. Despite this 
precaution sounds obvious, in practical terms it is very hard to insure such pure enrichment 
because patients are usually collected and screened for known genes over a large period of 
time and with different methods. Custom NGS- based panels of genes for targeted enrichment 
are a good option for homogeneous and up-to-date screenings of known retinal degeneration 
genes, under the condition that the price per sample becomes significantly lower than WES 
itself [96, 97, 129]. Finally, for dominant RP, the analysis of families or trios may be critical 
to filter candidate variants from WES/WGS very large lists of DNA changes and to 
compensate for lack of commonly mutated genes in unrelated patients.  
The hBrr2 protein, encoded by SNRNP200, is the core RNA helicase associated with the U5 
snRNA. It is responsible for the disruption of U4/U6 base pairing necessary for spliceosomal 
activation and for the U2/U6 base pairing for spliceosomal disassembly and recycling. The 
dynamics of Brr2’s functions are tightly and directly regulated by the PRPF8 C-terminal tail 
[56] and by the GTPase Snu114 (encoded by EFTUD2 in humans) [130]. AAR2 is a small 
interactor of PRPF8 in the immature U5 snRNP and prevents PRPF8’s binding to Brr2, which 
replaces AAR2 when the mature tri-snRNP is formed in the nucleus [131]. The genes 
EFTUD2 and AAR2 were chosen as candidate adRP genes because they are involved in the 
regulation of Brr2 activity and recruitment on the U5 snRNP, respectively. However, our 
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screening indicated that these genes are likely not involved in the disease. In particular, many 
heterozygous mutations of EFTUD2, the strongest candidate from our screening, have been 
linked to another set of congenital pathologies characterized by severe cranio-facial 
malformations [30]. This latter finding suggests that there might be different mechanisms 
underlying the development of these diseases and that we are still missing some key elements 
to link mutations of splicing factors to RP. Among all possible hypotheses, the one supported 
by the most numerous and convincing evidences indicates splicing defects as the triggering 
cause for degeneration of photoreceptors, which are unusually sensitive to splicing 
impairments. This theory implies a loss-of-function model, which is supported by several 
biochemical studies on tri-snRNPs associated mutations [35, 62, 68, 132] and by the 
haploinsufficiency of PRPF31 mutations, which is also reflected in the many cases of 
incomplete penetrance [41-43]. Interestingly, we have indeed found a novel case of 
incomplete penetrance in one family segregating the SNRNP200 p.R681C mutation. The 
affected members presented with typical symptoms of RP, but with variable severity, 
indicating variable expressivity as well. Two members of the family were healthy carriers of 
the mutation, and had no signs of RP, even at old ages. We started to investigate the causes of 
incomplete penetrance at the molecular level, by testing variations in expression of 
SNRNP200. We could only identify a possible reduction in total protein concentration at the 
steady-state in lymphoblastoid cell lines from carriers of p.R681C mutation. We plan to verify 
a possible mechanism of protein misfolding and degradation due to point mutations by 
measuring the protein levels in conditions where protein synthesis or proteasome machinery 
is blocked. Unless differences between asymptomatic and affected individuals are visible, this 
will not give clues on incomplete penetrance mechanism, but may confirm the 
haploinsufficiency model. Other factors - genetic or environmental - are likely to 
differentially influence hBrr2 expression or activity, and their identification could have a 
major impact on our understanding of the molecular basis of the disease, ultimately useful for 
clinical care.  
Current animal models of haploinsufficient RP-linked splicing factors have not been 
conclusive to provide a mechanistic model for photoreceptor degeneration, either because the 
phenotype was not present (as in the case of mouse models [67]) or because proper controls 
have not been provided (in the case of the Zebrafish model [48]). Mammal cellular models 
include transfected human cell lines (such as HeLa and RPE-derived cells [132, 133]) or 
patients-derived lymphoblastoid cells [68, 134]. Although they have provided important 
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information, these cell models have been criticized because they are not relevant for modeling 
retina-specific degeneration in RP. An emerging tool to study the effect of mutations at the 
cellular level is induced pluripotent stem cells (iPSCs). Indeed, patient-derived iPSCs 
differentiated into photoreceptors or photoreceptor precursors have been generated for a series 
of mutations in RP genes such as RP1, RP9, PRPH2, RHO, USH2A and MAK, helping to 
study photoreceptor degeneration pathways and possible clinical interventions [98, 135-137]. 
The validation in these cell models, which recapitulate the disease phenotype in specific 
genetic background and in a relevant tissue, will undoubtedly help to provide final prove of 
pathogenic mechanisms of splicing factors as well as potential targeted therapeutic strategies.  
The technological innovation in sequencing and genotyping technologies had a strong impact 
not only in the investigation of Mendelian disease but also in genetic research of complex 
diseases. The exceptional throughput and speed of sequencing allowed gaining deeper 
knowledge of human genomic variations and functional properties, useful in genome-wide 
association studies. For example, the 1000 Genomes Project has sequenced 2500 individuals 
from 25 worldwide populations, and catalogued common and rare variations. At the same 
time, the functional aspects of human genome were explored by the ENCODE Project [112], 
which performed extensive characterization of different cell types to annotate the human 
genome with regulatory regions such as enhancers, promoters and silencing regions, 
important for the functional characterization of GWAS signals. In our GWAS on 
hypertension, we identified a novel association with a regulatory SNP in the promoter region 
of NOS3. The risk allele determined a reduced transcription of endothelial nitric oxide 
synthase, and consequently a reduction of the vascular relaxing factor NO, predisposing to 
higher blood pressure. Furthermore, targeted NGS of the region surrounding the SNP in a 
panel of healthy and hypertensive individuals confirmed the rs3918226 polymorphism as the 
most strongly associated with hypertension.  
In conclusion, massively parallel sequencing protocols allow the rapid and low-cost 
investigation of Mendelian and complex diseases on a scale not previously imaginable. We 
are already realizing that the technological progress that gave us access to unprecedented 
amounts of genomic information will crash against our still limited understanding of how 
specific variants cause or influence a disease. The necessity of valid models to test the impact 
of DNA changes that are constantly being identified by next generation genetic studies will be 
a key focus of future and current genetic research. This will ultimately open the way to the 
improvement of therapeutic strategies and personalized medicine. 
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ABBREVIATIONS 
 
 
 
AAR2P A1-alpha2 repressin protein (yeast) 
adRP Autosomal Dominant Retinitis Pigmentosa 
APEX Arrayed Primer Extension 
arRP Autosomal Recessive Retinitis Pigmentosa 
ATP Adenosine Triphosphate 
BCA Bicinchonicic acid 
BRR2 Bad Response to Refrigeration 
cDNA Complementary DNA 
CEPH Centre d'Etude du Polymorphisme Humain 
cGMP Cyclic Guanosine monophosphate 
ChIP Chromatine Immunoprecipitation 
CNV Copy Number Variant 
CoLaus Cohorte Lausannoise 
CVD Cardiovascular Disease 
DBP Diastolic Blood Pressure 
DExH/D ATP hydrolysis motif: Aspartic Acid, Glutammic Acid, Histidine 
DNA Deoxyribonucleic acid 
dNTP Desossinucleotide Triphosphate 
EFTUD2 Elongation Factor Tu GTP-Binding Domain-Containing 2 
EH Essential Hypertension 
eQTL Espression Quantitative Trait Locus 
ERG Electroretinography 
FAM 6-carboxyfluorescein 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase 
GC Guanosine-Cytosine 
GMP Guanosine Monophosphate 
GWAS Genome Wide Association Study 
HEK293T Human Embryonic Kidney 293 cells 
HGMD Human Gene Mutation Database 
INL Innernuclear layer 
IPL Inner plexiform layer 
IS Inner Segment 
KIF3A Kinesin Family Member 3A 
LD Linkage Disequilibrium 
LR-PCR Long-Range PCR 
MAF Minor Allele Frequency 
MAK Male germ-cell associated kinase 
MGB Minor Groove Binder 
MPS Massively parallel Sequencing 
mRNA Messenger RNA 
NA Not Available 
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NGS Next Generation Sequencing 
NHP2L1 Non-Histone Chromosome Protein 2-Like 1 (S. Cerevisiae) 
OCT Optical Coherence Tomography 
OD Oculis Dexter 
OS Outer Segment 
OS Oculis Sinister 
PCR Polymerase Chain Reaction 
PDE Phosphodiesterase 
PDF Portable Document Format 
pre-mRNA Precursor Messenger RNA 
PRPF pre-mRNA processing factor 
RNA Ribonucleic acid 
RP Retinits Pigmentosa 
RPE Retinal Pigmented Epithelium 
SBP Sistolic Blood Pressure 
SNP Single Nucleotide Polymorphism 
snRNA Small Nuclear RNA 
snRNP Small Nuclear Ribonulcleic Particle 
SNU114 116 KDa U5 Small Nuclear Ribonucleoprotein Component 
ss Splice site 
TBS Tris-buffered Saline 
TFBS Transcription Factor Binding Site 
UHTS Ultra High Throughput Sequencing 
UTR Untranslated Region 
WES Whole Exome Sequencing 
WGS Whole Genome Sequencing 
wt Wild Type 
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